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In the absence of disease on endoscopy and failure to respond to empirical therapy, 
guidelines recommend manometry and reflux studies; however these investigations 
often fail to establish the physiological basis of oesophageal symptoms or guide 
therapy. Advances in technology may help provide insight into oesophageal function 
in health and disease and in turn direct management. The aim of this thesis was to 
explore the impact of introducing novel techniques and methodology through High 




Study 1: 110 patients who successfully completed standard catheter-based pH 
monitoring (C-pH) were compared with 134 patients who failed the study and 
progressed to 48 hour Bravo. The total reflux time (TR; total % time pH drops below 
4) was used as the diagnostic marker of reflux disease. Visceral sensitivity was 
assessed by Symptom Index (SI) and tolerability was measured with a questionnaire.  
Study 2: 38 patients who continued to have symptoms of reflux despite negative 
results with C-pH progressed to prolonged Bravo. ‘Worst day’ and ‘Average 
cumulative’ 24, 48, 72 and 96 hour Bravo measurements were compared to standard 
24 hour C-pH. 
 
High Resolution Manometry (HRM) 
23 asymptomatic volunteers who underwent HRM were compared to 18 patients 
presenting with oesophageal symptoms. Measurements of swallow responses were 
collected by varying workload on the oesophagus (changing bolus volume, 
consistency and patient position). Normative values from healthy subjects were 
formulated and were used to investigate patients. A novel dysmotility-symptom 
association parameter (Dysfunction Symptom Index; D-SI) was formulated. Clinical 





Study 1: 76% of patients had a pathological TR on day 1 or 2 compared to 49% of C-
pH (p<0.01). There was no difference in SI (p=0.28). A questionnaire demonstrated a 
preference for Bravo with reduced restriction, discomfort and dysphagia. 
Study 2: Using ‘Average’ and ‘Worst-day’ analysis, 61% and 76% patients were 
diagnosed with reflux disease based on either pathological acid exposure or reflux-
symptom association at 96 hours. Of 12 patients who underwent anti-reflux surgery, 
10 (83%) reported a good outcome at 2 years.  
 
HRM 
In health contractility and coordination improved with increased workload; from 
upright to supine and single liquid to solid swallows. Inter-observer agreement was 
high and normal values were formulated. Compared to healthy subjects, meal 
consumption was associated with more ineffective swallows in patients (28% vs. 
51%; p<0.001). No symptoms occurred with single water swallows. With the test 
meal 50% of patients exhibited symptoms and 75% of these had a pathological D-SI. 
Furthermore, compared to water alone, 67% patients had a manometric change in 
diagnosis during the test meal. 2 year follow-up studies suggest that these techniques 




Tolerance, satisfaction and diagnostic yield was high in those who underwent Bravo. 
Prolonged pH measurement also increased the diagnostic yield in patients in whom an 
initial catheter study was negative.     
 
HRM 
The introduction of novel metrics and a protocol that mimics normal eating and 
drinking was more likely to identify the culprit dysmotility and associate these with 
symptoms. 
 
In summary, these studies advance the utility of modern technology in oesophageal 
testing and appear to guide clinical management. 
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Chapter 1 
Background, Aims and Objectives 
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1.0 Background 
In health the oesophagus coordinates the transport of food and fluid from the mouth to 
the stomach while the oesophago-gastric junction (OGJ) acts as a gateway to allow 
passage of bolus and limit the inappropriate reflux of gastric contents. The OGJ does 
not act as a one-way valve; its dynamic nature also permits venting of gas (e.g. belch) 
and solids (e.g. vomit) where it is appropriate. The normal oesophagus is able to clear 
any remaining food and fluid residue quickly and efficiently. In harmony these 
processes limit contact of the bolus, acid and other chemicals with oesophageal 
mucosa. Disruption of this highly complex muscular motion and OGJ integrity results 
in the interruption of food and fluid delivery and/or gastro-oesophageal reflux. 
Symptoms produced may range in severity from mild heartburn and regurgitation to 
pain and dysphagia. 
1.0.1 Gastro-oesophageal reflux disease 
The Montreal Definition of gastroesophageal reflux disease (GORD) was developed 
by an International Consensus Group based on a systematic review of the literature 
(Embase, Cochrane trials register, Medline) from 1980 to 2006 in adults.1 This 
guideline is now used as a basis for prioritising research and permits a broad 
consensus among different regions of the world. It also clarifies and simplifies the 
classification for the diagnosis of GORD, Barrett’s oesophagus, as well as extra-
oesophageal disorders. (Figure 1.1) For the purposes of this thesis, only patients in 
whom Symptomatic Oesophageal Syndromes (Typical Reflux and Chest Pain 




Figure 1.1 Montreal Classification. The overall definition of GORD and its 
constituent syndromes. 1 
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Symptoms associated with Typical Reflux and Chest Pain Syndromes occur when 
gastric contents pass into the oesophagus at an increased frequency, are not 
effectively cleared or are sensed in an exaggerated manner. This can lead to mucosal 
damage and/or the perception of symptoms at varying degrees of severity.2  
 
GORD is one of the most common health problems of the modern Western world and 
its prevalence is increasing.3 Symptoms caused by GORD have an important impact 
on morbidity and quality of life.1,2 GORD is associated with reduced work 
productivity and absenteeism.4-6 European studies have shown that it can also be 
associated with an average monetary loss of €55–273 per patient per week.4  
 
Overall, treatment for GORD accounts for among the largest pharmaceutical 
expenditures on healthcare resources.5,7. The use of over the counter (OTC) 
medications is high in this group of patients.5,8,9 In the 2000 Gallup Study of 
Consumers’ Use of Stomach Relief Products, 36% of patients with GORD took OTC 
non-prescription medication, and 56% of those with prescribed acid reducing 
medication also continued to take OTC drugs for break through symptoms.10  
 
10-20% of the UK population have symptoms of reflux at least once per week.11  In 
2000, a community survey in the UK reported that the prevalence of reflux symptoms 
in adults was 29%. There was no difference between sex and age but GORD was 
more common in poorer communities.12 Approximately 25% of those with GORD 
sought medical attention. Of those 20% were 20–29 years of age and 45% were 60–
69-years of age suggesting that more patients visited their doctor as they grew older.12  
Interestingly socioeconomic status, sex and presence of irritable bowel syndrome did 
not influence the likelihood of seeking help, but the presence of nocturnal symptoms, 
and increasing the burden of co-existing upper GI symptoms (dyspepsia, nausea, 
vomiting and dysphagia) did.  
 
Apart from the typical symptoms of heartburn, other presentations include chest pain, 
dysphagia, chronic cough, hoarseness, laryngitis, as well as ear and nose problems.1,13 
Furthermore chronic reflux is related to the rising incidence of oesophageal 
adenocarcinoma, especially in those with Barrett’s columnar-lined oesophagus.14 
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Oesophageal cancer has increased more than any other common cancer with a 6-fold 
rise since the 1980’s.2 
 
Ambulatory reflux monitoring is essential in the investigation of patients presenting 
with symptoms suggestive of reflux, especially those who do not achieve 
symptomatic relief to acid reducing medication. Studies have shown that presenting 
symptoms are an unreliable guide to identifying oesophageal dysfunction and 
emphasize the need for objective testing in order to avoid inappropriate medical and 
surgical therapy.15 An early study by Klauser et al16 looking at presenting complaints 
of 304 patients with GORD symptoms showed that if either heartburn or acid 
regurgitation was the predominant complaint, specificity for GORD was high (89% 
and 95%, respectively) but sensitivity  was only 38% and 6% respectively. 
Furthermore a poor description of presenting symptoms made it impossible to identify 
the predominant complaint in more than 30%. 
 
1.0.2 Dysmotility 
Oropharyngeal dysphagia refers to a disturbance in the passage of food or fluid from 
the mouth to the oesophagus and is the ‘perception’ that there is an impediment to the 
normal passage of swallowed material. Very few studies report the prevalence of 
dysphagia in the community. Of 2200 residents between 25 and 74 years of age in 
Olmstead County, Minnesota, the overall prevalence of dysphagia was 13.5%.17 In 
one study of 313 patients in a primary care setting over the age of 62, up to 7% had 
dysphagia.18 Motility disorders of the oesophagus are much less common than reflux 
disease, but can lead to significant morbidity and reduced quality of life including 
food fear, anxiety during meals and avoidance of eating in public.19,20 Left untreated 
severe dysphagia can lead to dehydration, malnutrition and  respiratory infections.19,20 
The elderly, in particular are at an increased risk of developing dysphagia21 and life-
threatening aspiration pneumonia.22   
 
It is often difficult to differentiate symptoms of dysmotility from GORD as symptoms 
may be similar, dysmotility could be a consequence of chronic reflux or it may 
contribute to the pathophysiology of GORD.23 Of the 2200 Olmstead County 
residents, 30% of patients with GORD had dysphagia compared to only 4% of those 
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without GORD.17 Kahrilas et al. found that 25% of patients with mild oesophagitis 
and 48% of  those with severe oesophagitis had peristaltic dysfunction.24 Furthermore 
studies have shown improvement in peristaltic activity following successful anti-
reflux surgery.25 On the other hand, 38-75% of patients with achalasia (the most 
common and widely studied primary motility disorder) also have symptoms of 
heartburn,26-29 and the majority have received PPI therapy to erroneously treat 
presumed GORD by the time they were referred.30 Often the description of dysphagia 
in achalasia is vague and the classic description of dysphagia to solids and liquids is 
illustrated in only 75% of patients.31  Furthermore, pathological oesophageal acid 
exposure has been identified in up to 20% of patients with achalasia.32 In this group, 
abnormal pH studies are not usually a consequence of true acid reflux. Rather food 
stasis of consumed acidic foods or fluids mimic GORD; isolated prolonged episodes 
where the pH drops below 4 on pH studies occur as passage of food through the tight 
sphincter is impeded.29 (Figure 1.2) Furthermore, fermentation of bacteria in food 
residue can lead to lactic acid production which contributes to heartburn and pain and 





Figure 1.2 Ambulatory pH measurement in a patient with achalasia. A prolonged 
episode showing a pH<4 occurred due to stasis of acidic food within the oesophagus. 
(Reproduced from Kessing et al. CGH 2012.32) 
 
 
Therefore in most patients who present to the oesophageal lab, both dysmotility and 
reflux symptoms should be investigated simultaneously, and results of one should 
always be taken in context of the other. Even then, the diagnosis is dependant on the 
usefulness of the investigative tools available, the methodology used and the 
experience of the examiner in interpreting these results. 
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1.0.3 Advanced technology 
Understanding the pathophysiology of GORD and oesophageal dysmotility requires a 
detailed analysis of the dynamic structures of the oesophagus and LOS; however 
description of these structures is dependant on the reliability of the tools at hand. 
Limitations of the current standard used to investigate GORD and dysphagia are as 
follows: 
1. 24 hour catheter-based pH monitoring is normally used as the first line 
investigation for GORD; however it is not easily tolerated, it can reduce 
reflux-provoking activities and often misses events which do not occur during 
the short period of study. 
2. Conventional manometry (4-8 sensors; water-perfused or solid state) is the 
standard tool used to investigate dysmotility; however it has very poor spatial 
resolution, it provides a very basic assessment of the LOS and it does not 
reflect true ‘physiological’ swallowing behaviour.  
  
This thesis aims to investigate the use of novel and advanced technology to better 
understand the physiology of the oesophagus and LOS in health and disease in order 
to provide the opportunity for optimal medical or surgical management. Specifically, 
the systems that will be addressed are:  
 
1. Bravo pH monitoring; a wireless ambulatory system used to investigate 
GORD over a prolonged (>24 hour) period 
and  
2. High Resolution Manometry; an advance in the assessment of oesophageal 
motility which incorporates a catheter with 36 sensors. This provides 
improved anatomical and spatial resolution and (in this thesis) can also be 
adapted for use in a novel, more physiological and functionally relevant 
manner where the emphasis is shifted towards reproducing patient symptoms. 
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1.1 Normal Adult Oesophageal Anatomy  
The oesophagus is a muscular tube of approximately 25 cm connecting the pharynx to 
the stomach. Anatomically the cervical oesophagus (approximately 5 cm) extends 
from the crico-pharyngeus and the thoracic oesophagus terminates at the hiatal canal 
near the level of the 10th thoracic vertebrae where it flares into the gastric fundus. The 
intra-abdominal oesophagus (usually 1–2 cm) can vary in length depending on the 
presence/absence of a hiatus hernia. Functionally the LOS is identified 
manometrically by a high pressure zone between the distal oesophagus and gastric 
cardia. 
 
Similar to other parts of the gut, the oesophageal wall is histologically comprised of 
the mucosa, submucosa and muscularis mucosa. The length of the normal 
oesophageal body is lined by non-keratinised stratified squamous epithelium (with 
very few secretory glands). This joins with the glandular gastric columnar epithelium 
at the distal oesophagus as an abrupt transition (the anatomical Z-line). This can be 
the site of mucosal change associated with chronic reflux and oesophagitis of various 
stages of severity and/or Barrett’s oesophagus (a pre-malignant condition associated 
with the replacement of normal squamous epithelium with metaplastic columnar-lined 
epithelium.34) 
 
The muscularis propria of the oesophagus consists of the outer longitudinal and inner 
circular muscle layers. Although these function as a single unit, the musculature is 
divided into the proximal striated muscle (approximately 5.5%) and the mid/distal 
smooth muscle (approximately 60%) which are separated by a 4-5 cm transition at the 
level of the aortic arch comprised of both striated and smooth muscle (approximately 
4.5 cm distal to the crico-pharyngeus muscle).35 This naturally occurring area 
generates the weakest force of peristaltic contractions. In some, an abnormally wide 
transition zone can be associated with recurrent bolus retention and dysphagia and can 
therefore be a target for therapy.36 (Figure 1.3) In 2008, Ghosh et al showed that 14/25 
patients with increased proximal transition zone length and duration had dysphagia.37 
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Figure 1.3 Proximal transition zone. An area of transition from striated muscle to 
smooth muscle in proximal oesophagus.  
(Reproduced from Guili R, et al. Libbey Enrotext 199138 page 455-6.) 
 
1.2 Oesophageal Motility and GORD 
Swallowing initiates a highly coordinated complex sequence of events that permits 
the transport of the bolus from the mouth to the stomach. Voluntary swallowing 
initiates a pharyngeal contraction as well as ‘deglutitive inhibition’ of the smooth 
muscle oesophagus and LOS. In the striated muscle (cervical) proximal 1/3 of the 
oesophagus peristalsis is centrally mediated and is a consequence of sequential 
activation of the lower motor neurons (recurrent laryngeal vagus nerve) whose cell 
bodies are located in the nucleus ambiguous. The main excitatory neurotransmitter is 
acetylcholine (ACh) which acts on nicotinic cholinergic receptors. The most proximal 
portion of the striated cervical oesophagus is activated first and is followed by a 
sequential activation of neurons innervating more distal striated muscle levels.39 
 
In the smooth muscle portion of the oesophagus (distal 2/3), inhibitory (relaxatory) 
and excitatory (contractile) motor myenteric neurons are innervated by separate sets 
of pre-ganglionic fibres which originate from the dorsal motor nucleus of the vagus. 
These synapse with postganglionic intramural neurons located in the myenteric plexus 
located between the circular and longitudinal muscle layers of the oesophagus. Pre-
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ganglionic neurotransmitters are cholinergic (ACh) for both inhibitory and excitatory 
neurons while post-ganglionic neurotransmitters within the plexus differ: 39  
 
1) Inhibitory neurons release nitric oxide (NO) which inhibit contraction of the 
circular muscle layer by increasing the latency of contraction. This mechanism 
has its largest effect distally 
2) Excitatory neurons release acetylcholine (ACh) which mediates contraction of 
both the circular and longitudinal muscles. This mechanism has its largest 
effect proximally. 
 
Studies looking at the latency of contraction have shown that inhibitory innervation of 
smooth muscle produces a more prolonged latency distally in a sequential manner.40-42 
 
Therefore with initiation of a swallow inhibitory (predominantly nitroxinergic) 
neurotransmitters provoke an immediate relaxation of the entire oesophagus and LOS 
(deglutitive inhibition) which allows the bolus to pass through the oesophagus with 
minimal resistance.43-45 This inhibition does not last as long in the proximal as in the 
distal oesophagus. The subsequent excitatory (predominantly cholinergic) activity43 
produces a wave of smooth muscle excitation which results in a progressive, 
‘peristaltic’ contraction with distal latency.45  
 
Myenteric interneuron afferents also detect the presence of bolus as their afferent 
endings act as specialised sensors (mechanoreceptors and chemoreceptors). These 
produce an intrinsic response in which circular muscle contracts above (cholinergic) 
and relaxes below (nitroxinergic) the bolus. When well coordinated, effective 
clearance of the bolus is achieved in 5-10 seconds. Any disruption in this process may 
lead to bolus retention and symptoms.36,46 
 
Normal peristalsis activity can involve two mechanisms: 47  
1. Primary peristalsis; a centrally mediated response which is initiated by the 
voluntary swallow. Food which remains in situ distends the lumen and induces 
a secondary peristalsis. 
2. Secondary peristalsis; a peripheral response mediated by local neural reflexes.  
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Peristalsis is also required to clear the reflux of gastric contents which also involves 
primary and secondary mechanisms. Using manometry combined with 
videofluoroscopy, Kahrilas et al showed that even at low distal oesophageal peristaltic 
amplitudes of 20 mmHg, a single well-coordinated peristalsis activity will 
successfully clear a barium bolus.48 This highlights the importance of coordinated 
peristaltic activity in clearing the swallowed or refluxed bolus despite minimal 
contractile pressures.  
 
1.3 The Anti-reflux Barrier 
The oesophagus and stomach span two opposing pressurised environments divided by 
the diaphragm. At rest, most of the oesophagus lies in the negatively pressurized 
thorax (approximately -5 mmHg) while the lower 1-2 cm lies within the positively 
pressurised abdomen (approximately +5 mmHg). Therefore theoretically, if it were 
not for the anti-reflux barrier at the oesophago-gastric junction, the pressure gradient 
across the diaphragm should lead to back flow of gastric contents.  
 
Anatomically the OGJ is comprised of three distinct anatomical components which 
together form an effective reflux barrier: intrinsic LOS (iLOS), diaphragmatic crura 
(cLOS) and the clasp and sling muscle fibres of the proximal gastric cardia.49  The 
competence of the sphincter is determined by the integrity and overlap of the intrinsic 
and diaphragmatic sphincters. A wide separation between the iLOS and cLOS forms 
a hiatus hernia, contributes to LOS weakness and increases the frequency of transient 
relaxations. These in turn may increase susceptibility to reflux events. New and 
advanced technologies can delineate these components more clearly, and 
abnormalities associated with incompetence of the reflux barrier can be better 
appreciated. OGJ disruption may predispose to an increased gastro-oesophageal 
pressure gradient as a result of the higher intra-abdominal pressure. This can occur 
with obesity,50 with degradation of the OGJ as seen with increased age51 and hiatus 
hernia.52   
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1.3.1 Lower Oesophageal Sphincter 
The oesophageal body is phasic in nature and contracts transiently only upon nerve 
stimulation. The LOS is tonic in nature; it exhibits a continuous resting (basal) tone 
and relaxes on stimulation of the intramural nerves. The vagus nerve exerts both 
inhibitory and excitatory effects on the LOS.  Basal tone is dependent on 3 factors: 
myogenic tone, inhibitory nitroxinergic nerves and excitatory cholinergic nerves. 
Relaxation of the LOS starts within seconds of swallowing (deglutitive inhibition) and 
is mediated by the vagal inhibitory pathway and the release of nitric oxide at the 
initiation of swallow. This is followed by a slightly delayed and slow activation of the 
excitatory motor neurons.39 If neuronal activity is lost (eg. achalasia or vaogtomy) the 
unopposed myogenic tone renders the LOS in a continuous pressurised state. 
 
The LOS cannot be identified anatomically; however its sphincter-like properties 
(basal tone) can be detected manometrically as a high-pressure zone in the distal 
oesophagus proximal to the gastric cardia. In the absence of a hiatus hernia the OGJ 
(iLOS + cLOS) is 1-4 cm in length and spans the diaphragm. Anatomically the iLOS 
is located 1-1.5 cm proximal to the squamo-columnar junction.53 In health, its resting 
basal tone is reduced during deglutitive inhibition (swallowing), transient lower 
oesophageal sphincter relaxations (TLOSR), belching and vomiting. LOS pressure 
can vary in the same individual at different times54 as it responds to changes in 
posture55,56 during and after meals.57 Furthermore activities which increase the intra-
abdominal pressure and gradient across the diaphragm (i.e. abdominal compression, 
bending forward, straining and coughing) and those which drop the intra-thoracic 
pressure (sniffing, hiccoughing and deep breathing) also lead to a rise in the LOS 
pressure.  
 
The length of the LOS, and in particular its intra-abdominal component, is related to 
the intra-gastric pressure and linked with the development of reflux disease.58  
DeMeester et al showed that a low LOS basal pressure (<5 mmHg) and/or a short 
intra-abdominal segment (<1 cm) increases the incidence of GORD.59 This is most 




The concept of spontaneous lower oesophageal sphincter relaxation (LOSR) was first 
introduced by Dent in 1976 with the development of the manometry sleeve device (a 
5-6 cm sleeve that measures the maximum resting pressure within the LOS but is not 
affected by small displacements of the catheter).60 In health, physiological LOSRs can 
occur spontaneously (transient LOSR; TLOSR) in response to gastric (postprandial) 
distension56,61 and bloating resulting in a belch.2,62 It can also follow primary or 
secondary peristaltic activity (swallow-induced LOSR; SLOSR). TLOSRs usually 
occur within 5 sec from resting pressure and can last between 5 and 40 sec,63 or 
longer during SLOSRs.64 They are thought to be  triggered by mechanoreceptors 
within the proximal stomach which stimulate abdominal vagal afferents.39,65 TLOSRs 
occur very infrequently in the supine position.66 
 
TLOSRs are the most frequent mechanism of reflux and are proposed to be the only 
method by which reflux events occur when LOS pressures are not compromised.62 
Patients with GORD do not have an increased frequency of TLOSRs compared to 
healthy controls,67 and indeed TLOSRs contribute to reflux events in asymptomatic 
individuals.63,68 (Figure 1.4) Those with mild/moderate GORD do not necessarily just 
have increased TLOSR frequency,69 and not all TLOSRs are associated with reflux.70 
What differs is that the frequency and volume of acid reflux during TLOSRs is greater 
in those with GORD than healthy controls.67 Furthermore, disruption of the structure 
and function of the OGJ can compromise its integrity and contribute to the 
mechanism of reflux during these events. It is important to note that GORD is not 
only a result of increased reflux episode frequency but also of impaired clearance.71-73 
Therefore with progression of OGJ disruption, the likelihood of reflux events 
occurring during TLOSRs increases, as does the volume and stasis of the refluxate. 





Figure 1.4 Transient lower oesophageal sphincter relaxation (TLOSR). The LOS relaxes spontaneously and is followed shortly after by a 
‘common cavity’ during which there is equalisation of pressure between the oesophagus and stomach. The axial pressure plot (right) portrays the 
pressure dynamics at the position of the vertical red line on the trace (centre). This shows that the pressure below the diaphragm is greater than 
above. Gastric contents are therefore likely to flow down this pressure gradient and reflux into the oesophagus. A primary peristalsis terminates the 
TLOSR and clears the oesophagus. The intra-oesophageal pressure returns to baseline levels as does the pressure gradient on either side of the 
diaphragm. 
Images acquired by 36-channel SSI Manoscan 360.  
This Image is of the oesophagus of Rami Sweis (the author) after consuming a sandwich, and was presented on the cover of GUT in 2007. 
A detailed discussion of the High Resolution Manometry spatiotemporal plot is provided in section 1.5.3 
 33 
1.4 Ambulatory pH studies 
(Appendix 1 and 2) 
 
Most patients with reflux symptoms do not require a pH study. Often a typical history 
with endoscopic evidence of erosive oesophagitis (EO) or Barrett’s oesophagus or a 
good response to acid suppression are sufficient to establish a diagnosis (see PPI test 
in section 1.7). On the other hand, those with incomplete or poor response to acid 
suppression, atypical symptoms and in particular those with non-diagnostic 
endoscopy are likely to benefit from ambulatory pH monitoring, especially for those 
in whom the association between reflux and symptoms is uncertain. An emphasis on 
symptoms is essential in the overall assessment as a patient may still have GORD if 
the majority of typical symptoms are correlated in time with acid reflux events despite 
an overall oesophageal acid exposure within the normal range (‘the sensitive 
oesophagus’)74,75. On the other hand a negative symptom association with a pH study 
showing variables marginally above the normal range may not necessarily imply 
GORD. Differentiating those with Endoscopy Negative Reflux Disease (ENRD; 
Endoscopy negative, pH study positive) and Functional Heartburn (FH; Endoscopy 
negative, pH study negative with typical symptoms) from those whose symptoms are 
not due to acid reflux will have an impact on future management, especially as studies 
have shown that patients with a positive relationship between reflux and symptom 
events are more likely to respond to conservative or surgical therapy.76,77 
 
Standard ambulatory investigation is normally performed using a naso-oesophageal 
catheter with a distal pH electrode. In order to produce reproducible results, by 
convention most studies are carried out in a standardised manner: 
 
 Indications for 24 hour pH monitoring include: classic symptoms of 
oesophageal reflux which may or may not be refractory to acid reducing 
medication/antacids, atypical symptoms (e.g. globus, chronic cough) and 
dysphagia or those with a suspected motility disorder.  
 
 Proximal oesophageal acid reflux or layryngopharyngeal reflux (LPR), which 
may be associated with chronic cough, hoarseness, dental erosions etc. can be 
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investigated by placing pH sensors (normally 2) at multiple levels above the 
LOS or with the addition of Impedance-pH monitoring (see section 1.4.2)  
 
 An acid reflux episode, as recorded by a pH sensor, begins when oesophageal 
pH drops below and ends when pH rises above 4 in the absence of locally 
determined ranges.78 In Impedance-pH testing, a reflux episode is defined as 
weakly acid if it lies between pH 4 and 7 or alkaline if the pH  is greater than 
7.79 (see section 1.4.2) 
 
 pH monitoring is commonly preceded by manometry.33 (see section 1.5) 
Manometry is the most reliable method for determining the correct position for 
pH sensor placement. Alternatively the LOS high pressure zone has been 
shown to be 1-1.5 cm proximal to anatomical Z-line.53 Knowledge of this 
position can be used to determine the correct placement of the catheter tip in 
the absence of manometry, and is especially useful during the positioning of 
the wireless pH capsule. (see section 1.4.3 and Methods Chapter 2) 
 
 By convention, the distal pH sensor is positioned so that it lies 5 cm proximal 
to the upper margin of the manometrically determined LOS high pressure 
zone. As the oesophagus naturally shortens during swallow events, TLOSR 
and spasm, if positioned too distally it may frequently come into close 
proximity to the oesophago-gastric junction and may even dip into the 
stomach. This will lead to false positive reflux measurements80 (reduced 
specificity). Conversely, a sensor positioned too proximally will underestimate 
acid reflux measurements (reduced sensitivity).  
 
 pH monitoring is usually performed while off acid suppression therapy in 
order to provide a diagnosis and  determine the severity of acid reflux. 
However patients could be tested while on acid reducing medication in search 
of breakthrough acid reflux if symptoms are refractory to therapy.33 The latter 
is especially useful in Impedance-pH testing. (see section 1.4.2) 
 
 The study should be representative of routine daily life. Patients should 
therefore not modify normal daily ‘reflux provoking’ activities and should 
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reproduce their normal diet in order to improve test sensitivity. Conversely, 
foods and fluids with inherent acidity should be avoided to prevent inclusion 
of invalid non-reflux related acid measurements. (Methods Chapter 2).  
 
 All symptoms should be recorded in a diary card and/or directly onto the event 
marker within the digital recording device for reflux-symptom association 
analysis. (Appendix 2) 
1.4.1 Limitations of standard pH monitoring 
Limitations of standard catheter-based pH monitoring include  
i) intolerance to insertion of the catheter  
ii) patients may have difficulty keeping the catheter in place for the duration of 
the 24 hour study. Not uncommonly they may vomit or (in)voluntarily remove 
the catheter. It is reported that between 5 and 10% of patients are intolerant 
nasal catheter insertion.51   
iii) the nasal catheter is socially embarrassing and can result in altered behaviour 
which may not be representative of daily life,81,82 thereby resulting in a false 
negative (or positive) diagnosis of GORD. Studies that address this concept 
are lacking.  
 
Reflux events and symptoms are known to have a high day-to-day variability,83-85 
especially when reflux events are infrequent and symptoms are intermittent.86 The 
total percent of time pH drops below 4 within 24 hours during 2 consecutive days can 
vary by up to 3.2 fold. 87 Furthermore the 24 hour catheter test has been shown to 
have a reproducibility of only 70-80%.76 Therefore in those with intermittent reflux or 
symptom events, the clinical value and diagnostic yield of the 24 hour test may be 
reduced.83-85  
 
Nevertheless, in most centres (nationally and internationally), presently those who are 
intolerant to the pH catheter or are tolerant but have inconclusive results (i.e. based on 
very few reflux or symptoms events), have limited further investigation options as 
investigation often terminates with the naso-oesophageal catheter. Clearly failure to 
obtain a definitive diagnosis of GORD will result in inappropriate management 
decisions.  
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1.4.2 Multiple intra-luminal impedance + pH (MII-pH) 
Oesophageal symptoms are often related to disturbed bolus transport rather than acid 
reflux.88 Also persistent symptoms can be due to non-acid reflux despite adequate acid 
suppression.77 Acid reducing medications decrease typical reflux symptoms in the 
majority of patients; however these do not influence the frequency or proximal extent 
of reflux episodes which may be weakly or non-acidic, especially in the post-prandial 
period.89,90 Persistent weakly acid reflux events can continue to induce symptoms in 
patients taking these medications.91,92 Furthermore acid reducing medications have no 
effect on the reflux of other noxious substances produced in the stomach. Specifically 
pepsin (a proteolytic enzyme) and bile salts retain their damaging activity in weakly 
acid environments and have even been implicated in severe GORD, including 
Barrett’s oesophagus and laryngopharyngeal reflux (LPR) disease.93 Failure of PPIs to 
suppress the mechanism of reflux largely explains the lack of efficacy seen for PPIs in 
up to 40% of patients (higher in LPR).91,92,94 Impedance pH monitoring can be used to 
investigate these phenomena. 
 
Multiple intra-luminal impedance (MII) was first introduced in 1991 to detect the 
flow of gas and liquid through a hollow lumen.95 In physics, impedance is defined as 
the opposition to current flow, and is an inverse measurement of electrical 
conductance of contents within a lumen. Impedance varies with bolus conductivity: 
liquid bolus has high conductivity and low impedance while air has low conductivity 
and high impedance.  Therefore the arrival of a liquid bolus will result in a rapid 
voltage drop of over 50% from the nadir, and the successful clearance of the bolus 
leads to a rapid rise of the voltage back up to baseline. The opposite occurs with the 
passage of gas.  
 
A single electrode will detect bolus movement in the lumen while multiple electrodes 
determine the direction of this movement. Thus, antegrade (normal swallow) vs. 
retrograde (reflux, vomit or belch) can be differentiated with MII.  
 
MII is an ambulatory, catheter-based test used to determine the success/failure of 
bolus transit and the proximal extent of the refluxate thanks to the multiple sensors 
that span the catheter. Furthermore it can differentiate between liquid, gas and mixed 
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liquid/gas content of swallowed or refluxed material. MII has been shown to be 
reproducible especially for gas and mixed reflux events.96 
 
MII is usually combined with a pH sensor (Impedance-pH; MII-pH) to determine 
whether the refluxate is acidic (pH<4), weakly acidic (pH 4-7) or weakly alkaline (pH 
>7);79 an advance on ambulatory pH monitoring.  It is considered the most sensitive 
method for reflux detection and is theorised to improve diagnostic yield by 15-20% in 
experienced hands.91,97,98 Indications for its use are the same as for 24 hour pH studies 
(see section 1.4 above), and it is often also used in the assessment of atypical disease 
(e.g. LPR, aerophagea). MII-pH is also important in the detection of post-prandial 
reflux (often non-acidic and not accurately measurable with standard pH studies), and 
while on acid-reducing medication (as inhibition of acid does not alter the mechanism 
or frequency of reflux episodes but can still contribute to mucosal damage and 
symptoms).99-101  
 
Nonetheless, MII-pH is currently not recommended by the UK National Institute for 
Clinical Excellence (NICE) as a first line investigation for GORD. NICE guidelines 
published in August 2004 102 and BSG guidelines in 2006 78 did not include MII-pH 
due to the paucity of good quality studies available at that time. MII-pH is also more 
costly, and labour-intensive and requires a degree of expertise. Thus, it is not 
routinely available for use in many centres. Furthermore, MII-pH is another catheter-
based 24 hour study and therefore suffers from the same disadvantages of any other 
catheter-based study (intolerance, discomfort, altered behaviour; see section 1.4.1).  
 
In regards to studies in this thesis, MII-pH was not used. Patients in whom atypical 
reflux symptoms (cough, belch, sore throat) was the primary presenting complaint 
were not included. 
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1.4.3 Wireless pH Monitoring (Bravo®) 
The Bravo® pH system (Medtronic, Shoreview, Minn., USA) is an innovative, 
endoscopically placed, catheter-free pH monitoring system (Figure 1.5; described in 
detail in Methods Chapter 2). It is better tolerated than the catheter-based system and 
is preferred by unselected patients referred for pH investigation.103,84,104 Prolonged 
measurement (up to 96 hours) increases diagnostic reproducibility and is probably 








Figure 1.5 Bravo wireless pH monitoring delivery system and capsule. Process of 
insertion will be described in Chapter 2.  




Limitations of wireless pH monitoring  
Bravo may be less suitable for patients with predominant post-prandial symptoms or 
for the investigation of patients while taking anti-secretory medications as symptoms 
that may arise are often associated with non-acid reflux. A study off (1 day) and on 
(up to 3 days) acid reducing medication has been performed in an attempt to improve 
the diagnostic yield of the Bravo study, especially for those in whom typical reflux 
symptoms do not respond to therapy;108 however further studies are required to 
confirm the validity of this technique. Because of it’s higher cost and the need for 
endoscopy during capsule placement, UK NICE guidelines state that ‘wireless 
oesophageal pH-monitoring is most suitable for patients who do not tolerate nasal 
intubation’ of the standard catheter.109  
 
Considering the guidance from NICE, the efficacy of Bravo in the two groups of 
patients most commonly referred for Bravo in the UK were assessed in this thesis:  
1. Patients that fail to tolerate the catheter-based system may be offered catheter-
free pH monitoring (where available). Intolerance for other invasive diagnostic 
procedures such as colonoscopy is more common in the presence of functional 
gastrointestinal disease.110 Similarly, individuals that are intolerant to the nasal 
catheter are often considered to have ‘heightened sensitivity’, functional 
oesophageal symptoms or psychological disease. No studies have been 
performed to assess factors affecting tolerance of nasal intubation and to test 
whether these patients have increased visceral sensitivity. Furthermore it is not 
known whether the diagnostic yield in terms of pathological acid exposure or 
symptom-association justifies further investigation with catheter-free testing. 
 
2. Patients with typical reflux symptoms but a non-diagnostic 24-hr catheter-
based investigation are often considered to have ‘functional’ oesophageal 
symptoms; however, given that 1:3 patients have a different diagnosis if the 
pH study is repeated on 2 separate days51 and provided the limitations of 
catheter-based studies described above, a proportion may have false-negative 
results based on catheter-based studies and be denied appropriate therapy. 
Such patients are sometimes referred for wireless pH monitoring but no 
studies have assessed the diagnostic yield of Bravo in this group of patients. 
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1.5 Manometry 
‘The ideal manometric system would acquire continuous, high-fidelity pressure data 
from the pharynx to the stomach with circumferential sensitivity. The equipment 
should be cheap. The procedure should be quick and easy to perform and analyse. 
Presentation of pressure data should display not only oesophageal contractility but 
provide an accurate assessment of the forces that drive bolus movement, and identify 
(or exclude) abnormal oesophageal function as the cause of a patient’s symptoms.’111  
The aims of investigation of oesophageal symptoms are to understand the patho-
physiological mechanisms behind oesophageal symptoms and dysfunction, establish 
an appropriate diagnosis, guide rational management, and in turn improve the quality 
of life of the patient. 
 
Manometry is required for the diagnosis of those with suspected motility disorders 
which may be amenable to medical management and is essential for those under 
consideration for endoscopic therapy (e.g. pneumatic dilatation, botulinum toxin 
injection) and surgery (e.g. anti-reflux surgery, Heller myotomy).   
 
1.5.1 Standard Manometry 
Standard manometry measures the circumferential contraction, pressure wave 
duration and peristaltic velocity of oesophageal swallows. Therefore it provides 
information regarding the peristaltic and non-peristaltic activity within the 
oesophagus. It is also used to assess OGJ function and position and to facilitate 
placement of the pH catheter probe thereafter.33 Standard manometry is comprised of 
4-8 pressure sensors which span the length of the catheter and is available either as a 
water-perfused or solid-state assembly. Water-perfused catheters can also incorporate 
a ‘sleeve sensor’ (Dent Sleeve) designed to provide a more stable assessment of LOS 
pressure during breathing and swallowing than that achieved by ‘point pressure’ 
sensors. 
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The Normal Swallow (as assessed by standard manometry) 
A normal swallow of 5 ml of water starts with the contraction of the pharynx to propel 
the bolus towards the upper oesophageal sphincter which quickly relaxes. After 
deglutitive inhibition induces relaxation of the oesophagus and LOS, a propagated 
peristaltic wave helps the bolus progress down the oesophagus and the relaxed LOS 
permits the bolus to successfully pass into the stomach. Contraction amplitude 
(mmHg) is measured from the mean intra-oesophageal baseline pressure to the peak 
of the contraction wave. Normal amplitude values range from 30 mmHg in the 
proximal oesophagus to as high as 180 mmHg distally.  Contraction duration is 
usually up to 6 seconds and is measured from the onset of the major upstroke to the 
end of the pressure wave. Peristaltic velocity is normally approximately 5 cm/s in the 
distal (smooth muscle) portion of oesophagus.33 
 
In view of the natural axial movement of the LOS, a more accurate measure of 
sphincter pressures and relaxation was required. Dent developed a 6 cm sleeve which 
straddles the LOS and determines the location of the maximum pressure;60 however 
this advance could only be incorporated into the water-perfused catheter which is 
more labour intensive and expensive. 
 
While LOS function is of prime importance in the pathogenesis of acid reflux disease, 
its clinical measurement only provides an impression of (dys)function. Therefore 
objective evidence of GORD with ambulatory pH monitoring is always required. 
Manometry helps localize the LOS in order to accurately place the pH catheter tip (as 
described in section 1.4) as well as exclude primary motility disorders such as 
achalasia and diffuse oesophageal spasms which are likely to influence 
management.33 
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Conventional manometry classification of oesophageal pathology  
Classification of pathology using the conventional manometry catheter has been 
revisited on many occasions.112-114 A widely accepted definition of standard 
pathologies using the conventional manometry is presented below:115 
 
Achalasia   
 Absent peristalsis with incomplete LOS relaxation 
 LOS basal pressure may be hypertensive or normal 
Diffuse oesophageal spasm (DOS)  
 Simultaneous contractions in ≥20% of wet swallows 
• with/without repetitive/prolonged/high-amplitude contractions  
• with/without hypertensive resting LOS 
Nutcracker oesophagus    
 Peristaltic waves of high amplitude (mean >180 mmHg) 
Hypertensive LOS   
 LOS resting pressure >45 mmHg 
Hypotensive LOS    
 LOS resting pressure <10 mmHg 
Ineffective peristalsis    
 Low-amplitude oesophageal contractions (<30 mmHg) in ≥30% of wet swallows 
Non-specific oesophageal motility disorder  
Any combination of the following: 
• non-transmitted contractions in 20% of swallows 
• triple peaked contractions 
• retrograde contractions 
• isolated, incomplete lower oesophageal sphincter relaxation 
• prolonged-duration peristaltic waves (> 6 seconds) 
 
Using this classification, Dekel et al. present the distribution of oesophageal motor 
disorders amongst 403 patients with symptoms of dysphagia as a primary presenting 




Table 1.1 Summary of findings from 403 patients presenting with symptoms of 
dysphagia using conventional manometry. 
(Adapted from Dekel et al. APT 2003115) 
 
It is interesting to note from Table 1.1 that just over half (53%) of all patients studied 
had no identifiable pathology. It is unclear if this is indeed the case or if the tools and 
methodology used to investigate these patients played a role in reducing the 
sensitivity and specificity of recognising more subtle (or major) dysmotility.  
 
1.5.2 Limitations of standard manometry 
Standard manometry is readily available, is inexpensive and is the most commonly 
used method for measuring motor function and identifying motility disorders of the 
oesophagus;.111 however it has several downfalls: 
 
i) During a 24-hour period more than 1000 - 2000 peristaltic swallows occur 
with a wide variety of pressure events as normal eating and drinking 
behaviour ensues. Therefore many intermittent motility abnormalities are 
missed using the standard ten swallows of 5 ml of water.  
 
ii) With only 4-8 pressure sensors the ability of standard manometry to 
predict effective bolus transport is limited by poor spatial resolution. 
Segmental or focal abnormalities within the oesophagus, (wide break in 
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contractility, focal hyper/hypo-peristalsis, segmental spasm) will 
inevitably be missed.  
iii) With conventional manometry abnormalities are defined in terms of a few 
basic patterns: incomplete sphincter relaxations, oesophageal spasm, hypo- 
and hypertensive contractions and non-specific dysmotility. This 
classification is simple with poor inter-observer agreement in 
interpretation (even amongst experts) and only fair reproducibility.116,117 
Furthermore the majority of these ‘pathologies’ can also be found in 
asymptomatic individuals. Only primary motility disorders (such as 
achalasia and diffuse oesophageal spasm) can be diagnosed with 
reasonable confidence, although with recent advances in technology, even 
these have been re-classified.118,119 
 
iv) The LOS anatomy is poorly appreciated, especially in the context of a 
hiatus hernia or very weak LOS.  Furthermore, unless a water-perfused 
catheter with a Dent sleeve is used, the catheter does not take into account 
oesophageal shortening which may shift the LOS proximally (sometimes 
even above the sleeve device) therefore giving a false impression of LOS 
relaxation (pseudorelaxation).119 
 
v) Symptoms are rarely triggered by 5 ml water swallows in the supine 
position of fasted patients (as is the standard protocol). Patients usually 
complain of symptoms during eating or post-prandially as well as during 
manoeuvres that increase workload on the oesophagus and/or compromise 
the reflux barrier (free drinking, bending forward). 
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1.5.3 High Resolution Manometry 
The fundamentals of High Resolution Manometry were first established in the early 
1990s by Clouse and Staiano120,121 who developed a model by which a functional 
image of the oesophageal anatomy was generated from multiple pressure sensors on a 
catheter. (Figure 1.6a) This information was reconstructed into a 3-dimensional plot 
using time of peristalsis, distance down the oesophagus and pressure amplitude as its 
axes. The 3-dimensional plot was then superimposed onto a 2-dimensional image and 
the pressure changes were re-presented as a topographic plot. (Figure 1.6b). With the 
advent of micro-manometric water-perfused assemblies122,123, and later solid state 
catheter assemblies124,125 up to 21-36 sensors could be introduced, thereby 
considerably improving image resolution especially as changes in pressure were then 
assigned different colours. Therefore with its increased number of sensors and 
spatiotemporal representation of pressure activity, the functional segmental anatomy 
of the oesophagus could be appreciated. (Figure 1.7) 
 
Ongoing progress in research, technology and advanced software algorithms have also 
enabled HRM to compute measurements that are key to predicting successful bolus 
transport and are not possible with conventional manometry. Such parameters 
(Intrabolus pressure, Integrated relaxation pressure, Contractile front velocity; see 
Classification below and Methods Chapter 2) have been linked to improved diagnostic 
accuracy and are presumed to improve sensitivity to dysfunction that causes 
symptoms and are clinically relevant to the patient.111,126 In addition HRM can assess 
OGJ anatomy in greater detail and identify dysfunction that may predispose to 
GORD. It is important to note, however that although oesophageal pressure 
measurement is the most direct method for assessing motor function in the 
oesophagus and OGJ it is not a radiologic study and can only predict bolus transport 
by inference.  
 
Such features are unique to HRM and are important as symptoms and mucosal 
damage are more likely to occur due to a disturbance of bolus transport and poor 
clearance of refluxate rather than abnormal pressure events as described by standard 
manometry.111 Furthermore, an ‘electronic sleeve’ (e-sleeve), which emulates the 
Dent sleeve device of standard manometry, can be applied in order to provide stable 
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LOS measurements during analysis regardless of shifts in the catheter or patient 
position or of oesophageal shortening. This facilitates the positioning of the catheter 
and removes the need for the time-consuming pull-through technique required in 
standard manometry. Advantages and disadvantages of standard vs. High Resolution 
Manometry are presented in Table 1.2. 
 
 
Figure 1.6a      Figure 1.6b 
Figure 1.6 2 dimensional topographic reconstruction of a High Resolution 
Manometry spatiotemporal plot. 
a) Clouse and Staiano127 laid the foundations for HRM: time, catheter position and 
average pressure were reconstructed into pseudo-3 dimensional plots.  
b) The pseudo-3 dimensional surface plot displays peaks and troughs representing a 
peristaltic pressure wave as it progresses from the proximal oesophagus (background) 
to the LOS after-contraction (foreground). The contour plot of the same swallow is 
superimposed at the top of the figure. This demonstrates how the 3 dimensional data 
can be re-presented using concentric rings at 10 mm Hg intervals to depict changes in 
pressure.   
x-axis = time 
y-axis = position (down catheter) 
z-axis = pressure amplitude 
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Figure 1.7 High-resolution manometry spatiotemporal plot of normal peristalsis. The 
trace depicts oesophageal pressure activity from the pharynx to the stomach via 
pressure sensors spaced at <2 cm intervals. Recordings can be analysed and presented 
either as line plots (right; similar to conventional manometry) or spatiotemporal plots 
(left). The spatiotemporal plot presents similar information as the line plots: Time is 
depicted on the x-axis, distance from the nares on the y-axis and amplitude on the z-
axis. Pressure is represented as changes in colour (legend left). The virtual “e-sleeve” 
application provides measurement of LOS pressure and relaxation in the 
spatiotemporal plot, and is represented as brown in the line plot.  
 
The resultant HRM trace of a normal swallow demonstrates the segmental functional 
anatomy of the oesophagus. Deglutitive inhibition is seen as the synchronous 
relaxation of the UOS and LOS. This is followed by a coordinated peristalsis with 
increasing pressure duration as it passes distally.  (Images acquired by 36-channel SSI 
Manoscan 360). 





Table 1.2 Comparison between Conventional and High Resolution Manometry.  
 
It is interesting to note that with HRM, the spatio-temporal plot can be easily 
interpreted not only by the in-experienced user but also by the patient. With a brief 
description of oesophageal anatomy and function (e.g. ‘here is the top of the gullet, 
the bottom of the gullet and the beginning of stomach…and here is your swallow as it 
progresses down’), patients often enjoy watching their swallow initiate, progress and 
terminate. This ‘personal’ appreciation of oesophageal function helps not only with 
tolerability of the test but can also be therapeutic in itself as patients can ‘see’ where 
the problem lies (or does not), and take ownership of their own disease (or be 
convinced of the lack thereof). This is especially important in functional pathology, 
such as rumination128 (Figure 1.8), where patients often require persuading that the 
problem is not organic, rather it is a functional, subconscious yet learned behaviour 




Figure 1.8 Rumination syndrome. 24 year old female final year medical student with 
regurgitation, vomiting and weight loss. Recurrent ‘vomiting’ and regurgitation was 
affecting her quality of life; she was unable to eat in public and she was considering 
postponing her medical school exams. Endoscopy was normal. There was no 
improvement with acid reducing medication. HRM to water swallows was normal 
(left panel). Following 250 ml milkshake there were episodes of sharp increases in the 
intra-gastric pressure with concurrent relaxation of the upper oesophageal sphincter 
after which the milk shake entered her mouth (right panel). 
The aim of Biofeedback therapy is for diaphragmatic breathing to overwhelm the 
abdominal muscles and diaphragm. With perseverance, this newly learned behaviour 
should itself become subconscious and occur effortlessly during any rumination-
provoking event. 
(Reproduced from Sweis et al. Gut 2010128) 
 
Rumination syndrome is a benign, voluntary yet subconscious behaviour which 
occurs as a consequence of learned anticipation to gastric distension. Biofeedback 
therapy with diaphragmatic breathing provides the best prognosis. In this case 
following biofeedback therapy (administered by Rami Sweis) the patient’s symptoms 
completely resolved, she gained weight and was able to complete her final medical 
school exams with merit. 
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1.5.4 High Resolution Manometry classification of 
oesophageal pathology 
Classification of pathology using HRM has advanced the understanding of disease in 
the human oesophagus. This classification has been re-visited on several occasions 
over the last 5 years, each with a subtle advance in definitions and terminology. This 
process has been largely pioneered by the Chicago group at Northwestern University, 
USA.129-131 This HRM classification focused on the HRM system developed by Sierra 
Scientific Instruments Inc. (Los Angeles, CA, USA). Normative data have been 
derived using the Manoscan 36 channel circumferential solid-state hardware and 
Manoview analysis software (Sierra Scientific Instruments Inc.) The principles of 
analysis were intended to generalize to any HRM system. Since studies in this thesis 
have been performed, two further updated versions of the classification have emerged 
with few subtle changes.118,132 
 
The normal swallow was described in Figure 1.7. A more detailed assessment of 
analysis will be described in detail in the Methods Chapter 2 as well as in Chapters 5 
and 6. Oesophageal bolus transport depends on the balance of resistance through the 
OGJ, (intra-bolus pressure; IBP) and oesophageal closure pressure behind the 
bolus.133,134  
 
Unlike with conventional manometry, HRM classification considers the OGJ before 
the oesophageal body, with the rationale that any pathology within the OGJ will 
influence what happens proximally. Therefore an assessment of deglutitive OGJ 
relaxation and OGJ pressure morphology (i.e. presence of a hiatus hernia) need to be 
described first. 
I. OGJ classification 
OGJ relaxation 
Incomplete deglutitive OGJ relaxation is an essential feature in the diagnosis of 
achalasia. There is no accepted method for defining incomplete OGJ relaxation using 
conventional manometry. The Chicago group have shown that the optimal parameter 
for quantifying this measurement is the integrated relaxation pressure (IRP).134 IRP is 
defined as the ‘lowest mean eSleeve pressure for four contiguous or non-contiguous 
seconds within the relaxation window’. The relaxation window is a period of OGJ 
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relaxation that occurs after initiation of the pharyngeal swallow and terminates at the 
arrival of the peristaltic wave front (Figure 1.9 and Methods Chapter 2). This metric is 
automatically calculated by the proprietary software over 10 seconds from initiation 
to termination of swallow. The upper limit of normal is 15mmHg (with single water 
swallows). IRP has been shown to have a 98% sensitivity and 96% specificity for 
differentiating achalasia from control subjects, and is more accurate than the 3 second 
nadir relaxation pressure of previous calssifications.134 
 
 
Figure 1.9 Integrated relaxation pressure (IRP). Deglutitive relaxation window (black 
box) within a normal swallow from which the IRP is calculated (white boxes). This 
differs from the 3 second nadir pressure of previous classifications (dotted white box).  
(Figure reproduced from Ghosh et al Am J Physiol Gastrointest Liver Physiol 2007134) 
 
OGJ morphology 
With conventional manometry, there is little appreciation for the structural 
components that make up the OGJ. HRM can differentiate two sphincteric intra-
luminal pressure changes: intrinsic LOS (iLOS) + surrounding crural diaphragm 
(cLOS) (see section 1.3.1).  The cLOS component is most clearly visible in 
inspiration. By localising iLOS and cLOS, HRM can define three OGJ morphologic 
subtypes. 131 (Figure 1.10) 
Type I:  The 2 components overlap and there is no separation between iLOS and 
cLOS. This morphology is most commonly seen in healthy individuals 
Type II:  There is minimal but discernible separation between the iLOS and and cLOS 
(≤2 cm). This is defined as an intermediate condition between normal and a 
hiatus hernia (HH). 
Type III: The iLOS and cLOS are separated by >2 cm; the HRM signature of HH.  
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Figure 1.10 HRM with three OGJ morphologic subtypes.  
Type I (normal) 
Type II (≤2cm separation between LOS and crural diaphragm)  
Type III (>2cm separation between LOS and crural diaphragm).  
(Figure reproduced from Pandolfino et al Am J Gastro 2007 131) 
 
II. Oesophageal classification 
Oesophageal segment contraction  
(for more detailed definitions of terms please refer to Chapter 5) 
A swallow is categorized first by highlighting a 30 mmHg isobaric contour which 
circumscribes all pressure segments within the peristaltic wave that are at or above 
30mmHg. The software then calculates other HRM-specific parameters which help 
describe important swallow characteristics.  
Intra-bolus pressure (IBP) - the compartmentalised pressure between the distal 
contractile segment below the bolus and above the OGJ 
Contractile Front Velocity (CFV) - a measure of peristaltic velocity derived from 
the 30 mmHg isobaric contour as it circumscribes the distal (smooth muscle) 
contractile segment  
Distal contractile Integral (DCI) - a measure of contractile vigour within the distal 
peristaltic segment 
 
These novel metrics are essential for defining pathology in the oesophageal body and 
are the basis for the new HRM classification. Normal values were referenced to 
atmospheric pressure and the 30 mmHg isocontour. Furthermore, non-specific 
terminologies from conventional manometry classification such as ‘peristaltic 
dysfunction’ and ‘ineffective oesophageal dysmotility’ are abandoned. 
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I. Classification of individual swallows 
• Normal    
<3 cm defect (break) in distal segment 
CFV < 8 cm s-1 
  IBP < 15 mmHg 
  DCI < 5000 mmHg s-1 cm-1 
• Hypotensive peristalsis (Figure 1.11) 
Normal appearing peristaltic wavefront with a defect in the distal 
segment of ≥3cm  
(defined as ineffective oesophageal dysmotility with conventional 
manometry) 
Absent peristalsis (Figure 1.12)  
No propagating contractile wavefront  
  <3 cm contractile activity in >30 mmHg isobaric contour 
• Hypertensive peristalsis   
Normal appearing wavefront propagation 
  DCI > 5000 mmHg s-1 cm-1    
• Spasm  (Figure 1.14B) 
CFV ≥ 8cm s-1 
• Elevated IBP  (Figure 1.14A) 
IBP > 15 mmHg  
• Pan-oesophageal pressurisation (Figure 1.13) 
Oesophageal compression from UOS to OGJ with IBP >30 mmHg  
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II. Classification based on all (water) swallows during the study 
Following 10 swallows of 5ml of water, classification is then divided into those with 
impaired OGJ relaxation  and those with normal OGJ relaxation  
 
1) Impaired OGJ relaxation - (IRP ≥15 mmHg) &/or elevated IBP (≥15 mmHg) 
Achalasia (Figure 1.13) 
Classic achalasia 
Mean IRP ≥15 mmHg, absent peristalsis 
Achalasia with oesophageal compression 
 Mean IRP ≥15 mmHg, absent peristalsis 
 Pan-oesophageal pressurization with ≥20% of swallows 
Spastic (Vigorous) achalasia    
Mean IRP ≥15 mmHg, absent peristalsis 
 Spasm (CFV >8 cm s-1) with ≥20% of swallows 
Functional OGJ  obstruction (See figure 1.14A) 
 Normal CFV 
 Mean IBP >15 mmHg with ≥30% of swallows compartmentalized above OGJ 
(suggests obstruction at the OGJ) 
 
2) Normal OGJ relaxation (IRP <15 mmHg) and normal IBP 
Absent peristalsis   
100% swallows with absent peristalsis  
Hypotensive peristalsis 
Intermittent  ≥30% of swallows with hypotensive or absent peristalsis 
Frequent  ≥70% of swallows with hypotensive or absent peristalsis 
Hypertensive peristalsis  
Normal CFV, mean DCI >5000 & <8000 mmHg s-1 cm-1  
(and/or hypertensive LOS aftercontraction >180 mmHg) 
Spastic nutcracker   
Normal CFV, mean DCI > 8000 mmHg s-1 cm-1  
Distal oesophageal spasm (Figure 1.14B) 
Spasm (CFV > 8 cm s-1) with ≥20% of swallows 
Segmental spasm  limited to S2 or S3 
Diffuse spasm involving both S2 and S3 
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Figure 1.11 Break in peristaltic wave front of >3cm. In this case it is within the proximal oesophagus which is known as the proximal transition 
zone (PTZ).  (Reproduced from Ghosh et al. NGM 2008135) 
 
 
Figure 1.12 Absent peristalsis. The only visible pressure measurement identifiable within the 30 mmHg isobaric contour is <3cm in length. 
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Figure 1.13 HRM achalasia subtypes. Type I, Classic Achalasia (left); Type II, Pan-oesophageal pressurisation (middle); Type III, Spastic (or 
Vigorous) achalasia   




Figure 1.14 Functional OGJ obstruction vs. Diffuse Oesophageal Spasm (DOS). 
A) Functional obstruction at the OGJ with raised intra-bolus pressure. B) DOS with rapid CFV is attributable to spasm as the entire distal 
oesophagus is contracting simultaneously.  
(Figure reproduced from Pandolfino et al. NGM 2009131) 
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With the introduction of this ‘new’ classification, Pandolfino et al presented the 
distribution of oesophageal motor disorders amongst 396 patients presenting with 
primary symptoms of dysphagia. (Table 1.3) It is in interesting to note that compared 
to the 403 patients in Dekel et al (Table 1.1), the Chicago group describe nearly 25% 
less ‘normal’ findings with the use of HRM. This is likely because of the improved 
technology, new metrics and methodology; however it is difficult not to question the 
accuracy of these findings. With the improved sensitivity of this technology, could 
‘normal’ oesophageal function have erroneously been classified as ‘pathology’ 
regardless of its relation to patient symptomatology? This ‘new’ classification (as well 
as that using conventional manometry) is based on 5 ml water swallows in the supine 
position. This is not likely to trigger symptoms yet any apparent dysmotility event is 
taken into account. Unless patient symptoms are reproduced, questions remain 
regarding the relevance of ‘disease’ identified. It is on this premise that HRM studies 




Table 1.3 Summary of findings from 396 patients presenting with symptoms of 
dysphagia at Northwestern University Oesophageal lab in Chicago, USA.  
(Adapted from Pandolfino et al Am J Gastro 2008130) 
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1.6 Introduction of physiological challenges in High 
Resolution Manometry studies  
Studies which combine standard manometry and multiple intra-luminal impedance 
technology (MII) at various body inclinations and swallowed bolus viscosities (used 
as surrogate measures of increased workload on the oesophagus) have shown that at 
lower inclinations both liquid and viscous materials travel slower while the distal 
oesophageal amplitude increases.137,138 Furthermore TLOSRs and gas reflux events 
are suppressed in the supine position in both healthy volunteers and in patients with 
mild-moderate reflux disease.139 The effects of position on oesophageal peristalsis and 
lower oesophageal sphincter pressure assessed by conventional manometry alone 
have been less consistent.  
 
HRM and video-fluoroscopy have been applied to study the effect of position and 
bolus consistency on oesophageal function.57 No effect of position on LOS pressure 
was found in the thin, healthy volunteers used in the study. In contrast peristaltic 
pressure increased and velocity decreased as subjects moved from the upright to the 
supine position. Similarly, peristaltic pressure increased and velocity decreased 
progressively as subjects undertook dry, water and solid swallows respectively.57 
These observations confirm findings from studies which combined manometry and 
impedance studies (described above) which show that oesophageal function is not 
stereotyped but responds to the workload required for effective bolus clearance.137-139  
 
Similar to standard manometry, HRM normal values have been established for 
peristalsis and the OGJ using small volumes of water in the supine position.50,125 
However, HRM can facilitate the assessment of the dynamics of swallows in different 
positions, food consistency (solids) and volumes. In theory, such activities should 
provide a better physiological assessment of swallow as they act as a stressor to the 
oesophagus. Understanding the oesophageal response due to ‘physiological 
challenges’ is likely to be of clinical importance because most patients complain of 
swallowing problems, regurgitation or chest pain during eating or drinking (i.e. 
increased workload on the oesophagus) and during the postprandial period. Similar 
techniques have been reported to improve the sensitivity of investigation for 
functional and structural pathology (strictures, rumination, achalasia).126,140,141 
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Therefore this is likely to have an impact on diagnostic accuracy as the emphasis is 
shifted from identifying abnormal pressure events (as is currently performed with 
standard and HRM) to inducing and targeting symptoms that are relevant to the 
patient and identifying dysmotility events that are related to these symptoms. 
However the use of physiological challenge swallows (such as drinking freely, 
swallowing solids and eating) have not entered routine clinical practice probably 
because of the difficulty in interpreting the more complex pressure activity, the 
absence of normative values and the lack of a standardised methodology. This 
challenge will be addressed in this thesis. 
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1.7 Management of Reflux disease and dysphagia 
1.7.1 Reflux disease 
Proton Pump Inhibitors (PPIs) reduce gastric acid secretion and improve typical 
reflux symptoms in the majority of individuals; however 10-40% of patients have a 
poor response.94 The majority (up to 70%) have endoscopy negative reflux disease 
(ENRD; positive oesophageal acid exposure and/or positive reflux-symptom 
association) or functional heartburn (FH; negative oesophageal acid exposure and 
reflux-symptom association yet with typical symptoms of reflux).  In a systematic 
literature review of seven trials (1854 patients), Dean et al found that the pooled 
response rate to once daily PPIs at 4 weeks was 37% in ENRD.142 In contrast, those 
with erosive oesophagitis (EO; patients with endoscopic evidence of oesophagitis) 
account for only 30-40% of the GORD population;143 however there is at least 15% 
discrepancy between symptom resolution and mucosal healing, and up to 50% of 
patients with EO in whom symptoms recur while taking a PPI show no relapse of 
oesophageal inflammation.94 In large comparative studies, PPIs produced endoscopic 
healing in over 80% (over 90% with esomeprazole)144 while symptomatic relief was 
achieved in over 56% (up to 76% with esomeprazole)142,145 even after EO was healed 
macroscopically. In general, the proportion of ENRD patients responding to a 
standard dose of PPI is approximately 20–30% lower than in EO.94 Therefore, 
distinguishing EO, ENRD, FH and those whose symptoms are not reflux-related is 
important to target appropriate therapy, especially if anti-reflux surgery is under 
consideration. 
 
Patients with Barrett’s oesophagus have more severe oesophageal dysmotility than 
those with other forms of reflux disease or healthy controls.146-149 In addition, 
oesophageal sensitivity to (refluxed) acid is reduced and patients swallow less 
frequently therefore leading to delayed acid clearance.2 This combination of motor 
and sensory dysfunction is linked to increased severity of acid exposure,51 and in 
particular, highly prolonged reflux events that predispose to mucosal damage.150 
Patients with Barrett’s who have symptoms tend to respond well to acid reducing 
medication. On the other hand, patients with ENRD and FH may have borderline 
results on ambulatory reflux studies but have severe symptoms which respond very 
poorly to acid suppression.151 
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A ‘treat then test’ policy has long been a standard diagnostic technique for GORD in 
clinical practice. In the absence of alarm symptoms, the previous paragraphs have 
described how PPI therapy may improve symptoms in EO and ENRD. Those with 
typical symptoms of heartburn and chest pain are more likely to respond to PPI than 
those with volume regurgitation and atypical symptoms (cough, LPR).2,97,152,153 In 
2000, Fass et al. showed that the omeprazole test is as sensitive as ambulatory pH 
monitoring in diagnosing GORD in  patients with EO.154 Wang et al155 evaluated the 
accuracy of a using PPI treatment as a diagnostic test. They performed a computerized 
literature search using PubMed, MEDLINE, EMBASE, CINAHL, and Cochrane 
Controlled Trials Register databases for relevant articles published between 1966 and 
May 2004. They found that overall the PPI test had an acceptable sensitivity of 80% 
and specificity 74% in GORD patients with non-cardiac chest pain; however the 
dilemma of how to define the cause of symptoms and determine effective therapy in 
those with non-cardiac chest pain who do not respond to PPI therapy remains a 
challenge.  
 
Apart from those with ENRD and FH, reasons for why patients may fail to respond to 
PPI include poor or non-complinace,143 increased sensitivity to acid (and non-acid) 
refluxed material, sensitivity to distension within the oesophagus, anxiety and 
psychosocial stress.143,156 Contributing pathologies include disturbed bolus clearance, 
oesophageal dysmotility24 and behavioural disturbances157 (including rumination; 
Figure 1.8). Before embarking on further investigations, conservative management 
strategies are usually considered. Compliance and adherence to PPI therapy are 
usually addressed first. It is advised that patients take PPI twice daily, 30 min before 
breakfast and dinner for maximal efficacy. If this fails,  the PPI could either be 
doubled or changed.158 The only real lifestyle modifications shown to have a positive 
effect include weight loss and elevation of the bed head.159 Chewing gum after meals 
has shown promise.160 Although there is little evidence that altering specific foods 
works, reducing calorie content improves reflux and symptoms while reducing fat 
content does not improve reflux but it does reduce symptoms by up to 40%.161 The 
addition of a histamine 2 receptor antagonist (H2RA) provides a relative benefit of 
41% compared to placebo and it is now common practice to introduce ranitidine 
before bedtime to tackle nocturnal reflux.143 However it is suggested that the efficacy 
of H2RA is reduced in the long term due to development of  tolerance.162  
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Alginate antacid (e.g. Gaviscon Advance) has up to 60% relative benefit compared 
with placebo, and is as effective as H2RA.163 Alginate has a number of features that 
may protect the patient from both acid and non-acid reflux. As it is highly viscous, it 
forms a ‘raft’ that floats above the gastric contents and forms a plug which acts as a 
physical barrier to reflux.164-166 Also antacids within neutralize gastric acid more 
rapidly than PPIs.167 Furthermore, the alginate binds other noxious substances such as 
pepsin and bile, thus reducing their damaging effect on mucosa.168,169   Alginate 
containing antacids are normally consumed after meals and can be used in addition to 
other therapies (such as PPI). 
 
Reflux suppression can be induced with the GABAB agonist, baclofen (e.g. 5mg tds 
increased to 20 mg tds170). Baclofen is usually used as an adjunct to PPI therapy. It 
has been shown to reduce TLOSRs by 40-60% and reflux episodes by >40%171 and is 
effective even in the presence of a HH.172,173 Unfortunately the central side effect 
profile of Baclofen (e.g. dizziness, somnolence) makes it difficult for many 
individuals to tolerate it in the long therm. 
 
When all else fails, or if the patient chooses not to continue long term medical 
therapy, anti-reflux surgery is an option that may provide a ‘relatively’ more 
permanent solution. Rosenthal et al. showed that out 143 patients, pre-operatively 
88% had refractory GORD and 42% no longer wanted to continue life-long 
medication. In 82% the pre-operative reflux symptoms had disappeared after surgery 
and 94% were very satisfied with the outcome with an excellent resultant quality of 
life.174 However careful patient selection is paramount. Failure evoke any response to 
PPI therapy pre-operatively predicts poor outcome and evidence of pathological 
oesophageal acid exposure on pH testing is crucial.175 Furthermore, manometry might 
also help predict outcome as studies suggest that patients with a normal or raised 
mean LOS pressures pre-operatively are at increased risk for developing post-
operative dysphagia.176 
 
Therefore, in patients with symptoms suggestive of reflux disease, pH testing (with 
manometry) should be performed in those who are refractory to acid reducing (and/or 
other) medication, especially if they are under consideration for anti-reflux surgery. 
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1.7.2 Oesophageal dysmotility 
Unlike with GORD, oesophageal motor disorders are varied and treatment options are 
limited. This is partly because until recently the tools used to investigate them did not 
provide sufficient insight into the patho-physiological mechanisms behind the various 
disorders. Furthermore accurate testing prior to and following medical or surgical 
therapy has been a challenge. Thanks to the advent of recent novel and advanced 
technology, there has been renewed interest in the study of oesophageal function. 
Specifically tools such as HRM are routinely being used to study the efficacy of new 
therapies (medical and otherwise) to treat the many facets of oesophageal dysfunction. 
 
The following review of disease and available therapies mirror the HRM-based 
classification of dysfunction presented above.  
 
I. OGJ pathology 
Hypotensive OGJ pathology is normally linked to GORD. This was discussed detail 
in section 1.7.1. On the other hand, hypertensive and non-relaxing OGJ disease can 




Achalasia is the most commonly diagnosed primary motility disorder and is second 
only to GORD as the most common functional oesophageal disease. It has an annual 
incidence of 0.5-1 per 100 000 with no clear age predilection.177 Achalasia is 
characterised by loss of inhibitory enteric neurons. Its aetiology is unknown but one 
theory is that it is an auto-immune response triggered by a viral infection.177 Its 
manometric signature is impaired LOS relaxation and aperistalsis. Typically achalasia 
presents with symptoms of dysphagia for solids (100%) and for liquids (97%), chest 
pain (74%) and weight loss (60%).26 Investigations usually start with endoscopy 
and/or radiology to rule out anatomical lesions; however endoscopy is only diagnostic 




Figure 1.15 Barium swallows of achalasia. The left panel shows typical features 
(dilated oesophagus with ‘bird’s beak’ OGJ). The right panel is non-diagnostic. This 
is likely because it is seen early, prior to the oesophageal dilatation stage which 
follows prolonged outlet obstruction. (see figure 1.13) 
 
With standard manometry, achalasia is diagnostic in 90% of cases, while with HRM 
using the IRP metric sensitivity and specificity are 98% and 96% respectively.134 
Furthermore, the Chicago group have further subdivided achalasia into 3 subtypes 
each with its own phenotypic response to therapy.136  (Figure 1.13 and Table 1.4). 
Type II, the compression subtype, produced the most favourable outcome to any form 
of therapy (Botulinum toxin, pneumatic dilatation or Heller myotomy). Type I, 
classical achalasia, produced a reasonable response to dilatation and myotomy while 
the spasm subtype exhibited the worst outcome to any form of therapy. When 
compared to corresponding barium findings, it is theorised that Type II is the prequel 
to Type I which develops after a prolonged mechanical outlet obstruction. In this 
regard, it is important to investigate and identify achalasia early to achieve the most 
optimal response to therapy. It is important to note that Type II and III achalasia can 
only be diagnosed with HRM. 
 
 
Table 1.4 Response to therapy of achalasia subtypes: Classical, Compression, Spasm 
(Adapted from Pandolfino et al. Gastroenterology 2008136) 
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A Heller myotomy bisects the circular muscles above (usually 4-6cm), through and 1-
2 centimetres below the LOS into the gastric cardia. Although a raised LOS pressure 
is not a necessary diagnostic feature of achalasia, a study of 200 patients who 
underwent myotomy found that a predictor of post-surgical relief from dysphagia was 
a pre-operative raised LOS pressure.179 A ‘floppy’ (usually anterior Dor) hemi-anti-
reflux procedure is commonly performed to prevent post-operative GORD. One study 
of 43 patients randomised to myotomy with and without Dor fundoplication found 
that GORD occurred in 48% of those without and 9% of those with a wrap.180  
 
B. Structural outflow obstruction 
Eosinophilic oesophagitis (EoE) is an allergic immune T-cell–mediated 
hypersensitivity response leading to eosinophil activation and a fibro-inflammatory 
reaction.181 It is characterised by a dense oesophageal eosinophilia (≥15 eos/high 
power field; HPF) of the oesophageal epithelium with squamous hyperplasia.182 EoE 
can result in any combination of oesophageal symptoms; dysphagia, food bolus 
obstruction, reflux like symptoms or chest pain.183-185 It can manifest at any age but 
peaks between ages 20 and 50 years186 and is more common in males.187 Endoscopy 
can be normal although pathognomic features can sometimes be seen; linear furrows, 
mucosal rings, white exudates and plaques and crepe paper mucosa.183 Although 
diagnosis is not aided by pH monitoring,187 manometry can show features of outflow 
obstruction with a raised IBP/IRP. (Figure 1.14A, 1.16) 
 
A subgroup of EoE exhibit a  response to PPI therapy.188 Although systemic steroids 
lead to good histological and symptomatic response,189 swallowed topical 
corticosteroids (budesonide or fluticason) is now the main-stay of therapy.190-192 Other 
effective, yet less conventional therapies include elimination diets (e.g. six food 
elimination diet193), Leukotriene receptor antagonists (Montelukast)194 and 
oesophageal dilatation.195,196 
 
Other causes of structural outflow obstruction are a fibrotic stricture at the level of the 
OGJ due to chronic reflux (Figure 1.17) or a submucosal tumour (Chapter 7 Figure 
7.2). Therefore all patients with any form of resistance to flow within the oesophagus 




Figure 1.16 Eosinophilic oesophagitis (EoE). HRM of a patient with EoE showing 
outflow obstruction at the level of the LOS after swallowing bread. This is likely due 
to fibrosis which can result in late EoE. Interestingly in this case, water swallows 






Figure 1.17 Fibrotic stricture. 70 year old female with a long history of recurrent 
vomiting and chest pain not relieved with lansoprazole. Endoscopy showed Grade C 
Oesophagitis.  24 hour pH monitoring found evidence of severe GORD with 
pathology in the upright and supine positions as well as a positive reflux-symptom 
association for heartburn. 
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II. Oesophageal body 
 
A. Hypertensive dysmotility 
Nutcracker oesophagus is more common in younger patients, while diffuse 
oesophageal spasm (DOS) is more common in the elderly.115,197  In those presenting 
with non-cardiac chest pain, nutcracker oesophagus is the most common oesophageal 
motor disorder (up to 36%)198 while DOS is the least (<5%).199  It is important to note 
that DOS is not necessarily characterised by high amplitude contractions, rather 
simultaneous contractility in the smooth muscle oesophagus.199 Longitudinal studies 
do not support the concept of progression from nutcracker or DOS to achalasia,200 and 
there is no evidence of an inflammatory process or effect on myenteric neurons.201 On 
the other hand, there may be an imbalance between the excitatory and inhibitory 
innervations of the oesophagus as the numbers of choline acetyltransferase-positive 
myenteric neurones in nutcracker oesophagus are increased.202 Furthermore, studies 
have shown that compared to healthy subjects, DOS, nutcracker oesophagus as well 
as in achalasia exhibit a hypertrophy of the muscularis propria.203 Therefore these 
may all be possible targets for therapy.  
 
Currently only 1/3 of patients with hypertensive oesophageal motor disorders find 
medical therapy to be of benefit,204 although this is likely due to the paucity of 
therapies available and their high side effect profile.  
 
Conservative management 
Patients are normally initially advised to avoid trigger factors; avoid pro-cholinergic 
agents (e.g. caffeine), consume soft foods in order to reduce resistance to bolus 
passage as well as reduce stress and anxiety. In regards to medical therapy, a PPI trial 
and/or pH study should be considered first as there is a clear (yet unexplained) link 
between these conditions and GORD.205-207 If this fails, smooth muscle relaxants are 
commonly tried. Therapies included under this heading are nitrates, calcium channel 
blockers, phosphodiesterase type V Inhibitors, oil of peppermint and botulinum toxin 
injections.  
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Smooth muscle relaxants 
Nitrates have been shown to reduce contraction amplitude and increase the duration of 
swallow, thus promoting normal peristalsis and reducing symptoms.208-210 They 
appear to be most effective in patients with no evidence of GORD.209 Unfortunately 
many patients are unable to tolerate nitrates due to the side effects (dizziness and 
headaches), although patients with good response to short acting preparations seem to 
do well also on long-acting preparations.208,209 Calcium channel blockers (Table 1.5) 
reduce LOS pressure (35%) and peristaltic amplitude (60%) within 20-30 min of oral 
ingestion, and these effects can last up to 30 min. Nifedipine (20mg) has a greater 
effect than all other calcium channel blockers and Diltiazem has the least effect on 
LOS pressure or peristaltic amplitude.211,212 On the other hand, Richter et al showed 
that the effect of nifedipine is almost disappeared by 6 weeks.213 Furthermore, Richter 
and others have shown that improvement could not be correlated with changes in 
either LOS or oesophageal amplitude214 and that there is little or no benefit on 
symptom control.215,216 As with nitrates, the high side effect profile (hypotension, 
bradycardia, paedal oedema) reduces long term tolerability.  
  
 
Table 1.5 Calcium channel blockers. Summary of studies showing the degree of 
reduction in oesophageal contractility before and after administration of calcium 
channel blockers in patients with hypertensive oesophageal motor disorders. 
 
 
Phosphodiesterase V inhibitors (Sildenafil) inhibit the breakdown of nitric oxide in 
the synaptic cleft. This increase in intracellular nitric oxide induces smooth muscle 
relaxation. Sildenafil has been shown to improve oesophageal motility in nutcracker 
oesophagus, hypertensive LOS, focal and diffuse oesophageal spasms by reducing 
LOS resting pressure, prolonging the duration of LOS relaxation and reducing distal 
oesophageal contraction amplitude.217-220 At St Thomas Hospital in London, 
Sildenafil has been shown to improve symptoms.221 (Figure 1.18) 
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Figure 1.18 Focal spam treated with Sildenafil. 63 year old lady with central chest 
pain on swallowing. Left panel: baseline HRM trace after swallowing 5 ml of water 
showing focal mid-oesophageal spasm which reproduced her typical chest pain 
symptoms. Right panel: 50 minutes after administering 25mg Sildenafil, peristalsis 
normalized and symptoms disappeared even when she was challenged with solid 
swallows. 
(Reproduced from Fox M, Sweis R et al NGM 2007221) 
 
Botulinum toxin injected endoscopically into the LOS and/or distal oesophageal body 
can be used to treat stubborn hypertensive oesophageal motor disorders. This can 
improve or even relieve symptoms in >50% of patients for up to 1 year.222,223 A recent 
randomised controlled study showed that patients presenting with symptoms of 
dysphagia (rather than chest pain) had the most benefit.224   
 
Pain modulators 
The benefits of tricyclic anti-depressants, serotonin re-uptake inhibitors and other 
antidepressants are well established in functional GI disease, including the treatement 
unexplained non-cardiac chest pain.91,225-229 Although this group of drugs have no 
effect on oesophageal function per se, it is theorised that they reduce symptoms due to 
their effect on visceral sensitivity as they target the central nervous system and 
sensory afferents. Their influence on anxiety and depression which often co-exist with 
chronic functional syndromes is also beneficial. 
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Oesophageal dilatation 
Rigid and pneumatic dilation can be used in patients with DOS whose symptoms 
remain refractory. Although clinical trials are lacking, case series show that at least 
half have a good outcome although 1:20 have an increased risk of perforation or 
bleeding.230-232 At St Thomas’ Hospital in 1992, 20 out of 61 patients with DOS had 
pneumatic dilatations. 14 had a good response, 5 had a poor response and 1 had 
perforation. Of those with poor response, 3 proceeded to full length myotomy, 2 of 
whom had relief of symptoms.230  
 
Surgery 
A small group of patients with severe intractable symptoms might proceed to surgery. 
A procedure similar in principle to a myotomy for achalasia extends the dissection of 
the hypertrophied circular muscles as far up as the proximal transition zone. This is 
often also followed by an anti-reflux procedure to prevent post-operative GORD. 
Although there are no controlled studies, numerous case series have been reported 
since the 1960’s. Results are less good than for achalasia but recent reports describe 
good long-term functional outcomes in up to 80% of cases.233-235  
 
B. Hypotensive dysmotility 
Conservative management 
This group of oesophageal motor disorders includes those in whom there is a >3 cm 
break in contractility as well those with absent peristalsis. Although both are 
commonly associated with GORD, the latter can include syndromes such as 
autonomic neuropathy (e.g. diabetes) and connective tissue disorders (e.g. 
scleroderma). Unfortunately response to medical or surgical therapy is poor and 
conservative management is often the best that can be offered. Commonly patients are 
advised to eat upright, chew thoroughly, use liquids liberally (especially carbonated 
drinks) and avoid ‘difficult’ food items such as steak and dry bread. 
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GORD therapy 
Dysphagia is present in 20-50% of patients referred for anti-reflux surgery, many of 
whom have hypotensive dysmotility.176,236,237 In one study of 163 GORD patients 
about to undergo anti-reflux surgery, dysphagia was relieved in all but 5 of the 60 
who had pre-operative dysphagia.176 However, prior to embarking on surgery, an 
empirical trial with optimal doses of acid reducing medication should be considered 
with pH testing in those who do not respond (treat and test policy; Section 1.7.1). 
 
Contractility stimulants 
It is theorised that patients with hypotensive dysmotility have an increased activity of 
nitric oxide synthase within the smooth muscle, possibly with muscle fibre loss 
(myopathy) and replacement with fibrous tissue.202 These may be useful targets for 
therapy although in the case of muscle fibre loss stimulation mechanisms are unlikely 
to be effective.  
 
Domperidone (dopamine agonsit) is a common drug prescribed in the outpatient 
setting to treat perceived reduced gut motility disorders. Very few studies have 
assessed oesophageal emptying of solids following domperidone. A study of 12 
patients with diabetes mellitus and autonomic neuropathy showed that Domperidone 
did not increase solid oesophageal emptying compared to controls.238  
 
Erythromycin, a motilin agonist, is another prokinetic often prescribed. In a study of 
45 patients with diabetes mellitus, Chang et al showed that the mean transit time of a 
radionucleotide liquid and solid meals dropped from 9.32±1.12 to 6.28±0.91 s 
(p<0.05) after receiving a 2 week course of erythromycin.239 Chrysos et al showed 
that in patients with GORD, iv erythromycin improved oesophageal peristalsis and 
function by increasing LOS pressures as well as contractility and duration of 
swallows.240 
 
Bethanechol (Urocholine) is a direct-acting muscarinic receptor agonist which 
enhances the effect of acetylcholine directly at the postganglionic cholinergic 
receptors. It has been shown to increase LOS pressure and improve oesophageal 
contractility in healthy subjects.241 More recently in a study of 7 patients with 
hypomotility, Agrawal et al showed that bethanechol significantly increased distal 
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oesophageal contractions and bolus transit times for both liquid and solid swallows up 
to 40 minutes after ingestion.242 
 
A break of >3 cm in the 30 mmHg isobaric contour defines hypotensive 
dysmotility.131 It is not uncommon for such a break to occur in the proximal 
oesophagus. If consistent at the PTZ (Figure 1.11) this can lead to bolus escape and in 
turn symptoms (dysphagia, chest pain). In 2007 Fox et al showed that a 7 day course 
of Tegaserod, a partial 5-hydroxytryptamine 4 receptor agonist with prokinetic effects 
on the gastrointestinal tract, promoted mid-oesophageal contractility and shortened 
the proximal break in contractility thereby improving coordination and symptoms. 
With synchronous manometry and video-fluoroscopy, a radio-labelled bolus which 
had remained in stasis within the PTZ at baseline was seen to progress after therapy 
with ease.36 Unfortunately, in 2007 the USA Food and Drug Administration withdrew 
Tegaserod after concerns that it may increase the risk of heat attach and stroke. This 
decision was based on 13 cardiovascular events out of 11,614 who were taking the 
drug. Tegaserod can still be obtained on a named patient basis. 
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1.8 Aims and objectives 
With the advent of new technology (e.g. Bravo and HRM) there has been a resurgence 
of interest in the study of oesophageal function and disease. This technology provides 
a better understanding of the dynamic function and structure of the oesophagus and 
LOS. It also offers the opportunity to test the efficacy of new drugs and surgical 
techniques which was previously a challenge or even impossible. On the other hand, 
such sensitive techniques run the risk of reducing specificity as normal function can 
be perceived as being pathological. In order to differentiate these and to improve 
outcome, therapy needs to be directed at symptom-inducing dysfunction. (Figure 
1.19) It would be wrong to proceed to anti-reflux surgery in a patient with borderline 
pH measurements based on only one 24 hour pH study. Similarly to initiate medical 
or surgical therapy based on a few aberrant water swallows using manometry is 
unsafe. Ultimately the diagnosis reached is only as good as the tools and methodology 
used to define it.  
 
The purpose of studies in this thesis is to optimise the utility of advanced technology 
in oesophageal physiology by reproducing normal behaviour during pH and 
manometry testing. Advances in oesophageal physiology that will be explored in this 
thesis are:  
1. Prolonged wireless pH monitoring  




Figure 1.19 Therapeutic algorithm; therapy should target dysmotility associated with 
symptoms rather than any dysmotility event that may arise. 
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Bravo; Wireless pH monitoring 
NICE guidelines suggest that wireless pH monitoring should be reserved only for 
those who are intolerant of the nasal catheter.109 Wireless pH monitoring is available 
at only a few tertiary referral centres mostly for patients who are intolerant the nasal 
catheter. It is also increasingly used to study those with negative catheter-based pH 
studies yet ongoing typical symptoms.  
 
The aims of studies using Bravo in this thesis will be: 
1) To examine the tolerability and diagnostic yield of prolonged (48 hour) 
wireless pH monitoring in patients who failed standard (24 hour) nasal pH-
studies. 
2) To investigate whether prolonged (up to 96 hour) wireless pH monitoring 
improves the diagnosis in patients with ongoing symptoms suggestive of 
GORD but with negative standard (24 hour) catheter-based pH results.  
 
High Resolution Manometry 
With HRM although more physiological testing can be performed, this has not yet 
entered routine clinical practice. To induce relevant symptoms by reproducing normal 
eating and drinking is a novel concept which has not yet been assessed nor 
standardised.  
 
The aims of studies using HRM in this thesis are:  
1. To assess the effects of changing body position, bolus consistency and bolus 
volume (physiological challenge swallows) on oesophageal function in healthy 
volunteers and in turn to produce normative values. 
2. To assess the inter-observer agreement for ‘physiological challenge’ swallows 
in health. 
3. To assess the efficacy of novel methodologies, metrics and normative values 
acquired in health on the diagnostic yield and post-therapy outcome of patients 
presenting with typical oesophageal symptoms (reflux and dysphagia). 
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Chapter 2 
Methods and analysis 
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2.0 Introduction 
The methodologies described in this chapter are universal to all studies performed in 
this thesis. Variations or additions for individual experiments will be described in the 
corresponding chapters. Routinely patients will have had manometry performed in  
advance of the pH studies; however to follow the sequence of studies presented in this 
thesis, methodology for ambulatory pH testing will be presented first.  
 
Patients included in this thesis were recruited from the same pool of patients referred 
to the Oesophageal lab for the investigation of heartburn, regurgitation, chest pain and 
dysphagia as the primary presenting complaint. Referrals were received from within 
the hospital, the London area, Kent and sometimes beyond as the Oesophageal lab at 
St Thomas’ hospital is considered to be a tertiary referral centre of excellence.  
 
Methodology for the insertion and analysis of catheter-based and wireless pH 
monitoring83,85,103 as well as for the high resolution manometry36,125,243  are 
standardised and clearly described in the literature. The introduction of ‘physiological 
challenge swallows’ has also been explored in various formats using and 
technologies36,137,244,245 but have never been performed using the methodology and 
analysis techniques presented in this thesis. The intent was to replicate normal facets 
of behaviour while at the same time reproducing earlier ‘non-physiological’ studies 
for comparison.121,130,246,247 
 
2.1 Catheter-based pH Studies 
(Appendix 1 and 2) 
 
Patients with typical reflux symptoms of heartburn, regurgitation and chest pain were 
recruited from the routine referral pool. A thin (3mm) pliable catheter with at least 
one antimony pH sensor (Slimline™, Medtronic, Inc., Shoreview, MN) was 
calibrated at 25°C in pH 7.01 and pH 1.07 buffer solutions as per the manufacturer’s 
protocol (Medtronic Inc., Shoreview, MN). The LCD screen on the recorder provides 
a continuous pH reading to aid this process.  
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After numbing the nares and pharynx with up to 10 ml of Xylocaine spray (effects of 
which lasts no more than 10-20 minutes), the catheter was passed trans-nasally 
through the oesophagus while asking the patient to sip water through a straw to aid its 
passage. Gastric acid was detected on the receiver screen once the sensor reached the 
stomach. At this point the catheter was drawn back into the oesophagus and 
positioned so that (by convention) the pH sensor lies 5 cm proximal to the superior 
aspect of the manometrically determined LOS. The catheter was then connected to the 
portable digital data recorder (Digitrapper pH400, Medtronic, Inc., Shoreview, MN), 
and secured to the side of the face and neck with tegaderm. (Figure 2.1) The recorder 




Figure 2.1 Catheter-based pH monitoring. Typical placement and position of the 
nasal catheter for ambulatory pH monitoring and manometry. 
 
Patients were always provided with a diary to record symptoms, meal/snack start and 
finish times, changes in position (upright and supine) and the occurrence of 
symptoms. (Appendix 2) Although these events could also be recorded directly onto 
the digital device with up to 3 buttons pre-assigned to the patient’s unique symptom 
combination (e.g. heartburn, regurgitation, chest pain), a dual record of events (paper 
and electronic) was always used to minimise the risk of human error. Patients were 
recommended to pursue their normal daily activities and diet. In order to eliminate 
swallow-associated pH artefacts, patients were instructed not ingest acid-based foods 
and fluids such as fruits, citrus products, fruity and carbonated drinks or alcohol. Tea 
and coffee were only permitted if milk was added.  
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 Patients were required to return after 24 hours for catheter removal. Information 
collected from the device was then downloaded onto the proprietary software 
(Polygram net) in preparation for analysis. A new catheter was used for every patient.  
 
Dual channel catheters with an additional pH sensor located 15cm proximal to the 
LOS were sometimes used if patients had proximal or atypical symptoms (e.g. 
laryngo-pharyngeal reflux or cough). Although patients with atypical symptoms were 
not excluded, typical symptoms of reflux (heartburn, regurgitation or chest pain) were 
required to be the primary presenting complaint to fulfil inclusion criteria for studies 
in this thesis. For the purpose of studies in this thesis, only data from the sensor at 
5cm proximal to the LOS was analysed. 
2.2 Wireless pH Monitoring (Bravo®) 
(Appendix 3 and 4) 
 
All patients recruited for Bravo studies presented in this thesis were selected from the 
same pool of those referred to the St Thomas’ Oesophageal lab with typical symptoms 
of reflux (heartburn, regurgitation, chest pain with/without dysphagia). The selection 
process for Bravo patient recruitment adhered to guidelines set forth by NICE.102 
Apart from intolerance to the catheter or re-referral for ongoing symptoms following 
negative catheter-based studies, there was no bias in the selection of patients for 
Bravo compared to the catheter-based studies. 
2.2.1 Bravo calibration 
The Bravo capsule is oblong in shape; dimensions of 6.0 x 5.5 x 25 mm. It consists of 
an antimony pH electrode and reference electrode located on the distal tip as well as 
an internal battery and transmitter contained within the epoxy-coated capsule. (Figure 
1.5 and 2.2). The pH capsule sends a signal to the receiver through a radio frequency 
signal which is in the unregulated 433 MHZ band. 
 
The capsule was prepared in the oesophageal lab several hours prior to endoscopy. 
This 15-20 min procedure was routinely performed by the Oesophageal lab 
technicians. In accordance with the manufacturer’s protocol (Medtronic Inc., 
Shoreview, MN), the capsule was first activated by a magnetic switch and soaked in a 
 80 
pH 7.01 solution for 10 minutes before  being placed into a pH 1.07 buffer solution at 
25°C to complete the calibration process. The capsule and receiver were checked to 
confirm accurate signal capture and transmission of data.  
 
2.2.2 Bravo capsule insertion 
After an overnight fast all subjects were first required to visit the oesophageal lab 
where a detailed discussion regarding the Bravo technique and risks associated took 
place. Also instruction regarding diary card recording and Bravo operating instruction 
was provided. The patient was then sent to the endoscopy unit where the procedure 
was discussed again including the endoscopy technique and all questions were 
answered prior to being asked to sign the consent form for the procedure. 
 
Gastroscopy was performed in the left lateral decubitus position, usually under 
conscious sedation.  Mean doses for sedation (midazolam 7mg (0-10mg) and fentanyl 
67 mcg (0-150)) were somewhat higher than for diagnostic gastroscopy (midazolam 
4mg (0-5mg)) because the majority of these patients were sensitive to oro-pharyngeal 
manipulation (most having been intolerant to the nasal catheter) and because the 
procedure required several consecutive intubations.  
 
A complete gastroscopy to the second part of the duodenum was always initially 
performed and any pathology including oesophagitis, Barrett’s oesophagus and hiatus 
hernia were identified and their margins measured relative to the incisor teeth. 
Oesophagitis and Barrett’s oesophagus were classified according to agreed criteria; 
Los Angeles Classification248 and Prague classification respectively.249 (Appendix 5 
and 6) After the position of the squamo-columnar junction (SCJ) was confirmed, the 
gastroscope was removed and the Bravo delivery device was passed orally. (Figure 
2.2) The gastroscope was then re-inserted to confirm passage of the delivery device 
into the oesophagus (and not the trachea) before it was again withdrawn. The delivery 
device was then positioned such that the capsule was 6 cm proximal to the SCJ; the 
high pressure zone is 1-1.5cm proximal to the SCJ which is equidistant to the 
conventional pH catheter sensor target position of 5 cm proximal to the LOS.103 As 
the SCJ is not easily identifiable in circumferential Barrett’s oesophagus, the position 
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at which the gastric rugae ended and oesophageal mucosa began was used as an 
alternative landmark. 
 
When in position, an external vacuum pump was activated in order to apply suction to 
the pH capsule ‘well’, a 4 mm in diameter and 3.5 mm deep depression in the 
proximal part of the capsule (Figure 1.5). To confirm good apposition and retention of 
the adjacent mucosa within the well, the investigator ensured that the vacuum pump 
was stabilised at >510 mmHg for up to 60 seconds. This was always confirmed and 
timed by an endoscopy nurse assistant. A plastic safety guard on the handle of the 
delivery system was then removed and the activation button on the handle was 
depressed with the thumb (Figure 2.2A). This manoeuvre triggered a spring-loaded, 
stainless steel pin to be driven across the capsule well and through the retained 
mucosa, thus securing the capsule to the mucosal wall. The activation button was then 
twisted clockwise 1/8 of a turn and re-extended to release the capsule from the 
system. After withdrawal of the delivery device, capsule attachment and accuracy of 
positioning was always confirmed under direct vision with a final gastroscopy. A 
picture was always taken for the record. (Figure 2.2C) The receiver was then 
activated, and when confirmed on the LCD screen to be transmitting successfully 
recording would commence.  
 
The steps described were replicated for every patient included in Bravo studies of 




Figure 2.2 Bravo delivery system, capsule and receiver comes as a pre-packaged 
assembly.  The handle of the delivery system is separated from the housing of the 
capsule by an 80 cm 6 F long tube with markings on the side. (A1-3 and B). The 
delivery device (A and B) is normally inserted orally down the un-anaesthetised 
pharynx of a (normally) sedated patient. Markings on the side (A3) depict the distance 
from the incisors. The capsule is deployed 6 cm above the anatomical z-line (or 5 cm 
proximal to the proximal LOS high pressure zone) (C). The delivery system is then 
withdrawn and the receiver is synchronized. (D) It remains attached to the patient (via 
belt clip or shoulder pouch) for the duration of the study. Capsules fall off 
spontaneously (median 5 days).103 Complications requiring its early removal are rare 
in the literature and have never been required in its 9 years of use at St Thomas’ 
Hospital. 
(Images reproduced from various websites including Given Imaging. The endoscopy 
image (C) was from a patient in the study described in Chapter 4) 
 
Unlike with the catheter-based studies, Xylocaine was not used to anaesthetize the 
pharynx during insertion. Experience at St Thomas’ Hospital have shown that in cases 
of primary non-adherence, the capsule preferentially tended to migrate upwards; a 
capsule entering the anesthetised pharynx runs the risk of being aspirated. Such an 
adverse event has not occurred in any patient included in this thesis, nor indeed in any 
patient who has had a Bravo procedure at St Thomas’ Hospital thus far. 
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 Patients were requested to return after 48 hours. At this (2nd) visit data from the 
receiver was downloaded (Polygram net, Medtronic) and the capsule transmission 
checked by the lab technicians. 48 hours is currently the standard Bravo measuring 
time set by the proprietary software and is what is most commonly quoted in the 
literature.103,250 For the Bravo study presented in Chapter 3, analysis ended at 48 hours 
as per the standard. For the Bravo study presented in Chapter 4, if the capsule 
remained in situ and a good signal persisted, batteries were changed and the study was 
extended for a second 48 hours, thus providing a maximum recording time of 96 
hours.  
 
The Bravo capsule is known to remain in situ for a median of 5-6 days,103 and 
experience from the St Thomas’ Oesophageal lab is that 69% of capsules remain in 
place by day 4 with a 10% drop off rate every 24 hours from day 2 (Figure 2.3; 
unpublished data). Once the capsule drops, it is passed per rectum and is rarely 
noticed by the patient. 
 
The same advice to avoid acidic food and drink was given as for catheter-based 
studies in order to avoid swallow-associated acid artefacts as the catheter cannot 
differentiate between acid which is refluxed or swallowed. Otherwise patients were 
encouraged to undertake their ‘normal’ daily activities and diet. A similar diary card 
was provided and patients were advised to record all their activities and food/fluid 
consumption in detail. 
 
 
Figure 2.3 Capsule drop offs out of 91 consecutive patients between 2009-2010 at St 




2.3 pH monitoring analysis 
2.3.1 Oesophageal acid exposure 
Ambulatory pH monitoring provides an assessment of frequency and duration of 
reflux events as well as the degree of association between these events and symptoms. 
Standard analysis of reflux events undertaken in these studies included a measure of: 
 total number of reflux episodes 
 total acid reflux (TR) - the percentage of time that the pH drops below a 
certain value (by convention pH of 4) over 24 hours. TR has been shown to be 
the single most robust and reproducible diagnostic marker of GORD.251  
 upright and supine reflux – subdivisions of the TR 
 
Cut-off values 
According to the BSG Clinical practice guidelines a total percent time that pH drops 
below 4 (TR) of <5% is accepted as normal in the absence of locally determined 
ranges for defining the limits of physiological acid reflux.78  However a cut-off value 
of 4.2% is the most common published TR value quoted for catheter-based 
studies85,250 and 5.3% for wireless studies.103 The difference is not only because the 
wireless pH study is more prolonged (and thus likely to pick up more reflux events) 
but also because of the less restrictive effects on diet and physical activity which 
increases the frequency of reflux-provoking activities. In order to compare results 
with the current literature, for categorical analysis (i) a standard cut-off value of 4.2% 
for both procedures and (ii) a specific cut-off values of >4.2% for 24 hour catheter-
based studies and >5.3% for prolonged wireless studies were presented for all pH data 
in this thesis.103 For upright and supine acid reflux measurements¸ accepted normal 
values for the total percent time pH drops below 4 are <8.15% for upright reflux and 
<3.45% for supine reflux. At present, the literature does not differentiate cut-off 
values for upright and supine reflux between 24 hour catheter-based and prolonged 
wireless pH monitoring.78 
 
Worst day vs. Average analysis 
For prolonged studies data published in the literature usually quote the ‘Single worst 
day’ results. Alternatively the ‘Average’ of all days recorded could be used.85,103,250 It 
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is not yet clear which is more clinically relevant. Therefore studies in this thesis are 
presented using both ‘Worst day’ and ‘Average’ analysis for measurements of i) 
oesophageal acid exposure and ii) reflux-symptom association. These concepts will be 
explored in the corresponding chapters. 
DeMeester score 
As there is a wide day-to-day variability of oesophageal acid exposure for every 
individual,83-85 recorded variables are referenced to known control values. One such 
system is the revised Johnson-DeMeester (DM) score. This is a clinically validated 
system for assessing the severity of reflux disease. A composite score is calculated 
based on the number of reflux episodes and duration of acid exposure in the upright 
and supine positions (weighted towards the percentage time of supine oesophageal pH 
exposure).252 The agreed upper limit of normal for the DM score is 14.72.  However, 
DM is validated only for 24 hour studies using the catheter-based system. As the 
purpose of these studies is to compare catheter-based studies with prolonged (≥48 
hour) wireless pH monitoring, DM was not presented. 
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2.3.2 Measurements of symptom association 
To define the temporal relationship between reflux and symptoms, three symptom-
association analyses have been described for clinical reporting and research.76 These 
are routinely incorporated into commercial ambulatory pH proprietary software. By 
convention, an association is assumed if a reflux event precedes a symptom event 
within a two minute time window.  
1. Symptom Index (SI)253 
The proportion of patient symptoms that are related to reflux 
 
Number of reflux related symptom episodes  x 100 
Total number of symptom episodes 
 
A symptom association of ≥50% is considered to be positive (pathological). 
 
This is a common and simple tool and is automatically calculated by the dedicated 
proprietary software. This parameter has been shown to be a good predictor of 
response to therapy; patients with typical symptoms and evidence of oesophageal acid 
exposure with a positive SI have the best response to acid reducing medication.75 
Furthermore SI has been shown to be clinically useful in the assessment of visceral 
sensitivity.151 This was the primary symptom association parameter used in studies 
presented in this thesis. 
2. Symptom Sensitivity Index (SSI)254  
 
Number of reflux related symptom episodes  x 100 
Total number of reflux episodes 
 
SSI of ≥ 10% is considered to be positive (pathological).  
 
SSI does not take into account the total number of symptom episodes. This 
assessment is quoted with reducing frequency in the literature and has been shown at 
St Thomas’ Oesophageal lab to have a very weak correlation with reflux acidity and 
likelihood of triggering symptoms (unpublished). Therefore it was not included in 
studies presented in this thesis. 
3. Symptom Association Probability (SAP)255 
SAP is performed by dividing the 24 hour period into 2 minute segments and 
determining whether (or not) a symptom occurred 2 minutes prior to every episode of 
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reflux recorded. It uses a 2x2 contingency table (fisher exact test) to calculate the 
probability that the relationship observed between symptoms and reflux is not brought 
on by chance. The p value is then subtracted from 1 and multiplied by 100 to provide 
an SAP value as a %. So a p value of 0.05 is equivalent to an SAP of 95% (1-
0.05=0.95 x 100). By statistical convention an SAP of ≥ 95% is considered positive 
(pathological).  Independently SAP has been shown to be a good predictor of the 
success of anti-reflux surgery.256 This parameter was used in addition to SI in Chapter 
4 and was calculated manually to accommodate for the prolonged studies of wireless 
pH monitoring (see below) 
 
Standard analysis and report 
A typical Bravo report is shown in figure 2.4 and 2.5; a plot of the entire 48 hour 
study period is presented. By convention, a drop in the pH below 4 points to an acid 
reflux episode. The plot could be ‘zoomed in’ for closer scrutiny of any interval or 
length of time. This facility was useful whenever confirmation of automated analysis 
was required. Information completed in the diary card was entered into the computer 
manually. These included meals (as well as snacks and drinks) and periods when the 
patient was supine. Episodes that should be ignored and not analysed (e.g. if acid 
containing foods/drinks were consumed or periods where the signal was lost) were 
also registered. This exercise was performed routinely by either the researcher or the 
Oesophageal Lab technicians for all patients. Once all data entry and final 
amendments were completed, the software automatically analysed the study and 
produced a report which highlighted all essential landmarks: symptom events (red and 
pink lines), supine periods (green blocks), meal times (yellow bars) and periods to be 
ignored (purple). Data from the automated analysis was then interpreted clinically and 
a standard report was generated for every patient and delivered to the referrer. 
Therapeutic decisions were made by the referrer and not by the researcher. 
 
Further analysis related to the studies in Chapter 3 and 4 
Results for every 24 hour period (oesophageal acid exposure, SI and SAP) were 
presented as a separate set of tables. This was followed by a combined average 
measure of the entire study period. Figure 2.4 and 2.5 portray the first 24 hour Bravo 
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result of a typical patient as it would appear in a standard report. Definition of 
terminology in the report: 
• ‘Duration of period’ for reflux events - the total study time minus the periods to be 
ignored. This was then further subdivided into the time spent in the upright and 
supine positions. Unless specifically indicated prior to analysis, meal times were 
not automatically ‘ignored’ in these studies. Therefore careful and detailed 
instruction to avoid acidic foods/fluids was essential to avoid acid reflux artefact.  
• ‘Duration of period’ for symptom events - the software considered each symptom 
to comprise of a 2 minute interval. This 2 minute time window is required to 
detect an association with the preceding reflux event. Therefore, heartburn 
‘duration period’ of 4 minutes implies 2 heartburn episodes and a regurgitation 
‘duration period’ of 6 minutes implies 3 regurgitation episodes within the 24 hour 
time period.  
• ‘Number of Refluxes’ for reflux events - the number of reflux episodes subdivided 
into ‘Total’, ‘Upright’ and ‘Supine’.  
• ‘Number of Refluxes’ for symptom events – the values that appear beneath the 
Symptoms columns indicate the number of reflux-related symptom episodes 
which preceded every symptom (by up to 2 minutes). This value was important in 
calculating the symptom index (see next).  
• ‘Fraction time pH<4 (%)’ - the total percent time that the pH dropped below 4. 
Presented for ‘Total’ (TR), ‘Upright’ and ‘Supine’ periods.  
 
Although normally automated, SI and SAP could also be manually calculated; this 
was the standard for the prolonged studies presented in Chapter 4: 
1) SI (Symptom Index) 
As described above, SI is the total number of symptom-related reflux episodes 
÷ total number of symptoms x 100. An example, of the first 24 hours is 
presented in Figure 2.5; the total number of reflux-related regurgitation 
episodes was 1, and the total number of symptoms was 3 (6 minutes ÷ 2 = 3), 
therefore the SI would be 1 ÷ 3 x 100 = 33.3%.  
 
2) SAP (Symptom Association Probability) 
SAP is more complex. An assessment was made of how many reflux events 
and symptom events occurred separately, together or not at all. A fisher exact 
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test (2 x 2 table) was then annually created to fit this information and the SAP 
was calculated from the p value of the fisher exact test.  
 
Fisher exact test 2 x 2 table: 
 
R + Reflux events 
R- No reflux events 
S+ Symptom events 
S- No Symptom events 
 
An example of a manual SAP calculation using the fisher exact test for a 
patient used in the study presented in Chapter 4 using the information from 
Figure 2.5; within a 24 hour period the patient had 3 regurgitation symptom 
events and 64 reflux events but only 1 of these was associated with reflux. 
Therefore R+S+ was 1, R+S- was 64 – 1 = 63 and R-S+ was 3 – 1 = 2. To 
calculate R-S-, first the 24 hour period (24 hrs x 60 min = 1440 min) was 
divided into 2 minute intervals (1440 min ÷ 2 = 720). This value was then 
subtracted from the total number of ‘2 minute intervals’ during which 
regurgitation or reflux events did occur: 720 – (64 + 3) = 653. The fisher exact 




This produced a p value of 0.2443. Therefore, 1 – 0.2443 = 0.7557 which was 
then converted to a percentage (0.7557 x 100 = 75.6%). Therefore the SAP 
was 75.6%. A significant p value was considered to be <0.05 which is 
equivalent to an SAP of >95%. Therefore in this case, as the SAP was <95%, 
the result was non-significant and negative. 
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Another example (not presented in the figures) was a patient with 101 reflux 
events and 9 heartburn symptom events within a 24 hour period. If 6 of these 
were associated, the fisher exact test 2 x 2 table would appear as follows: 
  
 
This produced a p value of 0.0004 which gives a positive SAP of 99.96%, a 
significant and positive result. 
 
When performed manually, the parameters for reflux and symptom association can be 
re-calculated and extended to any length of time. The proprietary software already 
provides an average for the 1st 48 hours (Chapter 3), but the results need to be 
performed manually to include 3 and 4 day studies (Chapter 4). Furthermore, to 
optimise the reflux-symptom association in patients with very few symptoms, studies 
in Chapter 4 combined all symptom events to produce an overall reflux-symptom 
association value for any symptom. Both individual as well combined symptom data 




Figure 2.4 Typical 48hr pH trace for wireless pH monitoring. Detail of the plot is 




Figure 2.5 Bravo software results table. A sample table of a patient from Chapter 4 
showing a summary of the data calculated by the software in the first 24 hours. 
 92 
2.4 High Resolution Manometry (HRM) 
 
All healthy volunteers recruited for HRM studies in Chapter 5 were friends, family 
and colleagues of the investigator as well as junior doctors and fellows rotating 
through the Oesophageal lab and the St Thomas’ gastroenterology department. For the 
study in Chapter 6, consecutive consenting patients were recruited between December 
2008 and September 2009. Patients were selected from the same pool of those 
referred to the St Thomas’ Oesophageal lab with symptoms of heartburn, 
regurgitation, chest pain and dysphagia.  
 
 The 36 sensor solid state HRM catheter (used for all studies in this thesis) is 4.2 mm 
in diameter and consisted of circumferential pressure sensors 2.5 mm in length 
arranged at 10 mm intervals (ManoScan 360, Sierra Scientific Instruments, Mountain 
View, CA). This is covered by a silicone-based thermal plastic elastomer. Each sensor 
detects pressure from 12 separate loci around its circumference. (Figure 2.6) Using 
pressure transduction technology pressures from each locus is averaged. Computer 
processing then collects information from all pressure sensing elements to produce 
circumferential pressure measurements incorporating the entire catheter length which 




Figure 2.6 HRM sensors. Sensors are copper coloured cylinders (white vertical 
arrow) which are spaced at 10mm intervals. Pressure is detected from 12 loci around 
each cylinder circumference (1 locus = white horizontal arrow from the magnified 
sensor in the centre).  
(Reproduced from Colour Atlas of High Resolution Manometry, Jeff Conklin et al 
2009) 
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2.4.1 Decontamination and sheathing of the HRM catheter 
The HRM catheters are re-usable (up to 200 times) although their life-span can be 
extended (400 times or longer) with ongoing service. Therefore it is essential to 
maintain optimal disinfection without causing damage to the sensitive silicone coating 
or sensors. This was achieved by (I) disinfecting and (II) sheathing the catheter. The 
catheter was stored in its designated box after cleaning and in between uses for all 
patients. This technique was performed routinely by the investigator prior to and after 
every patient. 
I) Disinfection 
Disinfection was always performed with gloved hands and an apron in the 
Oesophageal Lab clinical room. The Tristel chemical biocidal wipe system was used 
to disinfect catheters prior to and after every use. (Figure 2.7) Tristel’s patented 
disinfectant incorporates three individually packaged sachets (wet wipes) and a foam 
pump. Decontamination was a 3-step process during which the length of the catheter 
would be carefully wiped in a unidirectional (proximal to distal) fashion with gloves 
changed prior to every step:  
1) Pre-clean wipe - composed of a ‘low-foaming surfactant system’ combined 
with ‘triple enzymes’ which produce an ultra-low surface tension suitable for 
cleaning of any hard surface. This removed organic matter which may have 
deposited on the catheter surface. 
2) Sporicidal, mycobactericidal, bactericidal, virucidal and fungicidal foam 
pump was directly applied to the second wipe to activate the disinfectant. This 
could kill almost any organism within 30 seconds of contact.  
3) Rinse wipe - this final wipe was impregnated with ‘de-ionised water’ and a 
‘low-level of antioxidant’ which removed and neutralized any chemical 
residue that remained.  
 
 
Figure 2.7 Tristel wipe disinfecting instructions.  
   (Taken from the Tristel fact sheet.) 
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II) Sheathing 
Manoshield™ (Sierra Scientific Instruments), a sanitary catheter sheath, was applied 
over the HRM catheter to minimise wear and tear and to act as a physical barrier 
between the patient and catheter. (Figure 2.8) A sheath was utilised for every subject 
who underwent HRM. 
 
 
Figure 2.8 HRM catheter sheath. After completion of the Tristel biocidal three step 
wipe, the catheter was covered with a thin layer of talk (left panel). Then the thin, 
hypo-allergenic Manoshield sheath was slid over the catheter (similar to a condom; 
middle panel). Once inserted to a designated pre-marked position at the tip, a foam 
‘slider’ was passed over the sheath to ensure all air residue was expelled (right panel). 
The slider was then secured at the hilt with an elastic band and the catheter was ready 
for use. If during calibration it was noted that some air residue remained within the 
sheath, the foam ‘slider’ could again be brought down to the tip, pulled back and 
secured at the original proximal position. 
 
2.4.2 Calibration 
After entering patient details, the prepared catheter was connected to the Manoscan 
system. The sheathed portion of the catheter was then inserted into the calibration 
chamber and sealed proximally. Sensors were then interrogated as the machine 
sequentially increased the compartmental pressure within the chamber up to 
300mmHg before dropping back to atmospheric pressure. The response characteristics 
of each sensing element ideally should be accurate to within 1 mmHg. Defective 
sensors were highlighted by the software and these were then masked manually. For 
studies in this thesis, catheters with >3 defective sensors were replaced.  
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2.4.3 Catheter insertion 
(Appendix 1 and 8) 
 
Patients were required to be alert and un-sedated for the procedure. Only Xylocaine 
1% was used to locally anaesthetize the nostril (2-3 sprays) and pharynx (5-6 sprays). 
The catheter was then inserted through either nostril and down the oesophagus while 
the patient sipped water through a straw in a similar manner to the pH catheter 
insertion technique. The oesophageal anatomical landmarks could be clearly 
visualised on the monitor as the catheter progressed down the oesophagus. Insertion 
was terminated as the catheter crossed the OGJ and entered the stomach. It was then 
withdrawn such that the Manoscan image included the entire oesophagus from the 
pharynx to at least 3 cm into the gastric cardia. The position of the LOS was 
confirmed by deep inspiration to highlight the diaphragm pressure inversion point 
(pinch). Once finalised, the catheter was taped to the side of the face and neck as it 
curled behind the ear to reduce catheter movement and pharyngeal irritation. (Figure 
2.1) Position from the nares was then recorded as a reference for automated 
calculations. 
2.4.4 HRM study 
All studies presented in this thesis were performed by the investigator. Tests were 
performed in the physiological upright seated position, an important variation to the 
original validation studies which were performed in the supine position.121,130,246,247 In 
healthy subjects, water and bread swallows were then repeated in the supine position 
(see later). Prior to initiation, study participants were instructed to inform the 
investigator of any symptoms they were to experience as soon as they occurred so that 
they could be marked directly onto the HRM trace. Subjects were never ‘prompted’ 
for symptoms during the analysis. Symptoms described during the study included 
pain, dysphagia, ‘sticking sensation’, belch, cough, regurgitation, nausea and 
vomiting.  
 
After a 5 minute adaptation period, subjects were asked not to swallow for 30 
seconds. This was required to measure resting (baseline) LOS pressure, the LOS 
margins, hiatus hernia as well as the upper oesophageal sphincter (UOS) relative to 
the nares. 
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5ml water swallows 
Subjects were administered 5 ml water swallows (via a syringe) and were requested to 
swallow each bolus ‘in one go’ and to withhold further swallows briefly thereafter. 
The start and end of every swallow was ‘framed’ manually on the screen as the 
swallows progressed. If more than one swallow was noted and/or if other events that 
could interfere with analysis were identified (e.g. cough, vomit, sniff, laughter), the 
swallow frame was deleted. Each swallow used for analysis was separated by an 
interval of 20s. Where the study protocol required, 5-10 individual water swallows 
were collected and measurements were repeated in the supine left lateral position. 
 
1 cc bread swallows 
Bread was prepared in advance by applying low fat margarine on a slice of brown 
(untoasted) bread. Each slice was cut in half, apposed, the crusts were removed and 
the bread was cubed into equal 1 centimetre pieces. During the study subjects were 
instructed to chew one cube of bread very well. When ready, subjects were instructed 
to signal with a raised hand. When appropriate (i.e. no intervening swallows or no 
other oesophageal activity) the patient was asked to swallow the bolus ‘in one go’. Up 
to 5 x 1 cc bread swallows were completed, and where the study protocol required, 
measurements were repeated in the supine left lateral position. The experience at St 
Thomas’ Oesophageal Lab corroborated other studies in that more than one swallow 
was sometimes required to clear the pharynx when swallowing solids.257  Therefore 
the number of pharyngeal deglutitions prior to effective distal oesophageal contraction 
was always recorded. 
 
Free drinking (Multiple Water Swallows; MWS) 
After water and bread swallows, where the study protocol required, subjects were 
requested to drink 200 ml of water freely through a straw without stopping. Drinking 
directly from the cup was discouraged as the larger volumes per swallow reduced the 
total number of swallows available for analysis. Furthermore, using a straw reduced 
movement of the head and neck during free drinking. If less than 200ml was drunk, 
the volume consumed was documented; although if they were able (and willing) the 
process was repeated. After completion of MWS, subjects were asked not to inhibit 
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their swallows as instructed during the 5 ml water or 1 cc bread protocol.  Symptoms 
during or after completion were recorded deciduously. 
 
Standardised Meal 
Where the protocol required, and only if subjects consented, a standardised meal was 
provided which the patients were asked to consume at a comfortable pace. In view of 
the diversity in culture and religion of the patients referred from London area and 
beyond, meat-based products were excluded. Therefore the meal comprised of a 
standardised cheese and onion pasty (Ginsters, Cornwall, United Kingdom; 195 g, 
500 Kcal, 34 g fat) and a 200 ml fruit-smoothie (ASDA Stores Limited, Leeds, United 
Kingdom; 100 Kcal, viscosity ~100 cPois.). (Figure 2.9) This was intended to be 
typical in volume, fat and calorie content of a standard western diet; a McDonald 
sausage McMuffin and milkshake.  No patient in these studies was wheat or gluten 
intolerant. Participants were instructed before the study to report symptoms as soon as 
they occurred.  
 
Figure 2.9 Standard meal (Ginster Cheese and Onion Pasty; 500 Kcal) and 200ml 
drink (ASDA lactose-free fruit smoothie; 100 Kcal) 
 
Post meal observation 
After the standardised meal, subjects were observed for a 10 minute period with the 
catheter in situ. Participants were instructed to behave (and swallow, belch etc.) 
normally. Again they were instructed to volunteer any symptoms if/when they 
occurred and close observation also permitted the investigator to mark any events that 
might not be volunteered by the patient (e.g. belch, rumination). 
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2.5 Analysis 
The techniques described in this section are not clearly defined in the literature and 
vary from one published study and one lab to another; however these methods are 
employed by most expert users (Chicago, Nottingham, Royal London) and were 
employed for all studies in this thesis. Proprietary software (Manoview version 2.0, 
Sierra Scientific Instruments, Mountain View, CA) was used to analyse all HRM data. 
The investigator repeated the analysis of patients and healthy subjects one year after 
the index measurement while blind to demographics, presenting symptoms and 
history to confirm that measurements corroborated with initial findings.  
 
2.5.1 Thermal compensation 
After study completion, the catheter was removed and allowed to hang at room 
temperature/pressure for a few seconds. At this instant the catheter would still be at 
body temperature but all pressure sensors would be exposed to atmospheric pressure. 
The software automatically set this pressure as ‘zero’ and would apply sensor-specific 
thermal correction to the entire manometric data set. This post-hoc calibration 
would also compensate for measurement drift that may have appeared (Figure 2.10) 
 
2.5.2 Swallow frame 
Each ‘swallow frame’ was interrogated and extended or reduced in order to 
incorporate only one swallow (from just prior to pharyngeal relaxation to the LOS 
aftercontraction) per frame. For 5 ml water swallows, a frame that did not comprise 
only one, uninterrupted swallow was not included. (Figure 2.11a and b) 
 
Solid swallows were not routinely framed during real time testing although they were 
marked manually for identification later. Therefore when being analysed, the original 
framed water swallows were deleted and new solid swallow frames were manually 
inserted. Unlike with water swallows, it was not uncommon if more than one 
pharyngeal swallow was required to propel a solid bolus. Only the contraction that 
followed the last pharyngeal swallow was framed and analysed. (Figure 2.12) The 
number of preceding pharyngeal swallows was counted and recorded. Pre-
conditioning of repeated swallows was not assessed. 
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To facilitate comparison between water and solid swallows, a 30 mmHg isobaric 
contour was used to define peristaltic integrity for all swallows.36,125 The isobaric 
contour is a line on the HRM plot which circumscribes all pressurised segments such 
that the pressure within is equal to or greater than a pre-specified pressure. (Figure 
2.13) As alluded to in section 1.5.4 (HRM classification of oesophageal pathology), 
an isobaric contour of 30 mmHg is the most relevant for HRM classification 
schemes.131 The qualitative and quantitative characteristics of every swallow were 




Figure 2.10 Thermal compensation process. The curser was placed at the end of the 
study and the thermal compensation function was applied. 
 
 
Figure 2.11a     Figure 2.11b 
Figure 2.11 Stepwise method of adjusting every HRM swallow frame to encompass 
only one, uninterrupted swallow. 
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Figure 2.12. Solid swallow analysis. The swallow frame needed to be inserted 




Figure 2.13 HRM with isobaric contour. A 30 mmHg isobaric contour (black line) 
circumscribes areas where pressure is equal to or exceeds 30 mmHg.  
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Figure 2.14 High resolution manometry swallow margins and landmarks. HRM of a normal swallow with pressure data presented as a 
spatiotemporal plot (STP). A 30 mmHg contour (black line) is superimposed on the image. Important landmarks are highlighted. The axial graph 
on the right shows the direction of flow relative to the pressure gradient at the site of the red curser (centre on the STP plot) 
This trace is from a healthy volunteer presented in Chapter 4. 
(UOS: Upper oesophageal sphincter; OGJ: Oesophago-gastric junction; PTZ: proximal transition zone). 
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 2.5.3 Gastric reference 
Distal sensors record the gastric pressure. This position can be manually defined. 
Variations in pressure with respiration increase if the sensor is too close to the 
diaphragm and during deep breathing. Therefore it is most reliable if the gastric 
reference is placed well within the gastric body. To standardise studies presented in 
this thesis, whenever possible the gastric reference was placed at a position at least 3 
cm distal to the distal LOS margin. In the presence of a hiatus hernia, the gastric 
sensor was always placed out-with the distal hernia margin unless the hernia was 
exceedingly large (>5cm) in which case the gastric reference sensor was placed within 
the hernia.  
2.5.4 Baseline LOS pressure and morphology 
OGJ marker positions 
Manoview automatically recognizes the upper and lower oesophageal sphincters by 
identifying the corresponding high pressure zones; however manual adjustment by the 
investigator was always required at baseline, especially if LOS sphincter pressure was 
reduced or hypertensive. Specifically, the principle LOS marker (yellow balloon in 
the axial trace of Figure 2.15) was placed at the maximum pressure point while the 
upper and lower LOS margins (proximal and distal yellow balloons above and below 
the principle LOS marker in Figure 2.15) were placed at the respective borders of the 
LOS. The principle, proximal and distal oesophageal LOS markers were also adjusted 
manually for every swallow to ensure accuracy.  
 
By interpolating pressure data across the LOS, a 6cm ‘virtual sleeve’ (the e-sleeve) 
was derived from HRM data, thus providing a single measurement across the OGJ. 
This function is analogous to the ‘Dent sleeve’ used in water-perfused conventional 
manometry.  It reduces the potential for inaccuracy that could arise from axial 
movement of the oesophagus by allowing for uninterrupted measurement of the 
maximum pressure along the length of the ‘virtual sleeve’. The e-sleeve makers 
(‘lollipops’ at the OGJ margin in the axial trace of Figure 2.15) were placed at either 
end of the LOS margins.  
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The transition point between the negative thoracic cavity and positive abdominal 
cavity (pressure inversion point; PIP) also required manual re-positioning at the start 
of analysis. This was considered to be the position of the diaphragm (cLOS).   
 
LOS and PIP markers assisted in defining OGJ morphology (discussed in section 
1.5.4). The presence of a HH was determined as a separation between the intrinsic 
LOS (iLOS) and crural diaphragm (cLOS/PIP). Although this separation was not 
fixed and sometimes appeared intermittently later in the study (e.g. during solid 
swallows or post-prandial period; Figure 2.16), by convention the presence/absence of 
a HH was classified only during baseline LOS measurement. In the presence of a HH, 




Figure 2.15 Upper oesophageal sphincter (UOS) and Lower oesophageal sphincter 
(LOS) margins using HRM. Note the principle (39 cm), proximal (38 cm) and distal 
(40.8 cm) LOS markers (yellow balloons) as well as the e-sleeve (orange lollipops) 
markers on the right of the axial trace. Also note the PIP and gastric reference makers. 
 
 
Figure 2.16 Transient hiatus hernia. Separation of the intrinsic and diaphragmatic 
lower oesophageal sphincter resulting in a transient hiatus hernia.  
UOS: Upper oesophageal sphincter; LOS: Lower Oesophageal Sphincter,  
iLOS: intrinsic LOS; cLOS: crural LOS.  
(reproduced from M. Fox and A Bredenoord Gut March 2008126) 
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2.5.5 Oesophageal peristalsis 
HRM was analysed in terms of the proximal-, mid- and distal-oesophageal segmental 
contractions, as defined by Clouse and Staiano:121,246 
(i) characteristic rise and fall of contractile pressure 
(ii) peristalsis velocity, 
(iii) duration of peristalsis  
 
Once the investigator completed the manual adjustments, swallows required for 
analysis were framed. (Figure 2.11 and 2.12) Then every oesophageal swallow was 
scrutinised and markers were re-adjusted (e.g. upper and lower sphincters, 
contractility margins, etc.) as required. (Figure 2.17) The functional oesophageal 
length and the length of time required for a peristalsis event to pass were measured 
manually. (Figure 2.18) An automated analysis of basic parameters produced standard 
values for every individual which the investigator entered into a database. Then using 
the 30mmHg isobaric contour, the proximal (striated muscle) and mid/distal (smooth 
muscle) peristalsis segments were localised as was the pressure trough (PTZ).246 The 
length, time interval, pressure and relation relative to the entire oesophagus (presented 
as a percentage) were manually calculated for every swallow. (see Chapter 5 for 
further detail).  
 
A typical spatiotemporal plot with the axial graph of a healthy volunteer highlighting 









Figure 2.18 HRM manual measurement of oesophageal length and peristalsis time.  
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2.5.6 Standardised meal free drinking and post-meal 
observation analysis 
A meal reproduces normal eating behaviour. It is more complex and laborious to 
analyse, there is no standardised technique and normative data is lacking. Therefore it 
is not routinely performed in Oesophageal centres. Novel analysis techniques for 
HRM while eating, drinking freely and for an observation period after are introduced 
in this thesis.  
 
In regards to the standardised meal, in addition to individual metrics described above, 
the overall success or failure of oesophageal function following every pharyngeal 
swallow was assessed. Then each successful swallow was manually framed and 
adjusted in preparation for automated analysis. (Figure 2.19)  
 
Three methods of analysis were undertaken during meal studies:  
A) Quantitative analysis of successful ‘framed’ swallows. Analysis of these was 
analogous to single solid swallows (described in section 2.5.2)  
B) Qualitative assessment of every pharyngeal and oesophageal activity  
(successful, ineffective, failed) 
C) Association of symptoms with dysmotility  
 
The analysis technique for HRM while eating, drinking and during post-prandial 
observation will be described in detail in the methods sections of Chapters 5 and 6. 
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 Figure 2.19 HRM during a meal. Spatiotemporal plot of swallows while eating. Successful swallows were framed in preparation for automated 
analysis. 
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2.5.7 Post-HRM pH monitoring  
HRM studies were routinely followed by catheter-based pH monitoring. Studies were 
performed off acid reducing medication by the Digitrapper™ Slimline™ (Medtronic 
Inc., Shoreview, MN) system using the standard technique for preparation, 
investigation and analysis presented in section 2.1. Total reflux (percentage 
oesophageal acid exposure of less than 4) was the primary outcome measurement on 
which GORD diagnosis was based with a diagnostic cut-off of 4.2%. Symptoms were 
associated with reflux if they occurred within 2 minutes following a reflux event. 
Reflux Symptom Index (SI) was assessed with a diagnostic cut-off >50%. 
 
2.6 Statistical analysis 
Statistical analysis specific to each study will be discussed in detail in the 
corresponding chapters. Common statistical analysis techniques used for all studies 
are described here. All were performed using the SPSS 16.0 package for Windows, 
SPSS Inc., Chicago, Illinois, USA and Microsoft Office Excel 2003. 
2.6.1 Ambulatory pH Monitoring 
Student’s t-test was used for quantitative variables and Fisher’s exact test for 
qualitative variables. Mann-Whitney-U and Wilcoxon tests were used for 
nonparametric analysis of the TR, UR, SR SI and SAP between and within groups 
respectively. Results are reported as Median (Inter-quartile range). P<0.05 was 
considered statistically significant. 
 
24 hour catheter-based study parameters were compared to 24 and 48 hour wireless 
pH monitoring measurements. Where required by the protocol the wireless study 
analysis was extended to 72 and 96 hours. For all prolonged studies (i.e. >24 hours), 
the single ‘Worst day’ and overall ‘Average’ measurements were used for the study 
duration. Furthermore for TR measurements, both cut-off values 4.2% and 5.3% were 
used for Bravo, and 4.2% was used for 24 hour catheter studies. 
2.6.2 High Resolution Manometry 
Student’s t-test was used for quantitative variables. Mann-Whitney and Wilcoxon 
tests were used for nonparametric comparisons of quantitative swallow parameters 
between and within groups respectively. The Friedman test was used for analysis of 
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variance for multiple comparisons of nonparametric data within groups (i.e. 
comparing water, bread and test meal parameters within the same patient group).  
Pearson’s coefficient (PC) assessed the strength of relationship between the frequency 
of effective swallows and the total time required to consume meals. P<0.05 was 
considered statistically significant. Results were reported as Median (Inter-quartile 
range) and Mean±Standard Error (Standard Deviation) 
 
Normative values were presented as 5th and 95th percentiles. For water and bread 
swallows, coefficient of variation (CV) (standard deviation ÷ the mean for each 
subject x 100 expressed as a percent) was used to assess the intra-subject variability. 
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 Chapter 3 
Patient acceptance and clinical impact 
of Bravo monitoring in patients with 
previous failed catheter-based studies 
 112 
3.0 Introduction 
Standard ambulatory investigation for patients presenting with symptoms suggestive 
of reflux is routinely performed using the naso-oesophageal catheter (C-pH).53,103 
Limitations are intolerance to catheter insertion and inability to retain the catheter in-
situ for 24 hours due to discomfort, gagging, nausea and vomiting. C-pH is also 
socially embarrassing and can have a negative impact on behaviour.81,82,109 Bravo is 
an innovative, wireless pH monitoring system which is better tolerated and can 
measure for prolonged periods (48 hours).103,85,104  
 
Patients who have Bravo performed are comprised of:  
1) Those who are intolerant to C-pH 
2) Those who have inconclusive results based on C-pH but have ongoing typical 
symptoms 
3) Those with anatomical abnormalities (e.g. nasal septal defect) which preclude 
catheter-based testing.  
 
The first two groups formulate the bulk of referrals to St Thomas’s Hospital and 
indeed in the UK.78,109 This chapter tries to answer two important questions:  
I) Are patients that are intolerant to the nasal catheter able to tolerate the 
Bravo capsule insertion and the 48 hour study that follows?  
II) Does the diagnostic yield in terms of pathological oesophageal acid 
exposure or reflux-symptom association justify investigation with Bravo? 
 
3.1 Aims 
It is assumed that as Bravo has a reduced impact on activities of daily living and that 
as studies are prolonged, Bravo collects more ‘relevant’ information for longer 
periods which will ultimately influence the diagnosis reached; however this theory 
has not yet been established. The aim of this study was to determine the tolerability of 
this group of patients to Bravo testing and to assess the diagnostic yield in terms of 
oesophageal acid exposure and reflux-symptom association over 48 hours in patients 
who have failed the nasal catheter. 
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3.2 Methods  
(please refer to Methods Chapter 2; additional methodology specific for 
this study will be described here)  
3.2.1 Study design 
This was a prospective study which examined the technical success, patient 
satisfaction and results of 48 hour Bravo pH measurement in patients intolerant of the 
pH catheter, and compared them with a contemporaneous group of patients that 
tolerated 24 hour C-pH. All patients had C-pH and Bravo procedures performed at St 
Thomas’ Hospital; however, prior to referral for Bravo the failed catheter-based 
studies had a widely variable referral base. 
Hypothesis: 48 hour wireless pH monitoring is well tolerated and can identify GORD 
in patients who failed catheter-based pH monitoring. 
3.2.2 Patients  
Between March 2004 and January 2008, 2749 consecutive patients were referred to a 
tertiary centre (St Thomas’ Hospital) for oesophageal manometry and pH studies. 
Results recorded in an electronic database and on paper records were collected. 2366 
patients were referred for standard C-pH of which 615 cancelled or did not attend for 
their investigation. Of the 2134 patients remaining, 383 with known primary motility 
disorders on manometry or barium swallows (e.g. achalasia and nutcracker 
oesophagus) were excluded from the study. In the same period 185 patients were 
referred for Bravo of which 156 (84%) undertook the investigation. 154/156 (98.7%) 
of those investigated successfully completed a (standard) 48 hour Bravo study. The 
majority of these patients (134/156 (86%)) were offered Bravo after having failed 24 
hour C-pH. (For inclusion/exclusion criteria please refer to Appendix 4) 
 
110 consecutive patients from the same referral pool and with similar primary 
symptoms had C-pH performed and were provided with an un-validated tolerability 
questionnaire on their return to the oesophageal laboratory 24 hours later (Appendix 
7). Those who failed manometry and C-pH and proceeded to Bravo also completed 
the same questionnaire on their return at 48 hours (Appendix 7). Endoscopic results, 
total percentage time pH drops below 4 in every 24 hours (Total reflux; TR) and 
Symptom Index (SI) were assessed in both groups.  
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3.2.3 Data analysis 
Oesophageal acid exposure measurements 
24 hour TR is the single most robust and reproducible diagnostic marker of GORD,251 
and is the most commonly used method for assessment in most laboratories and in the 
literature. Therefore identifying the 24 hour period with the highest acid exposure 
(TR) within the 48 hour catheter-free study was the primary outcome for this study. 
Average 48 hour results were also presented for comparison. Other parameters (e.g. 
number of reflux episodes) were not analysed separately to reduce the chance of type 
I errors related to multiple comparisons. 
 
As described in Chapter 2, to improve diagnostic accuracy different cut-off values 
between C-pH and Bravo were employed for TR.103,250,258 For categorical analysis, the 
effect of altering the cut-off value on diagnostic yield was assessed using:  
(i) a standard cut-off value of 4.2% for both procedures, and  
(ii) specific cut-off values of 4.2% for C-pH and 5.3% for Bravo in 
accordance with published values.103,258 
Symptoms Index 
The concept of measuring SI is discussed in detail in Chapter 2. Studies suggest that 
SI provides a clinically useful assessment of visceral sensitivity.151 By convention a 
symptom event was considered to be associated with reflux if it occurred within a 2 
minute time window after the reflux event.253  
3.2.4 Statistical analysis 
Student’s t-test was used for quantitative variables (age) and the Fisher’s exact test for 
qualitative variables (sex, endoscopy, categorical analysis of TR and SI). Mann-
Whitney-U test was used for nonparametric analysis of TR and SI as well as to 
compare scores from the tolerability questionnaire between C-pH and Bravo. P<0.05 
was considered statistically significant.  
 
Assuming a 30% day to day variation in oesophageal acid exposure,106 a sample size 
of 100 patients gives an 80% (beta 0.8) chance of detecting a 10% difference between 
C-pH and Bravo measurements.  
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3.3 Results 
3.3.1 Patient demographics 
Between March 2004 and January 2008, of the 1751 patients that had the catheter-
based test with no known primary motility disorder, 883 (50%) had a diagnosis of 
gastro-oesophageal reflux disease based on a pathological TR (% time pH<4). In all 
134/1751 (7.7%) could not tolerate the nasal catheter. This group of patients either did 
not tolerate the high resolution manometry (HRM) catheter (routinely performed prior 
to the pH study) or the pH nasal catheter itself. This is consistent with previously 
published data that 5-10% of patients are intolerant of catheter testing or fail to 
complete the 24 hour pH study.51 Reasons for failure in this cohort were:  
• intolerance of catheter insertion (HRM or C-pH) (84%) 
• intolerance of the catheter after intubation (7%)  
• vomiting of the catheter within the 24 hour monitoring period (9%) 
A further 22 patients had Bravo performed during this time period but were not 
considered intolerant of the catheter and thus not included in the study. These patients 
had Bravo performed either because of ongoing symptoms despite a negative 24 hour 
test (11/22; the focus of Chapter 4), a contraindication to nasal catheterisation (e.g. 
recent rhinoplasty; 3/22) or an expressed desire against nasal intubation (8/22).  
 
From the 134 patients who were catheter-intolerant and completed the Bravo 
procedure, the mean age was 46 (range 19-75; 58 males). These were compared to 
110 consecutive C-pH controls with a mean age of 49 (range 16-85; 44 males). 
94/134 (70%) Bravo patients and all C-pH patients completed the tolerability 
questionnaire. There was no difference in age (p=0.182) and sex (p=0.78) between 
these 2 groups.  
 
Endoscopy results were recorded in 126/134 patients who underwent Bravo and 
95/110 patients who underwent C-pH. (Table 3.1) There was no difference in 
endoscopic findings between the two groups (p=0.920). Almost all Bravo patients 
were on anti-secretory medication until one week prior to the procedure. Most of the 
C-pH group had their endoscopy performed at regional hospitals whereas the Bravo 
patients had their endoscopies performed at St Thomas’ Hospital by an endoscopist 
who took particular note of mucosal disease prior to capsule deployment. For Bravo 
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insertion, the mean (range) doses for sedation in those who initially did not tolerate C-
pH (midazolam 7mg (2-10mg) and fentanyl 67 mcg (50-150)) were higher than those 
for routine diagnostic endoscopy at St Thomas’ (midazolam 4mg (0-5mg) and 
normally without fentanyl). 
 
 
Table 3.1 Endoscopy in Bravo and catheter study (C-pH) groups. Endoscopic 
findings showed no difference between Bravo and C-pH (p=0.922) 
 
3.3.2 Oesophageal acid exposure  
Data for TR was available for 129/134 consecutive Bravo patients and 102/110 
consecutive C-pH patients. Continuous data analysis (Table 3.2a) showed a 
significantly higher median (IQR) TR between the average 48 hour Bravo (6.9) and 
24 hour C-pH (4.1) groups (p=0.001). Categorical analysis (Table 3.2b) also showed a 
higher prevalence of pathological TR on at least one day during 48hr catheter-free pH 
monitoring using a standard cut-off value of 4.2% for both techniques (98/129 (76%) 
vs. 49/102 (48%) respectively; p<0.001). Using specific cut-off values of 5.3% for 
Bravo and 4.2% for C-pH, the prevalence of pathologic oesophageal acid exposure on 
at least one day remained higher in the Bravo group (92/129 (71%) vs. 49/102 (48%) 
respectively; p<0.001.) Average 48 hour results showed a similar finding with higher 
prevalence of oesophageal acid exposure in the Bravo group using 4.2% as a standard 
cut-off value (88/129 (68%); p=0.003) compared to C-pH; however this difference 
was not significant using a technique-specific cut-off of 5.3% for Bravo (74/128 
(58%) vs. 49/102 (48%); p=0.179. (Table 3.3) 
 
There was no systematic difference in the incidence of pathologic TR between the 
first and second day of Bravo measurements using 4.2% or 5.3% as cut-off values 
(Table 3.4a and b); 15/129 (11.6%) patients had a different outcome on day 1 and day 
2 using 4.2% as a cut-off value and 16/129 (12.4%) using 5.3% as a cut-off value. 
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With Worst day analysis, there was a significant increase in the number of new 
patients diagnosed with GORD based on TR at 48 hours; 15 patients using 4.2% as a 
cut-off value (p=0.056) and up to 19 patients using 5.3% as a cut-off value (p≤0.05). 
Significance was lost with Average analysis; 5 additional patients had a positive TR 
using 4.2% as a cut-off value (p=0.600), 3 fewer patients compared to day 1 
(p=0.900) and 3 additional patients compared to day 2 (p=0.800) using 5.3% as a cut-




Table 3.2a    Table 3.2b  
Table 3.2 Bravo vs. C-pH Total reflux (TR). (a) Continuous analysis of TR was 
higher for Bravo at 48 hours than 24 hour C-pH. (b) Categorical ‘Worst Day’ analysis 
of diagnostic yield applying different cut-off values for % time pH<4 to define 
GORD. Pathological TR was higher on at least one day in the 48 hour Bravo than the 
24 hour C-pH group using either uniform (4.2%) or technique specific (5.3% and 




Table 3.3 Categorical analysis of ‘Average’ 48 hour Bravo analysis applying different 
cut-off values for TR to define gastro-oesophageal reflux disease. Pathologic 
oesophageal acid exposure was higher for 48 hour Bravo compared to 24 hour C-pH 
using a uniform TR cut-off value (4.2%) but not when using technique-specific TR 
cut-off values (5.3% and 4.2%). 
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Table 3.4a   
        
 
Table 3.4b  
Table 3.4 Categorical analysis for TR (total reflux) for Bravo on day 1 and day 2 as 
well at 48 hours using Worst day and Average analysis. 
(a) TR cut-off value of 4.2% (b) TR cut-off value of 5.3%. 
 
3.3.3 Symptom association 
Not all patients experienced symptoms (e.g. heartburn, regurgitation, chest pain) 
during the study. Patients with no symptoms were not included in the symptom 
specific analysis; having no symptoms is not the same as having a negative symptom 
association 
 
On continuous analysis (Table 3.5a) there was no significant difference in the median 
SI for heartburn (HB, the most common symptom) between the Bravo group at 48 
hours (38.5%) and 24 hour C-pH (33.0%); p=0.80.  
 
Categorical analysis (Table 3.5b) also showed no difference in SI for HB between 
Bravo (34/97) and C-pH (22/52) respectively; p=0.478. When SI for all potential 
reflux associated symptoms (HB, regurgitation, chest pain and cough) was pooled 
(Table 3.5c), there was also no significant difference between the Bravo (47/116) and 




Table 3.5a  
 
Table 3.5b      Table 3.5c  
Table 3.5. Comparison between continuous and categorical analysis for symptom 
Symptom index (SI) between 48 hour Bravo and C-pH groups. a) Continuous analysis 
for heartburn (HB; there was no difference in median SI scores for HB with Bravo 
compared to C-pH. b) Categorical analysis for HB; there was no difference in 
diagnostic yield for GORD based on SI for HB with 48 Bravo compared to C-pH. c) 
Categorical analysis for pooled symptoms (HB, regurgitation, chest pain, cough); 
there was no difference in diagnostic yield for GORD based on SI between Bravo and 
C-pH when all symptoms were pooled. 
3.3.4 Tolerance of Procedure 
92 of the 134 consecutive Bravo patients and 102 of the 110 consecutive C-pH 
patients completed the tolerability questionnaire had TR data available for analysis. In 
those that answered the questionnaire, diagnostic yield in terms of continuous and 
categorical analysis of oesophageal acid exposure between Bravo and C-pH (Table 
3.6) was similar to the overall results presented above. (Tables 3.2 and 3.3) The 
numbers of those who did not answer the questionnaire (Bravo n=36 and C-pH n=8) 
were too small for statistical comparison. Furthermore, there was no difference 
between those who answered the questionnaire and those who did not in terms of 
oesophageal acid exposure (Table 3.7a and b) or SI (Table 3.8a and b). For those who 
did answer the questionnaire, there was no difference in SI for heartburn, 
regurgitation or chest pain between day 1 and 2 (Table 3.9). Nor was there a 
difference between either day and ‘Average’ SI at 48 hours for HB (p=0.203 and 
p=0.692), regurgitation (p=0.637 and p=0.615) or chest pain (p=0.396 and p=0.764), 
nor when all symptoms were pooled. There was also no difference with SI for 




Table 3.6a  
 
 
Table 3.6b  
 
 
Table 3.6c  
Table 3.6. Total reflux (TR) for 48 hour Bravo and 24 hour C-pH for those who 
answered the questionnaire. a) Continuous analysis for TR between 48 hour Bravo 
and 24 hour C-pH. b) Categorical ‘Worst day’ analysis for TR between 48 hour Bravo 
and 24 hour C-pH. c) Categorical ‘Average’ analysis for TR between 48 hour Bravo 
and 24 hour C-pH. 
 
 
Table 3.7a      Table 3.7b  
Table 3.7 Questionnaire vs. No Questionnaire effect on TR. From the Bravo group, 
those who did and did not answer the questionnaires showed similar oesophageal acid 
exposure regardless of whether a) ‘Worst day’ or b) ‘Average’ analysis was used. 




Table 3.8a.     Table 3.8b  
Table 3.8. Questionnaire vs. No Questionnaire effect on Symptom Index (SI). 
‘Average’ SI for a) heartburn (HB; the most common symptom) and (b) pooled 
symptoms (HB, regurgitation, chest pain) for 48 hour Bravo who answered and did 





Table 3.9a  
 
 




Table 3.9 Bravo at day 1 with day 2 and ‘Worst day’ analysis at 48 hours for 
symptoms of a) heartburn, b) regurgitation and c) chest pain in those who answered 
the tolerability questionnaire. 
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3.3.5 Tolerability questionnaire 
The results of the tolerability questionnaire demonstrated a significant preference for 
the Bravo system compared to C-pH in almost all responses (Figures 3.1 to 3.4), with 
an overall satisfaction score of 4.4/5 vs. 3.5/5; p<0.001. All but one respondent that 
had undergone the Bravo study said they would recommend the procedure to another 
person compared to 73% that underwent C-pH (p<0.001). 96% patients that 
underwent both procedures preferred Bravo to C-pH despite the study being twice as 
long and requiring endoscopy. There was markedly less restriction of daily activities 
(Figure 3.2), throat discomfort (Figure 3.3), nasal discomfort and difficulty 
swallowing (Figure 3.4) during the Bravo study compared to C-pH (p<0.001 for all 
comparisons); however there was a similar amount of chest pain immediately 
following both procedures (p=0.646) (Figure 3.5). No complications occurred with 






Figure 3.1 Overall experience in Bravo and C-pH groups (1=very unhappy, 5=very 
satisfied). Patients favoured Bravo (p<0.001) 
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Figure 3.2 Restriction of everyday activities in Bravo and C-pH groups (1=very 





Figure 3.3 Throat discomfort in Bravo and C-pH groups. (1=very severe, 5=none). 
Patients favoured Bravo (p<0.001) 
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Figure 3.4 Swallowing difficulty immediately after insertion of Bravo and C-pH 





Figure 3.5. Chest pain immediately after insertion of Bravo and C-pH (1=very severe, 
5=none). No difference between either system (p=0.646) 
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3.4 Summary of results 
• Standard pH monitoring with a nasal catheter was not well tolerated by many 
patients and could lead to changes in diet and lifestyle that reduce reflux-
provoking activities. 
• Patient tolerance and satisfaction with the Bravo system was high with reduced 
restriction, discomfort and dysphagia, even in those who previously failed to 
tolerate catheter-based studies. 
• The prevalence of pathological acid exposure was higher in the patients who 
underwent pH monitoring by the Bravo system (76% pathological TR on day 1 or 
2) than an age and sex matched group that successfully completed the catheter-
based study (48%; p<0.01). 
• Patients that had failed to tolerate the nasal catheter study had no evidence of 
increased oesophageal sensitivity to reflux events as assessed by pooled symptom 
index (p=0.28). 
• Had Bravo pH measurement not been available, many patients that had failed 
catheter-based testing would not have received a definitive diagnosis, and 
treatment choices (e.g. surgery) in this group may have been suboptimal. 
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3.5 Discussion 
Studies suggest that between 5 and 10% of patients are intolerant of naso-gastric 
intubation or fail to complete 24 hour ambulatory catheter-based pH monitoring (C-
pH).51 In this cohort, wireless pH monitoring (Bravo) provides the means to obtain (or 
exclude) a definitive diagnosis of gastro-oesophageal reflux disease (GORD). The 
primary outcome of this study demonstrates that the Bravo technique is well tolerated 
and that pH measurement has a high diagnostic yield in these individuals. 
 
There were no differences in baseline demographic, clinical characteristics or 
endoscopic findings between those that successfully completed 24 hour C-pH (n=110) 
and those that failed to tolerate the nasal catheter and underwent 48 hour Bravo 
(n=134). Patient tolerance was improved and activities of daily living were better 
preserved for Bravo compared to C-pH. (Figures 3.1-3.4) Although some studies have 
reported chest pain to be increased in patients undergoing the Bravo procedure,82,103 
pain was not described as being serious with very few requiring removal. The current 
study found little difference in chest pain between the two modalities immediately 
after the procedure; 6/94 (6.4%) and 5/107 (4.7%) patients complained of severe chest 
pain for Bravo and C-pH respectively (p=0.646). Thus far at St Thomas’ Hospital, no 
patient has required the capsule to be removed for any reason over past 8 years of 
Bravo use. The relatively high doses of sedation required for Bravo capsule placement 
was likely due to intolerance of oro-pharyngeal manipulation in patients that failed to 
tolerate initial naso-pharyngeal intubation of the catheter-based studies..  
 
On continuous analysis, as reported by previous comparative studies, the Total Reflux 
(Total % time pH <4; TR) was higher in the Bravo than the C-pH group (6.9% (3-
10.8) vs. 4.1% (1.6-8.1); p=0.001).  On categorical analysis, the prevalence of 
pathologic acid exposure on at least one 24 hour period (Worst day analysis) during 
the 48 hour Bravo study was higher than for the 24 hour C-pH measurement (Table 
3.2) or for any individual 24 hour Bravo period (day 1 or 2) regardless of which 
diagnostic cut-off value was used (Table 3.4). Specifically, at 48 hours using a cut-off 
value for TR of 5.3% up to 19 new cases were found (p=0.01) and using a cut-ff value 
for TR of 4.2% 15 new cases were found (p=0.056). On other hand, if the diagnosis 
based on the ‘Average’ pH exposure over 48 hours was compared to 24 hour C-pH or 
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for any individual 24 hour Bravo period, then no significant increase in diagnostic 
yield was found (Tables 3.3 and 3.4). These findings were consistent with studies by 
Pandolfino et al and Scarpulla et al that showed analysis of the ‘Worst day’ increased 
diagnostic sensitivity in prolonged pH monitoring.85,103 It is unclear if the diagnostic 
yield of ‘Average’ measurements with technique specific cut-off values would change 
if the Bravo study was prolonged further to 72 or 96 hours, a feature unique to Bravo. 
96 hour studies would provide even more information (in terms of oesophageal acid 
exposure and symptoms) which should improve diagnostic confidence, especially in 
those with borderline results at 24 or 48 hours. This concept will be explored in 
Chapter 4 and a possible diagnostic algorithm will be re-visited in the Future 
directions Chapter 7. 
 
16/129 (12.4%) and 15/129 (11.6%) patients had different outcomes on day 1 and day 
2 using 5.3% and 4.2% cut-off values respectively. This is in keeping with a study by 
Gillies et al in which 10% of patients had their diagnosis changed when second day 
data was included.83 Consistent with other studies,103,250,259  the absolute number of 
positive tests between the first and second day did not change (Table 3.4). Rather the 
number of cases in which a positive reflux-symptom association can be established 
was increased with increased study duration.260 Studies from St Thomas’ Hospital and 
elsewhere have shown that prolonged study duration (up to 96 hours) reduced 
variation of oesophageal acid exposure measurements and improved test-retest 
reproducibility especially when using the more statistically robust Average analysis 
technique.85,106,261,262 Although the majority of patients in this cohort only had 48 hour 
studies (as was the standard at that time) patients at St Thomas’ Hospital are now 
routinely studied for up to 96 hours. 
 
Despite the intolerance of Bravo patients to C-pH there was no significant difference 
in the SI for heartburn or for pooled reflux-related symptoms between 48 hour Bravo 
and 24 hour C-pH monitoring (Table 3.5).  That is, despite discomfort from the 
catheter and intolerance, the association between perceived symptoms and reflux 
events did not change. Therefore, evidence from this study suggests that although the 
Bravo group had not tolerated the nasal catheter, in every other way they were 
representative of the same group (same amount of reflux symptom-association). 
These findings do not support the contention that patients that fail to tolerate C-pH 
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have ‘heightened sensitivity’ to distal oesophageal acid reflux. On the contrary, this 
group had at least as high a prevalence of pathological acid exposure as in C-pH 
(Table 3.2 and 3.3) and no evidence of visceral hypersensitivity as assessed by SI.151  
(Table 3.5) On the other hand, dual-sensor or Impedance-pH assessment to exclude 
proximal reflux sensitivity was not performed and is a weakness of this study. 
 
Some Bravo patients did not complete the tolerability questionnaire; although not 
statistically significant, the minority of patients that did not complete the 
questionnaire had a numerically higher prevalence of pathological acid  (Table 3.7). 
 
3.6 Conclusion 
In conclusion, this study compared a cohort of patients investigated by Bravo that had 
failed catheter pH monitoring to a contemporaneous, well-matched group of patients 
that successfully completed catheter studies. Patient satisfaction with Bravo pH 
monitoring was high and the technique was well tolerated, despite having previously 
failed to complete the catheter-based studies. There was no evidence to support that 
Bravo patients had higher oesophageal sensitivity to reflux events. Rather this group 
was unable to tolerate naso-pharyngeal intubation without sedation, and often 
required doses equivalent to those for interventional procedures.  
 
This study has important clinical implications. Although no health economic data was 
provided, Bravo is known to entail a greater cost than C-pH. Furthermore, an 
additional visit to hospital is required for endoscopic placement.  Nevertheless, had 
Bravo not been available, the many patients with pathological pH exposure would not 
have received a definitive diagnosis of GORD. This is likely to have impacted 
adversely on care and management decisions in many individuals, especially those 
under consideration for anti-reflux surgery. These findings support the 
recommendation that patients who fail to tolerate catheter-based testing should be 
offered catheter-free pH monitoring. In view of the improved tolerability and higher 
diagnostic yield for oesophageal acid exposure, 48 hour Bravo might be considered to 
be a better test than catheter-based studies. Furthermore, even more prolonged studies 
(72 or 96 hours) may have an impact on ‘Average analysis’ as more information 
becomes available. However such statements require evidence based on diagnostic 
outcome which was not achieved and was a major weakness of this study.  
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Chapter 4 
Diagnostic yield of prolonged Bravo in 
patients with reflux symptoms and 




Chapter 1 and Chapter 3 described how the diagnostic yield of catheter-based 24 hour 
pH monitoring (C-pH) was diminished due to key limitations: tolerability, effect on 
daily activities and high day-to-day variability in acid exposure and symptoms.81,83-86 
Such shortcomings can lead to a false negative or false positive diagnosis of GORD. 
Prolonged measurement (up to 48 hours) increased diagnostic reproducibility and 
sensitivity, especially in patients with intermittent symptoms.86 Furthermore, wireless 
monitoring was better tolerated and preferred by unselected patients.84,103  
 
More than 90% of patients tolerate the nasal catheter. According to ROME III,263 
patients with negative results but ongoing typical symptoms are considered to have 
‘functional’ oesophageal symptoms (i.e. functional heartburn); however given that 
one in three patients have a different diagnosis if the pH study is repeated on 2 
separate days51 and given its effect on patient behaviour, a negative, borderline or 
inconclusive result may be unreliable in the presence of ongoing typical symptoms. 




This study aimed to investigate whether prolonged (up to 96 hour) wireless pH 
monitoring improves the sensitivity of diagnosis and ability to identify reflux as a 
cause of symptoms in patients referred for a second opinion with ongoing symptoms 
suggestive of GORD but negative catheter-based pH results. Furthermore the clinical 
impact of prolonged Bravo was assessed at clinical follow-up 6–36 months after 
initiation of definitive therapy by the referrer based on the results of physiologic 
testing. 
Hypothesis: 96 hour wireless pH monitoring can identify patients with pathological 
oesophageal acid exposure and in turn influence management decisions in those who 
previously had negative 24 hour catheter-based studies. 
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4.2 Methods  
(please refer to Methods Chapter 2; additional methodology specific for 
this study will be described here) 
 
4.2.1 Study design 
This was a prospective study of patients who had successfully undergone 24 hour C-
pH with negative results but continue to have ongoing typical symptoms suggestive of 
gastro-oesophageal reflux disease (GORD) with the purpose of assessing whether 
prolonged catheter-free pH monitoring (96 hour Bravo) changed the diagnosis and 
could aid in predicting outcome following therapy. 
 
4.2.2 Patients 
Between November 2006 and February 2010, 246 patients underwent wireless pH 
monitoring at St. Thomas’ Hospital. Of those, 38 (15.4%) were referred following 
negative C-pH studies and ongoing ‘typical’ symptoms of reflux (heartburn, acid 
regurgitation). The majority of the catheter-based studies (35/38) had been performed 
at St Thomas’ Hospital and had similar demographic and clinical characteristics as the 
patients in Chapter 3 and previously published studies from the same unit.51,84  (Table 
4.1) Acid-reducing medications were discontinued for at least 5-7 days prior to 
ambulatory studies as per the current British Society of Gastroenterology guidelines.78 
The decision to refer for Bravo was made by the referring clinician based on a 
negative oesophageal acid exposure on the C-pH study. (For inclusion/exclusion 
criteria please refer to Appendix 4) 
Sedation 
For the Bravo insertion, mean (range) doses for sedation in those who initially 
tolerated C-pH (midazolam 5mg (0-10mg) and fentanyl 63.5 mcg (0-100mcg)) was 
lower than for those who were intolerant to the nasal catheter presented in Chapter 3 
(midazolam 7mg (2-10mg) and fentanyl 67 mcg (50-150)). Nevertheless, sedation 
remained higher than for diagnostic endoscopy at St Thomas’ Hospital (midazolam 
4mg (0-5mg) and normally without fentanyl). This is likely because the Bravo 
insertion technique required at least three consecutive endoscopy procedures to secure 
and confirm adherence (see Chapter 2). 
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Clinical follow-up 
The clinical impact of pH measurement on management decisions and clinical 
outcome was assessed. Patient follow-up was performed a minimum of 6 months 
(median 24 (range 6-36) months) after initiation of definitive therapy. Medical or 
surgical therapy management decisions were made by the referring clinician after 
receiving results of prolonged Bravo. Patients rated their symptoms as ‘good’, 
‘moderate’ or ‘poor’ during a telephone conversation. 
 
4.2.3 Data analysis 
Technical success and duration of prolonged Bravo was noted. Oesophageal acid 
exposure and reflux-symptom association were assessed as described previously. In 
both cases every 24 hour pH recording was analysed and categorized as being normal 
or pathological ‘diagnostic of GORD’ on the basis of the percentage time pH drops 
below 4 (Total reflux; TR)251 and/or manually calculated reflux-symptom association 
(Symptom Index; SI or Symptom Association Probability; SAP). Details regarding 
TR, SI and SAP as well as the manual calculation of the latter metrics were described 
in Chapter 1, 2 and 3. 
 
Furthermore, the effect of day-to-day variability of oesophageal acid exposure and 
(manual) symptom association on diagnostic yield based on 24, 48, 72 and 96 hour 
testing was calculated. If the Bravo capsule detached from the oesophagus before 96 
hours, the ‘final diagnosis’ was based on the best available evidence from the 
complete pH and symptom data prior to detachment. To achieve this, the last result 
was carried forward in reporting thus providing a ‘rolling cumulative’ outcome. This 
is standard practice and ensured that the best available data was used in clinical 
decision making. Capsule drop off was assumed when there was a sudden fall 
to  pH < 2 (suggestive of a drop into the stomach) followed by a rapid rise to pH > 7 
as the capsule passed into the duodenum.  
Oesophageal acid exposure  
TR as well as acid reflux in the upright (UR) and supine (SR) positions were 
documented. 24 hour C-pH measurements were compared to Bravo at 24, 48, 72 and 
96 hours. The ‘Worst day’ as well as the ‘Average’ 24, 48, 72 and 96 hour results 
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were presented. Because of the different TR normal values for C-pH and Bravo103,258 
for categorical analysis both: (i) a fixed diagnostic TR cut-off of 4.2% over the 
monitoring period for C-pH and Bravo studies (allows for direct comparisons) and (ii)  
a diagnostic cut-off of 4.2% (standard C-pH studies) and 5.3% (widely applied for 
Bravo studies) were applied to allow for technology-specific comparisons103,258 (see 
Chapters 2 and 3) 
 
Reflux-symptom association 
Symptoms were associated with reflux if they occurred within a 2 minute time 
window of a reflux event. SI and SAP were calculated manually.255 ‘Worst day’ as 
well as the ‘Average’ measurements were assessed as described in Chapter 3. For 
Bravo, analysis was performed by i) excluding those whose catheter dropped over 
time, and ii) including the last result prior to when the capsule dropped in which the 
last result was carried forward such that all patients were included in the final 
assessment (‘Average cumulative’ analysis). Analysis of individual typical symptoms 
(heartburn, regurgitation, chest pain) as well as the combination of all symptoms was 
recorded. The number of positive GORD diagnoses based on reflux-symptom 
association was compared for Bravo at 24, 48, 72 and 96 hours.  
 
4.2.4 Statistical analysis 
Student’s t-test was used for quantitative variables, and Fisher’s exact test for 
qualitative variables. Wilcoxon test was used for nonparametric analysis of TR, SI 
and SAP. Results were reported as median (inter-quartile range; IQR). P<0.05 was 
considered statistically significant.  
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4.3 Results 
4.3.1 Patient demographics 
38 consecutive patients with ‘typical’ symptoms of reflux and no diagnosis of GORD 
based on initial C-pH entered the study. Demographic, clinical and endoscopy data 
are detailed in Table 4.1. Typical symptoms of heartburn and acid regurgitation were 
reported by all patients. A proportion also reported less typical symptoms such as 
chest pain and cough (Table 4.1).  
 
Bravo was performed successfully in all patients with the intention of acquiring a 96 
hour pH recording. All patients completed at least 48 hours of Bravo. Capsule 
detachment occurred between 48 and 72 hours in 5 patients, and between 72 and 96 
hours in 12 patients. Therefore complete 96 hour recordings were available in 21/38 
(55%) patients. (Figure 4.1) No demographic or clinical factors (e.g. symptoms) were 
associated with early capsule detachment. Similar to patients in Chapter 3, no patient 
experienced more than mild swallowing difficulty or chest discomfort related to the 
procedure, and all patients described normal typical daily behaviour and diet during 
the Bravo study.  No capsules needed to be removed prematurely. Reflux events were 
correlated with symptoms to achieve a reflux-symptom association assessment. (see 
Appendix 3 for diary log) 
 
 





Figure 4.1 Detachment rate of capsules over 96 hours. No capsules detached <48 
hours from insertion. 
 
4.3.2 Oesophageal acid exposure 
Similar to patients in Chapter 3, median oesophageal acid exposure was higher for 
Bravo at 24, 48, 72 and 96 hours than 24 hour catheter-based pH studies. (p<0.05)  
(Table 4.2) 
 
Using the ‘Average analysis’ technique, prolonged wireless pH studies provided an 
objective GORD diagnosis based on pathological TR (using 5.3% cut-off) in 12/38, 
12/38, 11/33 and 10/21 patients at 24, 48, 72 and 96 hours respectively; however this 
excluded patients who’s capsule dropped pre-maturely in a sequential manner. Using 
a ‘last result carried forward’ approach such that results from all patients were 
considered, the ‘Average cumulative’ oesophageal acid exposure for Bravo was 
pathological at 96 hours in 14/38 (36.8%) using a diagnostic cut-off of 5.3% and 
15/38 (39.5%) using a diagnostic cut-off of 4.2%. (Figure 4.2) If ‘Worst day’ analysis 
was applied, pathological TR was present on at least one day in 18/38 (47.4%) using a 
diagnostic cut-off of 5.3% and 22/38 (57.9%) using a diagnostic cut-off of 4.2%. 
(Figure 4.2)  
 
Similar results were found if pathological acid exposure in the upright and supine 




Table 4.2 Total reflux (TR) in Bravo vs. C-pH. C-pH recorded significantly less oesophageal acid exposure (TR) compared to Bravo at 24, 48, 72 
and 96 hours. Similar findings were recorded in the upright (UR) and supine (SR) positions. There was no significant, systematic difference 
between 24, 48, 72 and 96 hour Bravo (all comparisons p>0.1). 
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Figure 4.2a          Figure 4.2b 
 
Figure 4.2 TR using ‘Average cumulative’ and ‘Worst day’ analysis for Bravo. Results are presented as the proportion of patients with (a) 




Table 4.3 Oesophageal acid exposure in the Upright and Supine positions. The ‘Average cumulative’ and ‘Worst Day’ analyses are presented for 
pathological (‘Bravo pos’) wireless oesophageal acid exposure at 24, 48, 72 and 96 hours. 
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 4.3.3 Symptom-association 
A median of 7 (IQR 4,15) symptom events were recorded by every patient on each 
day. All patients reported symptoms on at least one day during the study time period. 
The most common symptoms documented were heartburn (n=31), regurgitation 
(n=27) and chest pain (n=27). Atypical symptoms recorded included cough, sore 
throat, nausea and dyspnoea (n=7). Most patients recorded more than one type of 
symptom. (Table 4.4) 
 
Symptom Index (SI) 
When all reported symptoms were combined, 9/38 (24%) patients had a positive SI 
using ‘Average cumulative’ analysis at 96 hours (Figure 4.3 and Table 4.5). ‘Worst 
day’ analysis showed a positive SI in 23/38 (61%) patients (Figure 4.3 and Table 4.5). 
Similar results were observed also for individual symptoms (Table 4.6). Similar to the 
study presented in Chapter 3 (Table 3.9), no statistical difference was shown in SI for 
each individual day over time (p>0.1 for all).  
 
Symptom Association Probability (SAP) 
When combining all symptoms recorded during the Bravo study, 13/38 (34%) patients 
had a positive SAP using ‘Average cumulative’ analysis at 96 hours (Figure 4.3 and 
Table 4.5). ‘Worst day’ analysis showed a positive SAP in 24/38 (63%) patients 
(Figure 4.3 and Table 4.5). Similar results were observed also for individual 
symptoms (Table 4.7). Again, no statistical difference was shown in SAP for each 




Table 4.4 Symptoms reported during prolonged the prolonged Bravo study. Results are presented as median (inter-quartile range; IQR). 
 141 
  
Figure 4.3 Proportion of patients with pathological Symptom Index (SI) and Symptom Association Probability (SAP) using ‘Average’ (rolling 
cumulative) and ‘Worst day’ analysis when all symptoms were combined during prolonged Bravo. 
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Table 4.5 Symptom Index (SI) and Symptom Association Probability (SAP) 
manually calculated with all symptoms combined. A pathological SI or SAP for any 
symptom was recorded as a positive result. The ‘Average’ and ‘Worst Day’ analyses 
are presented using the ‘last result carried forward’ method.  





Table 4.6 Symptom Index (SI) calculated for individual symptoms. The ‘Average’ 
and ‘Worst Day’ (pathologic SI for any symptom rated as a positive result) analyses 
are presented using the ‘last result carried forward’ method.  
(Bravo = Wireless pH monitoring; HB = Heartburn; CP = Chest pain) 
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Table 4.7 Symptom Association Probability (SAP) calculated for individual 
symptoms. The ‘Average’ and ‘Worst Day’ (pathologic SAP for any symptom rated 
as a positive result) analyses are presented using the ‘last result carried forward’ 
method.  
(Bravo = Wireless pH monitoring; HB = Heartburn; CP = Chest pain) 
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4.3.4 Agreement of reflux-symptom association assessments 
Diagnostic agreement between a positive SI and SAP on rolling (Average cumulative) 
analysis incorporated fewer patients than that based on the ‘any single day’ (Worst 
day) analysis. At the end of the prolonged Bravo study 5 patients had a positive SI 
and SAP using ‘Average cumulative’ analysis and 19 patients had a positive SI and 
SAP using ‘Worst day’ analysis. (Figure 4.4)  
 
GORD diagnosis based on acid exposure and reflux-symptom 
association  
Agreement between positive oesophageal acid exposure (TR) and reflux-symptom 
association (SI or SAP) increased the overall number of patients diagnosed with 
GORD. Applying ‘Average cumulative’ analysis, 8/38 (21%) patients had a GORD 
diagnosis based on a positive TR as well as a positive SI or SAP. However, 23/38 
(61%) patients had a GORD diagnosis based on either ‘Average’ positive TR or 
positive reflux-symptom association. (Figure 4.5a) 
 
Applying ‘Worst day’ analysis, 17/38 (45%) patients had a GORD diagnosis based on 
a pathological TR as well as a positive SI or SAP on any day. On the other hand, 
29/38 (76%) patients had a GORD diagnosis based on either a positive TR or a 
positive SI or SAP on any day. (Figure 4.5b) It was on this basis that most referrers 







Figure 4.4 Agreement of positive Symptom Index and Symptom Association 







Figure 4.5 Diagnostic yield for GORD based on positive Total Reflux and any 
symptom association (SI or SAP) using (a) ‘Average cumulative’ analysis and (b) 
‘Worst day’ analysis. 
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4.3.5 Outcomes 
Treatment decisions were made by the referrer and were based on ‘Worst day’ 
analysis for acid exposure or reflux-symptom association following prolonged Bravo 
monitoring. Outcome at least 6 months after initiation of definitive therapy was 
available for 33/38 (87%) patients. 
 
Medical therapy 
26/38 (68%) patients had conservative therapy provided by the referring physician. 
This comprised of optimising either: 
i) acid-reducing medication (e.g. esomeprazole BD) (n=19; 5 lost to follow-up), or  
ii) dietary/lifestyle modification with or without alternative antacid therapy (n=2). 
The outcome for 21/26 patients was assessed at a median 24 months (range 12–36 
months). 9 patients had an improvement in symptoms and 12 described a poor 
outcome. Overall 9/9 (100%) and 9/12 (75%) had a GORD diagnosis based on 
pathological oesophageal acid exposure or positive reflux-symptom association 
respectively (p=0.361).  
 
Surgical therapy 
12/38 (32%) patients had anti-reflux surgery performed and outcome was assessed at 
a median 24 months (range 6 months (2 patients) – 36 months). Of these patients, 
9/12 had a positive diagnosis based on pathological oesophageal acid exposure 
(positive TR) and all also had a positive reflux-symptom association (positive SI or 
SAP). 1 other patient had pathological supine reflux only on day two and the SI for 
regurgitation was positive only on day three. Two patients had surgery despite 
negative ‘formal’ pH studies studies. Out of the latter two, one had pathological 
supine reflux only and a large hiatus hernia on endoscopy. The other had ongoing 
symptoms suggestive of non-acid food and fluid regurgitation with normal endoscopy 
and manometry with a recording of 119 symptoms over 96 hours most directly after 
meals. This was almost certainly suggestive of rumination, a voluntary yet 
subconscious repetitive learned habit resulting in a sudden increase in intra-abdominal 
pressure which overcomes the lower oesophageal sphincter basal tone and forces 
gastric contents into the oesophagus, and often, into the mouth.128,141 (Figure 1.8)  
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At follow-up, 10 patients had a good outcome and 2 patients had persistent reflux 
symptoms and were awaiting repeat pH studies. Of these 8 of the 10 with good 
outcome and 2 of the 2 with poor outcome had a clear positive diagnosis of GORD 
(p=1.0). Similarly, 7 of the 10 patients with good outcome and both patients with poor 
outcome had had at least a partial (50%) response to PPI therapy prior to anti-reflux 
surgery. A further patient with a good initial result had new-onset dysphagia after 6 
months that was shown to be due to a trans-diaphragmatic herniation of the wrap 
 
4.4 Summary of results 
• Catheter-based pH studies may be confounded by modified patient behaviour and 
day-to-day variation in reflux events and symptoms. 
• Wireless pH studies were better tolerated than catheter studies with reduced 
impact on patient activity and oral intake 
• Prolonged wireless pH monitoring had a high diagnostic yield of picking up 
pathological oesophageal acid exposure in patients with negative catheter-based 
pH studies as it reduced false-negative diagnoses; 47.4% and 36.8% using ‘Worst 
Day’ and ‘Average’ analysis respectively. 
• Prolonged wireless pH monitoring increased diagnostic sensitivity for significant 
reflux-symptom association; 73.7% and 44.7% had a positive SI or SAP using 
‘Worst Day’ and ‘Average’ analysis respectively. 
• Using ‘Worst-day’ and ‘Average’ analysis, 76% and 61% patients were diagnosed 
with reflux disease based on either pathological acid exposure or reflux-symptom 
association. 
• 10/12 Patients diagnosed with GORD based on prolonged wireless pH studies 




4.5.1 Oesophageal acid exposure and symptom association 
This prospective study reports a high diagnostic yield of prolonged (up to 96 hour) 
wireless pH monitoring (Bravo) in patients with typical reflux symptoms in whom the 
initial 24 hour catheter-based pH studies (C-pH) were negative. Patients diagnosed on 
the basis of this investigation and referred for definitive, surgical management had 
good outcomes.  
 
The demographic and clinical profile of the 38 patients recruited for this study (Table 
4.1) was typical of the larger group referred for pH studies at St Thomas’ 
Hospital.51,84 Similar to previous reports from the same unit,84 capsule deployment 
was successful in all patients and no adverse events were reported. Furthermore all 
patients reported normal food and fluid intake and all were able to undergo their 
routine daily activities. At least 48 hours of continuous pH recording were obtained in 
all subjects and 21/38 (55%) completed 96 hours, with a median capsule adherence of 
72 hours (3 days) (Figure 4.1) Although this was higher than that reported in other 
studies presented in the literature (e.g. Scarpulla et al reported a 41% completion rate 
to 96 hours)85 it was lower than the most recent internal audit at St Thomas’ 
Oesophageal lab in which 70% capsules were retained by day 4 with a 10% drop off 
from day 2.261 (Figure 2.3) This was likely multi-factorial:  
i) improved experience with the device deployment over the years, and  
ii) manufacturers that supply Bravo changed ownership and upgraded the 
delivery device on at least 2 occasions over the previous 6 years; however 
it is important to note that there have been no changes to the capsule 
mechanics, signalling and receiver pick up, nor with the proprietary 
software (Polygram net) used for this study during the same time period. 
Examination of the data provided insight into how prolonged Bravo studies might 
have increased diagnostic yield compared to 24 hour C-pH. 12/38 patients had 
pathological acid exposure (TR) in the first 24 and 48 hours (using ‘Average’ 
analysis), and 12/48 and 14/38 patients had pathological TR in the first 24 and 48 
hours using ‘Worst day’ analysis. From 48 to 96 hours there was a further increase in 
diagnostic yield based on pH measurement with 2 additional cases using ‘Average’ 
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and 6 additional cases using ‘Worst day’ analysis (Figure 4.2a). This was most 
pronounced with supine reflux (SR) in which pathological SR from day to day 
changed with the greatest frequency: 9/38 (day 1), 12/38 (day 2), 6/33 (day 3) and 
4/21 (day 4), and when using ‘Worst day’ analysis up to 50% patients became 
positive by 96 hours. (Table 4.3) 8 patients had pathological acid reflux on at least 3 
of the 4 days. Increasing the study from one to two days increased the median number 
of combined symptoms reported from 10 to 20 episodes/day (Table 4.4) and 
approximately doubled the number of reflux episodes and symptom episodes 
available for association. Prolonging the study further to 3 and 4 days increased the 
number of symptoms by a median of 10 episodes. Therefore although prolonging the 
study produced a modest increase in positive Total reflux from day 1 to day 4 using 
‘Average’ analysis, the increase was pronounced with ‘Worst day’ analysis and, 
consistent with previous studies, this increase was greatest for reflux-symptom 
association.86 (Figure 4.3 and Table 4.3-4.7) These findings imply that reflux events 
and symptom events have a wide day-to-day variability and by increasing the duration 
of study more reflux events and symptom events are available for analysis and this in 
turn increases the diagnostic yield compared to standard 24 hour C-pH studies. 
Interestingly ‘Average cumulative’ analysis results occasionally showed a drop in the 
numbers of those diagnosed with GORD. This was most notably seen for supine 
reflux (Table 4.3) where SR dropped from 12 patients with pathological findings at 48 
hours to 10 patients at 72 hours. This phenomenon was also recognised during reflux-
symptom association assessment (Figure 4.3 and Table 4.5) where SI dropped from 
10 patients with pathology at 72 hours to 9 at 96 hours and SAP dropped from 16 
patients with abnormal results at 48 hours to 13 at 96 hours. Again, the wide 
variability in reflux and symptom events from day to day would account for this 
discrepancy. As this calculation is cumulative, a pathological SR on one night in a 
borderline case may ‘dilute’ the averaged measurement over time. Therefore, 
‘Average analysis’ may be considered a more conservative assessment of pathology 
which increases the specificity for identifying true GORD; a positive result is more 
likely to be true whilst borderline results are normalised over time. On the other hand, 
‘Worst day’ analysis is more likely to identify those with intermittent symptoms 
therefore increasing the sensitivity for identifying GORD, although this also increases 
the likelihood of false positive results. This is in keeping with Scarpulla et al85 who 
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showed that whilst ‘Worst day’ analysis maximised diagnostic yield at 48 hours, 
‘Average’ measurement was more likely to improve diagnostic accuracy. A consensus 
on which technique is most appropriate has not yet been reached in the literature, nor 
was the focus of this study to answer this question; therefore both results were 
presented in this thesis to inform the reader. 
 
4.5.2 Diagnostic agreement 
The causes of symptoms are non-specific and patients commonly reported various 
symptoms in response to reflux events. Heartburn was the most common symptom 
recorded; however the majority of patients complained of at least 2 different 
symptoms per day with a median number of any symptoms reported of 7 (4,15) per 
day and 30 (14,59) over the entire study (Table 4.4). No patient remained symptom 
free during the 96 hour monitoring period. Using ‘Average cumulative’ analysis for 
all symptoms, 9/38 (24%) and 13/38 (34%) patients had a positive SI and SAP at the 
end of the study respectively (Figure 4.3 and Table 4.5). The effect of individual 
symptoms was also presented for SI and SAP and these too showed a similar trend. 
(Tables 4.6 & 4.7) As expected, pathological findings were more common using 
‘Worst day’ analysis as 23/38 (61%) and 24/38 (63%) patients had a positive SI and 
SAP at 96 hours respectively.  
  
A diagnosis of GORD based on positive SI or SAP was present in 17/38 (45%) 
patients using the ‘Average’ analysis and in 28/38 (74%) patients using ‘Worst day’ 
analysis (Figure 4.4). Again, the increase in diagnostic yield over time was greater 
with ‘Worst day’ than ‘Average’ analysis. When measurements of oesophageal acid 
exposure (TR) and reflux-symptom association (SI or SAP) were combined, the 
diagnostic yield was high with 61% receiving a diagnosis of GORD based on well-
validated criteria (described in Chapter 1 and Chapter 2) and a conservative analysis 
method using the ‘Average cumulative’ technique. This yield increased further to 
76% if the diagnosis was based on ‘Worst day’ analysis. It is important to re-iterate 
that ‘Worst day’ analysis is the most often quoted in the literature 103 and is used in 
clinical practice at St Thomas’ Hospital as well as other major oesophageal centres 
(personal communication with the Chicago group at Northwestern University 
Hospital and Digestive Diseases Centre, Nottingham). Furthermore, clinicians 
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commonly formulate their therapeutic decisions based on ‘Worst day’ results of either 
TR (even isolated pathological SR) and/or reflux-symptom association. 
 
4.5.3 Outcome 
The clinical utility of any investigation and diagnosis is based on its ability to guide 
effective management. Studies have shown that pathologic oesophageal acid exposure 
or reflux-symptom association on pH testing predicts a positive outcome after 
definitive anti-reflux surgery.77,175,264 Furthermore, guidelines recommend against 
surgical management in the absence of a definitive GORD diagnosis.78,265 Thus a false 
negative result on pH testing can have important consequences for the management of 
this patient group and it may be more prudent to ‘rule out’ than ‘rule in’ a diagnosis of 
GORD in this patient group.266  
 
This study reported excellent control of reflux symptoms following anti-reflux 
surgery in 10/12 patients with a negative C-pH study that then received a definitive, 
positive GORD diagnosis on Bravo. The two patients that did not have good symptom 
control had persistent acid reflux-like symptoms. In contrast, only 34% reported a 
good response to optimal conservative therapy (all had GORD); whereas 66% had a 
poor response or were lost to follow-up (9 had GORD). Three of these patients with 
objective evidence of GORD were awaiting surgery and one with evidence also of 
delayed gastric emptying was being treated with prokinetic drugs.  The remaining 5 
patients with poor response to PPI had a diagnosis of GORD based on positive reflux-
symptom association to only a few reflux events. Studies have shown that the 
outcome of surgery is similar in patients with GORD diagnosis based on pathological 
acid exposure or positive reflux-symptom association.77,264 However, whilst such 
individuals may profit from surgery, the primary problem in such cases is likely to be 
visceral hypersensitivity rather than reflux per se 151 and, similar to the patients 
without GORD, it is likely that in these cases treatment with low-dose tricyclic 
antidepressants or directed at reducing chronic visceral pain was preferred by the 
referring clinician. Preliminary reports suggest that a high symptom index on 
prolonged pH-symptom monitoring predicts a poor outcome to Omeprazole 
treatment,151 but numbers in this study were too small to test this hypothesis. 
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This study included 10 patients with mild (Grade A) erosive disease. However, 
studies have shown that oesophagitis LA grade A is not uncommon in asymptomatic 
individuals and that grade A oesophagitis and endoscopy negative reflux disease 
(ENRD) have similar clinical characteristics and physiology (manometry and pH 
studies).267 Moreover, longitudinal studies have shown an important cross-over 
between LA grade A oesophagitis and ENRD groups on repeated endoscopic 
studies.267 Therefore, the presence of grade A oesophagitis does not preclude the need 
for investigation and should not be considered diagnostic for GORD.  In line with 
published guidelines, it is the policy at St Thomas’ Hospital to proceed with anti-
reflux surgery only in the presence of pathological results on physiologic testing,78,268 
even in the presence of pathologic endoscopic findings. Although all patients who 
proceeded to anti-reflux surgery had an initial trial of acid-reducing medication, to the 
best of the investigator’s knowledge the decision for escalation to surgery by the 
majority of referring clinicians/surgeons out with St Thomas’ Hospital also adhered to 
the same published national guidelines. 
4.6 Conclusion 
In conclusion, prolonged wireless pH monitoring had an important clinical impact in 
patients presenting with typical reflux symptoms but negative catheter-based studies. 
Additionally, without a definitive diagnosis, many in this patient group would not 
have received effective therapy based on C-pH results. In most centres at least one in 
three patients that undergo C-pH studies have a negative test result.51 This study 
suggested that if a false-negative diagnosis was suspected, and especially if there was 
a possibility that behaviour may have been modified (catheter discomfort or social 
embarrassment), then prolonged wireless pH studies should be considered. Moreover, 
in patients with intermittent reflux and symptom events on C-pH studies, prolonged 






Normative values and inter-observer 
agreement for liquid and solid bolus 
swallows in upright and supine 
positions and normative values for free 
drinking, standardised meal and post 
meal observation in the upright seated 
position as assessed by oesophageal 




Conventional manometry (with 5-8 pressure sensors) uses point pressure 
measurements to define peristaltic activity and oesophago-gastric junction (OGJ) 
relaxation. Abnormal function is characterised by a few basic patterns: hypertensive, 
hypotensive (‘ineffective’) or absent contractility, oesophageal spasm and incomplete 
OGJ relaxation.78,113 Studies have shown that if normal oesophageal function is 
preserved, bolus transport is almost always successful; however in the presence of 
dysmotility, apart from spasm and hypotensive contractility, the association between 
bolus transport and symptoms is weak with conventional manometry alone.46 
Moreover reproducibility and inter-observer agreement for classification of pathology 
using conventional manometry is only fair.116,269 Many diagnoses based on 
conventional manometry are subjective, sometimes based as much on patient 
presentation as objective measurements of contractility126 making the clinical 
significance of oesophageal dysmotility uncertain.  
 
High Resolution Manometry (HRM), with spatiotemporal presentation of pressure 
data using 21-36 sensors (Figure 5.1), increases the accuracy with which oesophageal 
bolus transport can be predicted and is more sensitive to clinically relevant 
dysfunction that induce symptoms.111,126 HRM-based oesophageal and OGJ normative 
values have been established for 75 asymptomatic controls using a 36 sensor, solid-
state Manoview catheter.125,131,247 Swallows were performed in the supine position 
using 10 x 5 ml water swallows therefore allowing for direct comparison with 
conventional manometry. However swallowing in the supine position does not reflect 
normal behaviour and may be poorly tolerated by patients with ‘true pathology’ and 
impaired bolus transport. Furthermore, symptoms are rarely reproduced after 
swallowing small volumes of water.126 The inclusion of upright solid bolus swallows 
increases the sensitivity for identifying clinically relevant dysmotility;126,270-274 
although this has not yet entered routine clinical practice because standardised 
methodology and normative values are lacking. Although reproducing normal 
swallow behaviour is more likely to induce typical symptoms and provide information 
that is more relevant to the patient, so far no studies have routinely used normal eating 
and drinking to recognise oesophageal pathology. An assessment of oesophageal and 
lower oesophageal behaviour after a meal may also be of value as it may provide 
insight into the mechanisms of reflux in health and disease.  
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Normal values for single liquid and solid swallows in the upright position have been 
reported using a 21 sensor water-perfused HRM catheter, a system which is no longer 
widely used in clinical practice.36 Moreover, only basic parameters were reported 
(contractile length, pressure and velocity in the proximal, mid and distal oesophagus) 
and data was not analysed with HRM metrics and methodology currently in use.36 An 
assessment of normal swallow behaviour (free drinking, eating a standardised meal 
and post-meal observation) have never been formally assessed with 36 sensor HRM.  
 
Solid swallows differ from standard water as they are not always transported through 
the oesophagus with a single peristaltic contraction. Pouderoux et al showed that even 
in healthy subjects up to 4 swallows may be required to achieve clearance of a single 
solid bolus.257 Solid swallows produce complex pressure activity and, as the analysis 





Figure 5.1 High resolution manometry of a normal swallow. Important oesophageal 
landmarks are highlighted. A 30 mmHg isobaric contour was applied. The axial graph 
on the right shows the direction of flow relative to the pressure gradient at the site of 
the red curser (centre). Lower oesophageal sphincter margins are demarcated in the 
axial graph on the right. 
(UOS: Upper oesophageal sphincter, OGJ: Oesophago-gastric junction, PTZ: 
proximal transition zone). 
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 5.1 Aims  
This chapter aims to provide a stepwise analysis of oesophageal function utilising 
current and novel metrics customised for the analysis of 36 sensor solid state HRM.131 
A standardised methodology was proposed and normative values were presented for 
single liquid and solid bolus swallows in the upright and supine positions. An 
assessment of inter-observer agreement then provided confidence that these 
techniques are reproducible. Peristalsis and OGJ function of HRM pressure data in 
both positions and bolus consistencies were compared. In some, swallow assessment 
during a standardised meal followed single bolus testing. Normative values were 
presented and results were compared to upright single bolus water and bread 
swallows. Finally a standardised methodology and reference values were presented 
for free drinking as well as a ten minute post-prandial observation period. A close 
record of symptoms reproduced during and after the meal was made. 
Hypothesis: The challenge of increasing bolus volume and consistency while 
swallowing will influence oesophageal function in a predictable and reproducible 




(please refer to Methods Chapter 2; additional methodology specific for 
this study will be described here) 
 
5.2.1 Study design 
This was a single centre prospective study of normal subjects performed at the St 
Thomas’ Hospital Oesophageal Laboratory. Each subject underwent High Resolution 
Manometry (HRM) in the upright seated and supine (left lateral) position. This 
provided reference values and compared oesophageal peristalsis and OGJ function in 
both positions for liquid and solid swallows. Additionally, inter-observer agreement 
of measurements derived from HRM pressure data was reported. A subset of the same 
patients proceeded to assessment during free-drinking and eating (standardised test 
meal) followed by a 10 minute post-meal observation period. All studies were 
performed in the upright position from which further normative values were derived. 
Oesophageal peristalsis and OGJ function of swallows during water, bread and test 
meal swallows were compared. A stepwise analysis of oesophageal function utilizing 
metrics customized for the analysis of HRM data was applied.131  
 
Ethics was approved by the St Thomas’ Hospital Research Ethics Committee in 
February 2008 (REC reference 07/Q0702/3) – see Appendix 9 
 
5.2.2 Subjects 
23 healthy volunteers were recruited (11 Male: 12 Female; age range 20-56 years, 
BMI range 18-33). None had symptoms suggestive of reflux disease or oesophageal 
dysfunction, nor were any taking medication known to affect oesophageal function or 
gastric acid secretion. (For inclusion/exclusion criteria please refer to Appendix 8) 
 
Swallows 
After a 5 minute adaptation period, subjects were provided with 5 swallows of 5 ml 
water administered with a syringe (liquid swallows) followed by 5 swallows of 1 cm 
cube (1 cc) of bread (solid swallows). Measurements were repeated in the upright 
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(seated) and supine (left lateral) positions. Further details of methods were described 
in section 2.4 of Chapter 2. 
 
10 of the 23 asymptomatic healthy volunteers (6 Male: 4 Female, age range 20-45) 
provided consent also to drink 200 ml of water freely (Multiple Water Swallows; 
MWS) followed by a standardised test meal. These subjects were then observed for a 
10 minute post-prandial period. All were instructed to inform the examiner of 
symptoms as soon as they occurred. Further details of methods were described in 
section 2.4 of Chapter 2. 
 
5.2.3 Data analysis 
Swallow effectiveness for single swallows and the test meal 
Following pharyngeal deglutination, a swallow was classified as peristaltic or non-
peristaltic. Non-peristaltic swallows were divided into  
i) Ineffective peristalsis - defined as either ≥3 cm spasm (>5.3 cm/s; 
simultaneous contraction) or ≥3 cm break in the 30 mmHg contraction 
front of the distal oesophageal segment (Figure 5.2) 
or 
ii) Failed peristalsis  - defined as either absent peristalsis or if contractility 
was <3 cm in length in the distal oesophageal segment within the 30 
mmHg isobaric contour.  
In regards to failed peristalsis, as in previous publications,36,125,247,275 distal 
oesophageal parameters could not be calculated and the swallow was not included in 
summary calculations of normative values; however for the test meal, the number of 
ineffective and failed swallows was included in the overall assessment of ‘swallow 
effectiveness’ and was defined as the frequency of: 
i) Successful swallows 
ii) Ineffective swallows 






Figure 5.2 HRM of an ineffective solid swallow in a healthy subject. The first non-propagating pharyngeal swallow was quickly followed by an 
ineffective peristalsis (spasm). This was not associated with dysphagia, pain or discomfort. All other solid swallows that followed were normal. 
This is an example of how healthy subjects also can present with episodes of ineffective dysmotility, but in the absence of symptoms such events 
were considered to be of questionable significance. 
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HRM parameters and definitions  
(Figure 5.1, 5.3 and 5.4) 
 
Primary outcome measurements known to be associated with effective bolus transport 
were semi-automated; calculated automatically after the peristaltic markers and LOS 
pressure margins were manually repositioned: 
• Proximal transition zone (PTZ) length; a parameter that reflects 
coordination between the proximal and distal contractile segments. The PTZ 
was defined as a separation between the proximal and mid-distal contraction 
front using a 30  mmHg isocontour.36,125,243 (Figure 5.4) 
• PTZ nadir pressure; this was calculated using a semi-automated function in 
the Manoview software (Smartmouse) which calculates the average pressure 
within any fixed area. The PTZ nadir pressure for every swallow was 
measured within the proximal and mid-distal 30 mmHg-derived contraction 
separation. (Figure 5.4) If no break occurred within 30 mmHg, the isobaric 
contour function was manually increased to the pressure at which a break 
appeared within the PTZ region and this was considered to be the PTZ nadir 
pressure. 
• Contractile Front Velocity (CFV); velocity of peristalsis of the distal 
contractile segment referenced to a 30 mmHg isobaric contour.36,125  
• Distal Contractile Integral (DCI); measure of contractile vigour of the distal 
contractile segmental. A parameter that integrates the length (cm), contractile 
pressure (mmHg) and duration (sec) of the distal contraction segment.36,125 
• Integrated Relaxation Pressure (IRP); a parameter that reports the lowest 
mean electronic Sleeve (e-Sleeve) pressure for four continuous or non-
continuous seconds during OGJ relaxation.134 This is a measure of 
compartmentalised pressure between the hiatal canal and the peristaltic 
wavelength (intra-bolus pressure; see below) which takes into account the 
mean gastric pressure for every swallow. It is really a measure of the bolus 
being forced through the OGJ and, can therefore gauge the obstruction of flow 
through the OGJ.  
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Secondary parameters needed to be measured manually using the 30 mmHg 
isocontour (Figure 5.4):  
• Peristaltic oesophageal length; from the lower border of the upper 
oesophageal sphincter (UOS) to the upper border of the lower oesophageal 
sphincter (LOS). 
• Proximal contraction length; from the lower border of the upper oesophageal 
sphincter to the start of PTZ 
• % proximal contraction length; proximal contraction length corrected to the 
total oesophageal length: 
Proximal oesophagus length  x  100 
   Total oesophageal length  
• Distal contraction length; from the end of the PTZ to the upper border of the 
LOS 
• % distal contraction length; distal contraction length corrected to the total 
oesophageal length 
Distal oesophagus length  x  100 
Total oesophageal length  
 
• Distal contraction wave duration; the length of time required for a peristalsis 
contraction wave to pass down the distal oesophagus. (Figure 5.3) 
• Contractile pressure (Amplitude); measured at 3, 7 and 11 cm proximal to 
the upper border of the OGJ (these measurements were provided for direct 
comparison with conventional manometry metrics). 
• Intra-bolus Pressure (IBP); 3 second average of compartmentalised pressure 
below the peristaltic contraction and 1 cm above the OGJ. (Figure 5.3) 
 
During the test meal, to standardise and facilitate comparison between water, bread 
and meals, a uniform 30 mmHg isobaric contour defined peristaltic integrity for all 
swallows.36,125 Primary HRM parameters associated with successful bolus transport 
measured during the standardised test meal were:  
• Integrated Relaxation Pressure (IRP) 134 
• Intra-bolus Pressure (IBP) 
• Contractile Front Velocity (CFV) 36,125 
• Distal Contractile Integral (DCI)36,125  
• Also breaks in the 30 mmHg pressure contour were recored36,125,243,246   
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Figure 5.3 High Resolution Manometry of a normal swallow. Important landmarks 
and metrics essential for predicting bolus transport are highlighted. A 30 mmHg 
contour (black line circumscribing peristalsis) is superimposed on the image.  
(UES: Upper oesophageal sphincter; PTZ Proximal transition zone; EGJ: Oesophago-
gastric junction; IRP: Integrated relaxation pressure, IBP; Intra-bolus pressure, DCI; 
Distal Contractile Integral.)  
(Reproduced from Sweis et al. NGM 2011.276) 
 
 
Figure 5.4 Proximal transition zone (PTZ) measurement technique. (A) After initial 
semi-automated analysis and manual re-positioning, (B) the isobaric contour was 
adjusted to 30 mmHg. (C) The PTZ nadir pressure (bordered by the 30 mmHg-
derived proximal and distal peristaltic segments) was calculated using the Manoview 
‘smart-mouse’ function. (D) Then the vertical length of the proximal (a) and distal (c) 
peristalsis segments as well as the PTZ (b) were measured with the ‘smart-mouse’ 
function and these were corrected to the total length of the oesophageal peristalsis (d). 
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Primary analysis assessed the association between dysmotility and symptoms; 
however apart from during the post-prandial observation period, as no healthy subject 
reported symptoms, symptom association will be covered in Chapter 6. 
 
Multiple Water Swallow (MWS; Free drinking of 200 ml water) 
Primary analysis: 
A semi-quantitative assessment of oesophageal motor suppression and LOS outflow 
obstruction was made during MWS.277 Primary parameters measured during the free 
drinking of 200ml water included: 
• Total volume of water swallowed (without stopping) 
• Total number of swallows required to complete the drink (without stopping) 
• Total time required to complete the  drink (without stopping) 
• Presence/absence of oesophageal clearance contraction after MWS completion 
• Presence/absence of an LOS after-contraction after MWS completion 
• An un-validated score of the degree of obstruction to flow of water was rated: 
0 - no contractions, 1 - almost complete contractions, 2 – partial contractions, 
3 – minimal contractions, 4 - no suppression of contraction/complete 
obstruction.  
 
Secondary MWS analysis measurements included: 
• Number of swallows required to relax the LOS using the 15 mmHg isocontour 
+ the % corrected to the total number of swallows required to complete the 
drink 
• Time required to relax the LOS using the 15 mmHg isocontour + the % 
corrected to the total time required to complete the drink 
• Oesophageal shortening measured as the difference in LOS position pre- and 
post-MWS. The pre-MWS resting LOS position was measured just prior to 
free drinking and the post-MWS position was measured at the initiation of the 
post-peristalsis after-contraction. 
• LOS pressure difference from pre- to post-MWS. The LOS pressure was the 
mean pressure within a 1 cm area from the proximal to the distal LOS 
margins. The difference in LOS pressure was calculated as the difference in 
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pressure just prior to initiation of MWS and at the initiation of the post-
peristalsis after-contraction. 
• Volume per swallow was calculated as the total volume of water drunk 
divided by the total number of swallows required to finish the drink (without 
stopping) 
• Volume of swallow required before LOS relaxation was calculated as the 
predicted volume of every swallow (see point above) multiplied by the total 
number of swallows required before LOS relaxation using the 15 mmHg 
isobaric contour. 
 
Post meal observation period 
During the ten minute observation period, transient lower oesophageal sphincter 
relaxations (TLOSRs), swallow-related lower oesophageal sphincter relaxations 
(SLOSRs) and other events associated with a common cavity (e.g. rumination) were 
recorded.  
 
A TLOSR was defined according to standard criteria:278  
1) absence of swallowing for 4 sec before and 2 sec after the onset of LOS relaxation 
  (this differentiated a TLOSR from an SLOSR by the absence of a swallow during 
the preceding 4 seconds) 
2) a common cavity with an abrupt rise of ≥5 mmHg in intra-oesophageal pressure  
3) spontaneous fall in LOS pressure at a rate of ≥1 mmHg/s 
4) time from onset to complete relaxation of ≤10sec 
 
Finally, the frequency and time that the LOS gradually lost pressure (drift >10 sec) 
which was not associated with a common cavity was recorded. Supra-gastric belching 
was not assessed as concurrent impedance testing was not available. 
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5.2.4 Statistical methods 
Comparing the oesophageal response documented on HRM and barium studies to 
physiologic challenge in 17 healthy volunteers, Fox et al36 revealed an average 
increase of 20% and 10% in contractile pressures for the mid- and distal-oesophagus 
moving from the upright to the supine positions respectively. Similarly, comparing 
liquid and solid swallows revealed an increase of 28% and 16% in contractile 
pressures for the mid- and distal-oesophagus respectively. Therefore for the current 
study, recruitment of at least 20 volunteers was required.  
 
Spatiotemporal plots of upright water and bread swallows were assessed by 3 
investigators and supine swallows were assessed by 2 investigators. The Intra-class 
Correlation Coefficient (ICC) was used to interpret agreement for manually derived 
parameters corrected for chance. An ICC of <0.2 implies little, >0.5 good and >0.80 
almost perfect agreement.279  The study protocol was lengthy and the analysis (if 
completed in detail) was time consuming. Therefore results from a random subset of 
12 healthy volunteers were analysed and rated by the assessors following a brief 
period of training. 
 
Mann-Witney and Wilcoxon tests were used for nonparametric comparisons of 
quantitative swallows. P<0.05 was considered statistically significant. Friedman test 
was used for analysis of variance for multiple comparisons of nonparametric data 
within groups (i.e. comparing water, bread and test meal parameters within the same 
patient group).  Results were reported as Median (Inter-quartile range; IQR) and 
Mean ± Standard Error (Standard Deviation). Normative data was presented with 5th 
and 95th percentiles. Pearson’s coefficient (PC) assessed the strength of relationship 




5.3.1 Single bolus swallows 
Participants 
Manometry was well tolerated and technically adequate swallows were successfully 
acquired in the upright and supine positions for liquid (23 subjects) and solid (21 
subjects) swallows. A median of 5 liquid and 4 solid swallows were available for 
analysis in each position. (UL = Upright liquid; US = Upright solid; SL = Supine 
liquid; SS = Supine solid). The overall number of swallows and peristaltic success for 
every bolus consistency and body position are described in Table 5.1.  
 
The distal oesophageal contractile response showed an increased number of 
simultaneous (spasm) and failed contractions for solid than liquid swallows in the 
upright (LU 13.9% vs. SU 32.1%; p=0.004) and supine (LS 7.6% vs. SS 23.0%; 
p=0.039) positions. On the other hand there was no difference in the frequency of 
nonperistaltic swallows with shift in position of the same consistency (LU 13.9% vs. 
LS 7.6%; p=0.550 and SU 32.1% vs. SS 23.0%; p=0.276). (Table 5.1)  
 
Swallowing behaviour with liquid and solid bolus during the HRM 
study 
A median (range) of 1 (1,1) and 1 (1,3) pharyngeal swallows were required to 
swallow liquid and solid bolus respectively. 11/21 participants required 2 pharyngeal 
swallows and 1 subject required 3 swallows on at least one occasion to clear the 
pharynx of bread prior to the appearance of a distal oesophageal contraction. There 
was no difference in the key parameters which describe the distal oesophageal 
contraction (PTZ length, CFV, DCI) following multiple compared to single 
pharyngeal deglutitions (p = NS for all). 
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Functional anatomy of the oesophagus 
Oesophageal peristalsis (Figure 5.4 and 5.5; Table 5.2 – 5.4) 
Overall oesophageal length was not altered by change in consistency (Liquid 21.8 
(20.6,24.3) cm vs. Solid 22.5 (20.5, 23.9) cm; p=0.537). Proximal Transition Zone 
(PTZ) length was smaller for solid than liquid swallows and in the upright (LU vs. SU 
p<0.001) and supine (LS vs. SS p=0.002) positions. These remained significant when 
corrected for total oesophageal length (LU vs. SU p<0.001 and LS vs. SS p=0.002). 
PTZ length was also smaller when moving from the upright to supine positions for 
liquids (LU vs. LS p=0.002) but not solids (SU vs. SS p=0.08); however these were 
both significant when corrected for total oesophageal length (LU vs. LS p=0.002 and 
SU vs. SS p=0.023). (Table 5.3, Figure 5.4). Similarly PTZ mean pressure was higher 
for solids than liquids in upright (LU vs. SU p=0.001) and supine (LS vs. SS p<0.001) 
positions as well as in the supine than upright position for liquids (LU vs. LS 
p=0.042) and solids (SU vs. SS p=0.005).  
 
The proximal contractile segment (proximal to the PTZ) was not affected by changes 
in bolus consistency in upright (LU vs. SU p=0.560) and supine (LS vs. SS p=0.079) 
positions nor with change in position during liquid (LU vs. LS p=0.094) and solid 
(SU vs. SS p=0.926) swallows. These parameters remained non-significant when 
corrected for oesophageal length (LU vs. SU p=0.073; LS vs. SS p=0.085, LU vs. LS 
p=0.159 and SU vs. SS p=0.835 respectively). On the other hand, the distal contractile 
segment increased in length for solid compared to liquid swallows in the upright (LU 
vs. SU p=0.004) and supine (LS vs. SS p=0.016) positions, and on moving from the 
upright to the supine position for liquids (LU vs. LS p<0.001) and solids (SU vs. SS 
p=0.013). However when corrected for oesophageal length, distal oesophageal length 
did not change for solids when moving from upright to supine position (LU vs. SU 
p=0.002, LS vs. SS p=0.014, LU vs. LS p=0.001 and SU vs. SS p=0.099). (Table 5.3 
and 5.4) 
 
Results for the primary parameters describing oesophageal function are presented in 




Table 5.1 Oesophageal response to liquid and solid bolus in upright and supine positions. Peristaltic swallows were more frequent for liquids than 
solids in both the upright and supine positions 
 
 
Table 5.2 HRM normal values for primary parameters describing oesophageal function for liquid and solid bolus swallows in the upright and 









Figure 5.5 Liquid and solid bolus swallows in the upright and supine positions. Note 
the improvement in coordination between proximal and mid-distal contraction waves 
and the increase in contractile vigour that occurs with movement from upright to 
supine position and with solid bolus consistency.
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 (5.5)(9.1,16.2)(4.8)(5.3,12.2)






Distal contractile integral (mmHg cm-1s-1)
(1.4)(3.1,4.5)(0.8)(2.6,3.3)
35%3.9±0.35.32.83.324%3.1±0.24.12.13.2Wave duration (mean at 3.0 & 7.0 above LES) (sec)
(33.5)(42.6,84.6)(29.8)(38.8,70.6)
48%70.2±7.3134.031.163.952%57.5±6.2102.123.352.0Wave amplitude (@11.0 above LES) (mm Hg)
(55.6)(62.5,116.2)(39.3)(56.0,91.2)
56%99.5±12.1188.241.490.549%79.8±8.2148.431.572.5Wave amplitude (mean, 3.0 & 7.0 above LES) (mm Hg)
Peristaltic Vigour (Contractile pressure, DCI)
(1.3)(2.4,3.5)(1.0)(3.0,3.5)
40%3.2±0.34.41.83.229%3.4±0.24.82.33.3Contractile front velocity (cm/s)
(1.6)(2.4,3.9)(2.2)(3.2,4.9)
44%3.6±0.35.32.03.749%4.4±0.47.72.63.8Onset velocity (between 7.0 & 3.0 above LES) (cm/s)
(1.1)(2.7,3.7)(1.1)(3.3,4.0)
33%3.3±0.24.71.93.229%3.7±0.25.92.23.5Onset velocity (between 11.0 & 3.0 above LES) (cm/s)
Peristaltic velocity
(2.6)(14.1,16.9)(2.5)(13.1,16.0)
16%15.6±0.620.712.914.917%14.6±0.518.111.314.7Distal contractile segment @ 30mmHg (cm)
(1.4)(5.2,6.4)(1.8)(4.1,6.7)
24%5.8±0.37.53.45.735%5.2±0.47.33.05.3Proximal contractile segment @ 30mmHg (cm)
(1)(0,1)(1)(1,2)
134%1±020060%1±0201PTZ time @ 30mmHg (s)
(18.7)19.1,51.3)(12.3)(10.9,25.1)
53%35.0±4.158.011.534.065%18.9±2.645.46.015.1PTZ mean pressure @ 30mmHg (mmHg)












96%1892.6±397.15845.6404.61116.690%1058.7±198.02444.0180.7734.4Distal contractile integral (mmHg cm-1s-1)
(1.0)(2.9,4.2)(0.5)(2.8,3.4)
28%3.6±0.25.52.33.517%3.1±0.14.22.53.0Wave duration (mean at 3.0 & 7.0 above LES) (sec)
(30.2)(42.2,71.5)(22.0)(30.5,64.3)
50%59.9±6.6116.020.151.147%46.8±4.684.022.239.3Wave amplitude (@11.0 above LES) (mm Hg)
(38.2)(63.8,122.4)(34.6)(53.3,97.8)
43%88.4±8.3153.545.674.646%75.0±7.2137.135.857.4Wave amplitude (mean, 3.0 & 7.0 above LES) (mm Hg)
Peristaltic Vigour (Contractile pressure, DCI)
(0.9)(2.4,3.4)(2.2)(3.1,4.4)
28%3.2±0.24.42.03.254%4.1±0.55.52.63.6Contractile front velocity (cm/s)
(2.8)(2.5,4.0)(2.5)(3.5,5.5)
70%4.0±0.66.01.93.751%4.9±0.59.22.64.1Onset velocity (between 7.0 & 3.0 above LES) (cm/s)
(1.4)(2.7,4.0)(1.1)(3.3,4.2)
37%3.7±0.36.32.13.527%3.9±0.26.12.53.5Onset velocity (between 11.0 & 3.0 above LES) (cm/s)
Peristaltic velocity
(2.9)(12.4,15.5)(2.9)(11.1,14.5)
21%14.3±0.618.710.014.523%12.8±0.618.08.612.8Distal contractile segment @ 30mmHg (cm)
(1.9)(4.5,7.3)(1.8)(3.6,6.1)
31%5.9±0.48.53.75.437%4.9±0.46.92.65.0Proximal contractile segment @ 30mmHg (cm)
(1)(0,1)(1)(1,2)
119%1±030155%2±0412PTZ time @ 30mmHg (s)
(13.9)(12.9,29.5)(7.2)(8.3,17.9)
57%24.3±3.049.010.320.353%13.6±1.524.95.012.3PTZ mean pressure @ 30mmHg (mmHg)









Table 5.4 HRM parameters defining the functional anatomy of the oesophagus.  
(PTZ = Proximal transition zone break in contractile pressure front; CV = Coefficient 
of variation) 
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 Lower Oesophageal Sphincter 
The median (IQR) LOS basal pressure was 22.9 (13.7,27.0) mmHg in the upright and 
18.9 (12.8,26.4) mmHg in the supine position (p=0.516). The median (IQR) LOS total 
length was 3.2 (3.0,3.6) cm and the intra-abdominal length was 2.0 (1.5,2.6) cm. This 
did not change between liquid and solid swallows in the upright (LU vs. SU total 
p=0.680 and intra-abdominal p=0.459 LOS length) or supine (LS vs. SS total p=0.513 
and intra-abdominal p=0.566 LOS length) position respectively. (Table 5.5) No 
healthy subject had a hiatus hernia at baseline.  
 
 
Table 5.5 Lower oesophageal sphincter (LOS) measurements. Upright and supine 
basal pressure, total and intra-abdominal length for liquid and solid swallows.  
Baseline LOS pressure was the same for liquid and solid swallows. Total and intra-
abdominal length was measured separately for every swallow.   
 
Integrated Relaxation Pressure (IRP) and Intra-Bolus Pressure (IBP) 
IRP was higher for solids than liquids in both positions (LU vs. SU and LS vs. SS; 
p<0.001 for both). At the same time IRP was higher in the upright than the supine 
position for both bolus consistencies (LU vs. LS p=0.002, SU vs. SS p=0.004) (Table 
5.2, Figure 5.6)  
 
Similarly IBP was higher for solids than liquids in both positions (LU vs. SU and LS 
vs. SS; p<0.001 for both) as well as in the upright than the supine position for both 
bolus consistencies (LU vs. LS p=0.029, SU vs. SS p=0.006) (Table 5.4, Figure 5.7) 
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Peristaltic velocity 
There was a significant decrease in contractile front velocity (CFV) for solid 
compared to liquid swallows in the upright position (LU vs. SU p=0.01). This 
decrease in CFV did not reach significance in the supine position (LS vs. SS 
p=0.186). Also no effect on CFV was observed for position change for liquids and 
solids respectively (LU vs. LS p=0.118, SU vs. SS p=0.663). (Table 5.2, Figure 5.8).  
 
Contractile vigour 
Contractile vigour (DCI), was greater for solid than liquid swallows in the upright 
(LU vs. SU p<0.001) and supine (LS vs. SS p=0.001) positions. All parameters 
increased also with change from the upright to the supine positions although these 
effects were not significant (LU vs. LS p=0.287 and SU vs. SS p=0.543). (Table 5.2, 
Figure 5.9)  
 
These trends were consistent also for point measurements of contractility. Proximal to 
the LOS, contractility was higher for solid than liquid bolus in upright (LU vs. SU 
p<0.031) and supine (LS vs. SS p<0.001) positions. Although all parameters 
increased with change from upright to supine positions these did not achieve 































Figure 5.10 Effects of position change and bolus consistency on mean contractility at 
3 and 7 cm proximal to the LOS 
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Inter-observer agreement  
For parameters derived manually from spatiotemporal plots in the upright and supine 
position, the Intra-class Correlation Coefficient (ICC) between 3 assessors was >0.5 for 
all parameters measured using liquid and solid swallows. This implies very good 
agreement. The only exception was for velocity which was non-significant for both 





Table 5.6 Inter-observer agreement. Intra-class Correlation Coefficient (ICC) between 
single liquid and solid bolus swallows for manually derived parameters in the upright 
and supine positions.  
ICC <0.2 = little, >0.5 = good, >0.80 = excellent agreement 
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5.3.2 Test meal, Multiple water swallows and post-prandial 
observation 
Participants 
Manometry was tolerated and technically adequate swallows were acquired for 5 ml 
water, 1 cc bread and test meal for all 10 of the 23 healthy participants who agreed to 
carry on with the study protocol. This also included free drinking of 200 ml water 
(MWS) and a post-prandial observation period. The 13 who did not consent expressed 
concern at having a catheter in situ for longer periods and preferred to complete only 
the standard protocol of 5 ml water and 1 cc bread. No healthy subject was found to 
have a major motility disorder during the standard 5 ml water swallows (i.e. 
aperistalsis, oesophageal spasm, achalasia).  
 
Water, bread and meal swallows in health: Motility and Function  
(Table 5.7 and Figure 5.11) 
There was a significant improvement in co-ordination (shorter median PTZ length and 
increased median pressure) during the test meal (0.7 cm and 42 mmHg) compared to 
water (3.2 cm and 13.7 mmHg) and bread (2.3 cm and 26.3 mmHg) swallows 
(Friedman p=0.004 and p=0.002 respectively). There was also an increase in the 
median contractile vigour (DCI) of the distal oesophageal segment during the test 
meal (1735.0 mmHg cm-1 s-1) compared to water (919.2 mmHg cm-1 s-1) and bread 
(934.0 mmHg cm-1 s-1) swallows (Friedman p=0.001). There was no difference in IRP 
between the meal study, single water (p=0.262) or bread (p=0.208) swallows. On the 
other hand, there was a steady increase in the overall median IBP from water (6.8 
mmHg; p=0.005), to bread (12.0 mmHg; p=0.017) and the test meal (19.4 mmHg; 
Friedman p=0.001). CFV was more rapid during water (3.7 cm/s; p=0.005) and bread 
(3.2 cm/s; p= 0.012) swallows than the test meal (2.1 cm/s; Friedman p=0.002).  
 
Lower oesophageal sphincter (LOS) 
LOS baseline studies were performed once at the start of the test after the patient 
acclimatised to the presence of the catheter (see Methods Chapter 2).  LOS baseline 
pressure (19.0 (11.8, 27.7) mmHg), total LOS length (3.2 (2.9,3.2) cm) and intra-




Table 5.7 Key parameters describing oesophageal motility and function in healthy subjects during water swallows, bread swallows and the test 




Figure 5.11a         Figure 5.11b 
Figure 5.11 Effect of changing bolus consistency (water, bread, meal) on primary parameters known to affect bolus transport. (n=10) Results are 
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Swallow effectiveness for standardised meal 
The median consumption time for the standardised meal was 399 (range 307-550) 
seconds and a median (IQR) of 29 (27,32) pharyngeal swallows were required to 
complete the meal. Of a total of 325 swallows, 167 (51.4%) were observed to be 
effective while 158 (48.6%) were non-peristaltic; 52 (16%) were ineffective (spasm or 
break in contractility ≥3cm) and 106 (32.6%) failed (<3 cm contraction). There was 
no correlation between the number of effective swallows and the time required to 
consume the meal (PC 0.351 p=0.320). (Figure 5.12) A representative HRM plot of 
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Figure 5.12 Frequency of effective swallows required to consume the meal over time 
in 10 healthy subjects. 
(PC = Pearson’s correlation) 
 
 
Figure 5.13 Frequency of effective swallows during a standardised test meal in a 
healthy volunteer. Labels are assigned to define the character of every 
pharyngeal/oesophageal deglutition. 
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 Multiple water swallows (MWS) in health  
A median (IQR) of 15.5 (11.8, 20.3) swallows were required to drink 200 ml water 
over a period of 22 (19, 29) seconds. (Table 5.8) A median (IQR) of 2 (0,3) swallows 
were required to open the LOS during free drinking. It was calculated that each 
swallow comprised a median of 13.5 ml, and an average of 25.6 ml (out of 200 ml) of 
water needed to be swallowed to achieve LOS opening at 15 mmHg. Furthermore, the 
oesophagus shortened by 0.3 (0.0,0.7) cm and the LOS pressure increased by 7.6 
(5.4,14.5) mmHg after completion of the MWS. (Table 5.9)  
 
8 out of 10 subjects had a post-MWS effective ‘clearing’ peristalsis event and 8 out of 
10 also had an effective LOS after-contraction. (Figure 5.14) 
 
 
Table 5.8 Oesophageal function during and after multiple water swallows (MWS) for 
10 healthy volunteers.  
 
 
Table 5.9 Secondary analysis results for Multiple Water Swallows (MWS) in 10 
healthy volunteers. 




Figure 5.14 High resolution manometry of a normal 200 ml water swallow showing deglutitive inhibition and relaxation of the oesophagus and 
LOS followed by an effective ‘clearing’ post-MWS peristalsis and LOS after-contraction. In this example 5/19 pharyngeal swallows were required 
to open the LOS at 15 mmHg (isobaric contour) after which water passed freely into the stomach. The post-peristalsis LOS contraction also 
prevented reflux of gastric content. 
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5.3.3 Symptoms 
No healthy volunteer complained of symptoms during the water, bread or test meal 
study. Therefore a symptom-dysmotility association analysis was not performed; 
however this will be described in detail in Chapter 6. 
 
Post-prandial observation 
During the 10 minute post-meal observation period, healthy participants exhibited a 
median (IQR) of 2.0 (1.3,3.5) episodes of spontaneous (TLOSR) and 1.0 (0.0,1.0) 
swallow-related (SLOSR) relaxations of the LOS with common cavity events. These 
were associated with a median (IQR) of 2 (2,4) belch events. Furthermore, a gradual 
LOS drift >10 seconds with loss of pressure but no common cavity was seen in 3/10 
healthy volunteers over a median of 15 (maximum 25) seconds. No volunteer 
complained of adverse symptoms (discomfort, chest pain, nausea or vomiting). (Table 
5.10) A representative post-prandial HRM plot typical of a healthy individual is 




Table 5.10 Post meal observation in 10 healthy volunteers. Parameters are presented 
as median (IQR) 
(TLOSR = Transient lower oesophageal sphincter relaxation; SLOSR = Swallow-






Figure 5.15 Post meal observation period in a healthy volunteer (a) A typical HRM trace showing 1 SLOSR followed by a common cavity event 
and belch. This was then followed by an effective ‘clearing’ peristalsis. (b) Example of a common cavity event with 3 TLOSRs as well as 2 






5.4 Summary of results  
• High Resolution Manometry can be used to measure physiological, clinically 
relevant swallows of liquids and solids in the upright seated position. 
• As workload on oesophageal function increased with movement from the upright 
to the supine position and from liquid to solid swallows, oesophageal contractile 
response was slower (lower contraction front velocity), better coordinated (shorter 
proximal transition zone) and more vigorous (greater distal contractile integral).  
• There was significant agreement between independent observers for manually 
measured parameters during liquid and solid swallows derived from HRM 
spatiotemporal plots in both positions and viscosities; intra-class correlation 
coefficient between 3 assessors was >0.5 for all parameters measured 
• Results presented in this chapter can be used as reference values and the technique 
can be replicated in clinical practice. These were used to study the effects on 
patients in Chapter 6.  
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5.5 Discussion 
The most appropriate and clinically relevant measurement protocol for oesophageal 
manometric studies has not been established. Currently, for both conventional and 
high resolution manometry,  diagnostic classifications are based on repeated small 
volume swallows of water in the supine position.113,131 This non-physiological testing 
method does not represent normal behaviour and symptoms are rarely triggered. It has 
been suggested that using the physiological, upright seated position and including 
solid swallows increases the sensitivity to symptomatic dysmotility and 
dysfunction;270,271,273,274,280,281 however this is not routine practice, a standardised 
method is not available, reference values have not been established and interpretation 
of data is more complex. High resolution manometry, with its spatiotemporal 
representation of pressure data, can facilitate the analysis of oesophageal motility,282 
and can provide a better understanding of oesophageal function and structure during 
‘challenge swallows’ (e.g. solids). Studies presented in this chapter propose a 
conceptual shift in the assessment and classification of oesophageal motility. Instead 
of restricting to small volume water swallows in the supine position, normative values 
for key HRM parameters of peristaltic and OGJ function are presented for swallows 
of different volumes, consistencies and positions. Furthermore inter-observer 
agreement provides confidence that these techniques are reliable and reproducible.  
 
Standard parameters of oesophageal function for liquid swallows in the supine 
position (LOS basal and relaxation pressure, peristalsis velocity) were similar to 
published values.131 Only contractile pressures and DCI were somewhat lower than 
those reported by Ghosh et al.125 which used HRM equipment from the same 
manufacturer (Manoview). Although the reason for this is not clear, it is likely related 
to differences in demographic factors between the population groups in each study 
(e.g. age, obesity and racial background).50,283,284 The effects of position and bolus 
consistency on oesophageal function were consistent with previous studies using 
standard and high resolution manometry.36,137,244  
 
The most important findings in this chapter were that in healthy subjects as the 
workload on the oesophagus increased with movement from the upright to the supine 
position and in particular from swallowing liquids to solids, oesophageal contractile 
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response was slower (slower contraction front velocity (CFV)), better coordinated 
(shorter proximal transition zone (PTZ) with increased nadir pressure) and more 
vigorous (greater distal contractile integral (DCI)). (Tables 5.2-5.4) Bolus 
characteristics and position change both affect the coordination of peristaltic 
contraction in healthy, asymptomatic volunteers by promoting contractility in the 
distal segment. Preservation of the oesophageal response to solid bolus or swallowing 
in the supine position may provide useful options to test the oesophagus’ ability to 
respond to ‘physiological challenge’ (which increases workload on the oesophagus).   
 
Although normal LOS relaxation was observed for all swallows, IRP increased during 
solid swallows compared to liquids. Possible explanations for this phenomenon are 
that there may be more friction between the solid bolus and the luminal wall.126 In 
addition, there was a small but consistent rise in IRP from the supine to the upright 
seated position. This was unexpected and is likely to be due to the increased 
hydrostatic forces in the distal oesophagus in the upright position. Also changes in 
OGJ anatomy may alter resistance to flow across the OGJ during this shift in 
position.285 Further testing with fluoroscopy or MRI studies may help describe this 
phenomenon.  
 
The coefficient of variation (CV) was used to identify the degree of intra-individual 
variation for each parameter, and indeed there was a high degree of variation for all 
measurements. This was particularly true for point measurements of contractility and 
distal segment contractile vigour (DCI) for which CV exceeded 100%. These findings 
confirm previous reports of increased variation in healthy individuals125,131,247 (as well 
as in patients; Chapter 6). More importantly, the high frequency of ‘abnormal’ yet 
asymptomatic peristalsis (especially hypotensive, hypertensive and simultaneous 
contractions) in healthy individuals demonstrates that manometric findings should not 
be classified as ‘dysfunction’ or considered abnormal unless they are coupled with 
symptoms; a concept that will be further explored in Chapter 6. 
 
Even among experts in specialist centres, the inter-observer agreement for 
manometric classification of individual water swallows using conventional 
manometry is only fair to moderate.269 Until now, an inter-observer assessment for 
HRM findings during solid swallows or position shift has not been performed in 
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routine practice. Semi-automated analysis of key parameters is provided by the 
proprietary software; however all require accurate pre-analysis demarcation of 
swallow margins and re-positioning of markers (described in Chapter 2). This 
becomes considerably more arduous with ‘challenge’ swallows (single solid and test 
meal). Nevertheless, this chapter demonstrates that despite the increased level of 
complexity, such novel techniques and measurements are easy to learn and are 
reproducible as significant agreement was achieved between independent observers 
for manually derived parameters during challenge swallows even after only a brief 
initial period of training. It is interesting to note that inter-observer agreement for 
peristaltic velocity and, to a lesser extent other parameters, was reduced in the upright 
than the supine positions. The observers reported that this was often a result of 
difficulty in the placement of measurement landmarks in the upright position due to 
reduced coordination (wide proximal transition zone) and low contractile pressures, 
especially with water swallows. This was not unexpected, and was clearly seen in 
Table 5.2-5.4 and Figure 5.5; contractility decreased and PTZ widened significantly 
from the supine to the upright seated position as workload reduced and the 
oesophagus relies more on gravity for bolus transport. Nevertheless, when looking at 
results from all healthy subjects, there was no statistical difference in the vigour of 
contractility (DCI) nor in the bolus transport velocity (CFV) between the upright and 
supine positions for either consistency (Table 5.2 and 5.4 and Figures 5.8-5.10). 
Furthermore, when corrected for total oesophageal length, PTZ coordination (% distal 
segment length) did not change for solids when moving from the upright to the supine 
position. (Table 5.3) These findings imply that, at least for solid swallows, the upright 
position imposes sufficient force which is at least comparable to the supine. On the 
other hand, as the upright position was better tolerated and more physiological and as 
solid swallows increase the workload on the distal oesophagus, it was considered the 
preferred method for patient testing at St Thomas’ Hospital. Chapter 6 will show that 
compared to water alone, swallowing solids in the upright position and consuming a 
standardised meal was a better discriminator for identifying pathology than with water 
swallows as relevant symptoms were more likely to be induced. 
 
It is important to describe why ICC (intra-class correlation coefficient) was preferred 
to Kappa analysis for inter-individual variability. Kappa analysis is most suitable for 
comparing 2 assessors and although the Fleiss statistic can be used to extend the 
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measure to multiple assessors both Kappa and Fleiss statistic of analysing inter-
assessor agreement are suitable only for nominal or ordinal-level data,286 while 
quantitative measurements were compared in this study. 
 
Compared to the standard small volume water and bread swallows, DCI, coordination 
and (in most cases) intra-bolus pressure improved with the increased workload of the 
standardised meal (Table 5.7, Figure 5.11b). These findings are consistent with results 
from previous studies.36,126 Interestingly IRP appeared not to change (Table 5.7, 
Figure 5.11a). One possible explanation is because unlike the continuous nadir 
pressure used in early manometric measurements, the automated IRP parameter 
chooses 4 continuous or non-continuous seconds with the lowest mean pressure 
across the LOS within the deglutitive period while gastric pressure remains a stable 
reference.134 Therefore, as long as there is no intrinsic and continuous structural 
resistance to flow or functional pathology at the OGJ (i.e. as long as there is a non-
continuous 4 second period within the deglutition in which IRP relaxes) effective 
clearance can be achieved and IRP should be normal. 
 
Stationary HRM studies can provide insight into the structure and function of the OGJ 
(LOS pressure, intra-abdominal LOS length, hiatus hernia size) in more detail than 
conventional manometry.247,287 However in the absence of concomitant impedance-
pH monitoring or fluoroscopy, baseline HRM measurements using 5ml water 
swallows are not able to predict the severity of reflux or the likelihood that symptoms 
may occur during or after meals.  On the other hand after the standardised meal a 10 
minute postprandial observation period provided insight into the behaviour of the 
OGJ in the healthy oesophagus. After a refluxogenic test meal and smoothie, transient 
(TLOSR) and swallow associated (SLOSR) lower oesophageal spincter relaxations 
were observed in healthy subjects. Many of these were accompanied by common 
cavity events (i.e. reflux); however almost all of these were then followed by a well 
coordinated ‘clearing’ peristalsis. Moreover, apart from the occasional belch, subjects 
were almost never conscious of these events taking place. This study standardised the 
methodology and analysis technique for the postprandial observation period (see 
Chapter 6 for the assessment of patients). 
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5.6 Conclusion 
This study provided normative values for oesophageal peristalsis and oesophago-
gastric junction function in healthy individuals during the physiological upright seated 
position. Single water and bread swallows were followed by free drinking and, in 
those who consented, a reflux provoking test meal which was typical of a western 
diet. Then a brief post-prandial observation period assessed the mechanistic effect of 
the OGJ and oesophagus. HRM spatio-temporal plots for upright single swallows 
were compared with standard supine swallows for both liquid and solid swallows. 
Significant differences for key variables measured in the upright and supine positions 
and for liquid, solid and test meal swallows confirmed that the oesophagus responds 
predictably to increased workload by improving coordination, increasing contractility 
and reducing velocity of peristalsis. Variations in response to body position and bolus 
consistency imply that different normative values should apply for every study 
condition. Taken together, the consistency of these results with the literature (e.g. 
supine water swallows) and the positive inter-observer agreement provide assurance 
that measurements acquired using these techniques are valid and can be reliably 
applied in research and in clinical practice. Normative values methodology presented 
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Dysphagia and other symptoms associated with impaired oesophageal function 
usually occur while consuming food or drink. Heartburn and symptoms of gastro-
oesophageal reflux occur mostly after meals. Presenting symptoms alone are an 
unreliable guide to identifying oesophageal dysfunction.15,16 If clinical history and 
endoscopy are inconclusive then guidelines recommend oesophageal manometry and 
pH studies;78,288 however in many patients conventional manometry (with 5-8 
pressure sensors) also fails to establish the cause of symptoms.111,126 Furthermore, the 
clinical relevance of this assessment is open to question because small volume water 
swallows are not representative of normal drinking and eating behaviour as they do 
not ‘challenge’ oesophageal function and rarely trigger symptoms. 
 
Presently normal values for both conventional and high resolution manometry (HRM) 
are obtained from 5 ml water swallows in the supine position.78,125,247,288 In Chapter 5 
HRM normative values were presented and a high inter-observer agreement was 
documented for both water and bread swallows in the standard supine and 
physiological upright seated positions.275 Consistent with previous studies in healthy 
volunteers,36,137,244 the oesophagus responded to the ‘physiological challenge’ of 
changing position and bolus consistency by improving coordination and increasing 
the vigour of peristaltic contractions. In patients, Daum et al245 showed that similar 
results were seen with non-erosive reflux disease; however failure to respond to the 
‘challenge’ of solid swallows was associated with pathological acid exposure on 
ambulatory pH-studies and the presence of erosive oesophagitis. This suggests that 
HRM studies with bread swallows increase sensitivity to clinically relevant 
dysfunction. This chapter tested the hypothesis that the same methodology should also 
demonstrate a mechanistic link between oesophageal dysfunction and oesophageal 
symptoms.    
 
The diagnosis of gastro-oesophageal reflux disease (GORD) is established with 
ambulatory pH studies either on the basis of increased oesophageal acid exposure or 
the association of reflux events with symptoms.2 The latter provides a direct 
explanation for patient symptoms289 and can guide management.77,151,175,268 As yet 
ambulatory HRM is not available but stationary HRM facilitates the description of 
complex pressure events that are induced with solid swallows and identifies 
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symptomatic dysfunction not detected by conventional studies;111,290 however a 
standardised dysmotility-symptom association parameter has not yet been proposed. 
Additionally, as demonstrated in the previous chapter, HRM facilitates the assessment 
of the oesophago-gastric junction (OGJ) and the degree of separation between the 
intrinsic and diaphragmatic components of the OGJ in hiatus hernia. It can also 
identify transient lower oesophageal sphincter relaxation (TLOSR), reflux (common 




The detection of abnormal pressure events in close temporal association with 
symptoms has inherent face validity. A novel methodology for HRM analysis of 
oesophageal function during a standardised test meal, free drinking and the post-
prandial period was presented in Chapter 5. The aim of this chapter was to provide an 
assessment of oesophageal motility and function in patients with endoscopy negative 
dysphagia, chest pain and symptoms suggestive of gastro-oesophageal reflux.78,113 
Results from healthy volunteers presented in Chapter 5 were compared with patients. 
A novel parameter that measures the association between dysmotility and symptoms 
(similar to the Symptom Index of ambulatory pH studies) was proposed. The final 
diagnosis, management and outcome of patients were assessed at 2 years follow-up to 
provide insight into the reliability and clinical utility of this methodology. 
 
Hypothesis: In patients with symptoms of reflux and dysphagia, eating and drinking 
will identify pathology and induce symptoms not seen with standard small volume 
water swallows. Furthermore these finding based on these techniques should 
influence management decisions. 
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6.2 Methods  
(please refer to Methods Chapter 2; additional methodology specific for 
this study will be described here) 
6.2.1 Study design 
This was a prospective study of patients presenting with typical symptoms of reflux 
with/without dysphagia. Patients underwent a similar protocol to healthy volunteers 
described in the Methods of Chapter 2 and Chapter 5, albeit only in the physiological 
upright position; small volume single bolus water and bread swallows, free drinking, 
standardised test meal and post-prandial observation. Measurements associating 
symptoms with dysmotility were determined. Patients were then followed up to two 
years after initial diagnosis. 
6.2.2 Patients 
18 patients were referred for investigation of typical GORD-like symptoms 
(heartburn, acid regurgitation) of whom 7 also had symptoms of dysphagia. All 
patients completed five x 5 ml water and five x 1 cc bread swallows. This was 
followed by free drinking of 200 ml of water through a straw (Multiple Water 
Swallow; MWS) and eating of a refluxogenic test meal (cheese and onion pie and 
200ml fruit smoothie). The study was terminated after a 10 minute postprandial 
observation period. Reference values from the 10 healthy volunteers who completed 
the study protocol (Chapter 5) were used to define pathology. (For inclusion/exclusion 
criteria please refer to Appendix 8) 
6.2.3 Data Analysis 
Data acquisition and analysis was identical to that described in Methods sections of 
Chapter 2 and Chapter 5. Primary analysis compared the occurrence of oesophageal 
dysmotility, symptoms and their association in both healthy volunteers and patients. A 
secondary analysis compared patients with pathological (GORD) and normal 
(Functional Heartburn; FH) results on ambulatory pH monitoring. 
Single bolus swallows 
Single swallows of 5 ml water and 1 cc bread were performed in the physiological 
upright position. Details of the metrics analysed was presented in section 5.2.3. 
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Standardised test meal 
I. Primary HRM parameters for meal studies were similar to single bolus swallows: 
• Integrated Relaxation Pressure (IRP) 
• Contractile Front Velocity (CFV) 
• Breaks in the 30 mmHg pressure contour 
• Distal Contractile Integral (DCI)  
• Intra-bolus Pressure (IBP) 
 
II. Primary HRM functional measurements included: 
• the frequency of successful/ineffective/failed peristalsis following every 
pharyngeal swallow 
 
III. Primary MWS functional measurements included:  
• Total volume 
• Total number of swallows 
• Total time required to complete the drink 
• A semi-quantitative assessment of oesophageal motor suppression 
0 = complete inhibition of contractility 
1 = almost complete (<3cm contraction) inhibition 
2 = partial (incomplete peristaltic contractions or spasm) inhibition 
3 = minimal (complete peristaltic contraction or spasm) inhibition 
4 = repeated contractions / no inhibition  
• Presence/absence of a post-MWS clearance contraction  
• Presence/absence of a post-MWS LOS after-contraction. 
 
IV. Primary post-meal functional measurements included: 
• Frequency of Transient LOS relaxations (TLOSRs) 
• Frequency of Swallow-related LOS relaxations (SLOSRs) 
• Frequency of common cavity (reflux) events in both TLOSRs and SLOSRs 
• Total number of other events that may be associated with reflux (e.g. slow 
drift of LOS pressure to zero, rumination) 
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Association of pressure events with symptoms 
Only symptoms volunteered by the patient were recorded on the HRM spatio-
temporal plot and were included in the analysis. Symptom-associated oesophageal 
dysfunction (SAD) was defined as a symptom event reported up to 10 seconds after a 
dysmotility or dysfunction (including reflux) event on HRM. Oesophageal 
Dysfunction-Symptom Index (D-SI) was defined as the number of SAD events 




This parameter was similar to Reflux-related Symptom Index described during 
ambulatory reflux studies. (Methods Chapter 2, Chapter 3 and 4) D-SI was assessed 
with a diagnostic cut-off >50% 
 
Dysmotility episodes were not used as the denominator (i.e. a parameter akin to the 
Symptom Sensitivity Index) as it would not be possible to differentiate between 
‘dysmotility’ leading to dysfunction and normal function; up to 49% of swallows in 
asymptomatic healthy individuals were not peristaltic and many of these were non-
propagating pharyngeal swallows. (Chapter 5) 
24 hour catheter-based pH monitoring 
All patients had 24 hour catheter-based pH monitoring (C-pH) using Digitrapper™ 
Slimline™ (Medtronic Inc., Shoreview, MN) while off acid suppressant 
medication.259 A standard technique for preparation, investigation and analysis was 
employed (see Methods Chapter 2). Total Reflux (TR; percentage oesophageal acid 
exposure below pH 4) was the primary outcome measurement on which GORD 
diagnosis was based and standard diagnostic cut-offs were implemented.78,85,103,250 A 
symptom event was considered to be related to a preceding reflux event if it occurred 




Diagnosis and follow-up 
HRM findings and diagnosis based on the physiological challenge techniques and 
novel metrics described above were compared with the clinical outcome up to 2 years 
follow-up. Follow-up was based on patient self-reported outcome assessment and/or 
referring physician/surgeon written/verbal assessment of progress. (See Chapter 2) 
 
6.2.4 Statistical analysis 
Mann-Witney and Wilcoxon tests were used for nonparametric comparisons of 
quantitative swallow parameters between and within groups respectively. P<0.05 was 
considered statistically significant. Friedman test was used for analysis of variance for 
multiple comparisons of nonparametric data within groups (i.e. comparing water, 
bread and test meal parameters within the same patient group). Fisher exact test was 
used to assess the difference in the frequency of effective and ineffective oesophageal 
and LOS aftercontraction between the groups. 
 
Pearson’s coefficient (PC) assessed the strength of relationship between the frequency 
of effective swallows and the total time required to consume meals between healthy 
subjects and those presenting with symptoms. 
 
6.3 Results 
6.3.1 Participant demographics 
10 asymptomatic healthy volunteers (male:female 6:4, age 20-45; described in 
Chapter 5) and 18 patients (male:female 5:13, age 32-76) were recruited. Patients 
reported heartburn (n=17) and/or acid regurgitation (n=12) as well as dysphagia 
(n=7), chest pain (n=8) and one had recurrent cough. (Figure 6.1)  
 
Endoscopy 
Endoscopy findings included 8 with normal mucosa (i.e. non-erosive mucosa and no 
hiatus hernia), 4 with grade A oesophagitis and 3 with a short (<3 cm) segment of 
Barrett’s oesophagus. Endoscopically, a small hiatus hernia (<3 cm) was visualized in 


























































Figure 6.2 Endoscopy findings among the 18 patients studied. 7 patients had hiatus hernia overall, 4 of whom also had Barrett’s oesophagus or 
Grade A oesophagitis.  
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Manometry and ambulatory pH monitoring 
Manometry was tolerated and technically adequate swallows were acquired for water 
swallows and the test meal for all volunteers and patients. One patient stopped the 
post-meal observation early due to intolerance. Following ambulatory pH monitoring, 
11/18 (65%) patients had a diagnosis of GORD based on a pathological total 
oesophageal acid exposure (TR; median 11.1% (IQR 6.4%,15.5%)). Of those, 9 also 
had a positive reflux-symptom association (SI >50%); 5 for heartburn alone, 3 for 
regurgitation alone and 1 for heartburn, regurgitation and chest pain together. The 
remaining 7 patients (39%) had normal acid exposure (median 0.9% (IQR 
0.1%,1.8%)) and no reflux-symptom association with ambulatory reflux studies (i.e. 
Functional Heartburn (FH)). 3 of these had no dysphagia symptoms at presentation. 
 
6.3.2 Water, bread and meal swallows in healthy subjects and 
patients: Motility and Function  
 
As was seen with healthy subjects (Chapter 5), during the test meal patients exhibited 
an improvement in co-ordination (shorter PTZ length; Friedman p<0.001 and 
increased PTZ nadir pressure; Friedman p<0.001) as well as a more vigorous distal 
contractile force (DCI; Friedman p=0.003) compared to 5ml water and bread 
swallows. There was no change in IRP between bread and test meal (p=0.396). 
Compared to water swallows, although IRP was greater during the test meal, this did 
not quite achieve statistical significance (p=0.061). There was no change in 
contractile velocity of the distal segment between water, bread and meals (p=0.936). 
(Table 6.1) 
 
In the GORD group (n=11), IRP, IBP, DCI and PTZ nadir pressure increased and 
PTZ length decreased with the standardised meal compared to water or bread 
(Friedman p<0.05 for all). This suggests a more peristaltic, coordinated and vigorous 
contraction. Although changes in velocity were not significant, semi-automated 
landmarks were not always easily applicable during the test meals thus making 
accurate calculation difficult. (Table 6.2 and Figure 6.3). 
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7/18 (39%) patients had normal measurements on pH monitoring and were defined as 
having Functional Heartburn (FH). Of these 4/7 (57%) had symptoms of dysphagia at 
presentation. All 7 patients also had symptoms of heartburn ± regurgitation or chest 
pain. (Table 6.3) In this group, IRP and IBP did not change from water swallows to 
the standardised meal, nor was there a difference in the distal contractile vigour or 
front velocity (p=NS for all). On the other hand, coordination did significantly 
improve from water to standardised meal; shortened PTZ length and raised PTZ nadir 




Table 6.1 Key parameters describing oesophageal motility and function for all (n=18) 
 
 




Figure 6.3a         Figure 6.3b 
Figure 6.3 Effect of changing bolus consistency (water, bread, meal) for primary parameters known to affect bolus transport in patients with 
GORD (n=11). Results are presented as median values.  
(IRP = Integrated Relaxation Pressure; IBP = Intra-bolus Pressure; PTZ = Proximal Transition Zone; CFV = Contractile Front Velocity; DCI = 
Distal Contractile Integral)  
























IRP (mmHg) IBP (mmHg) PTZ break P
(mmHg)















Table 6.3 Key parameters describing oesophageal motility and function in patients with Functional Heartburn (n=7). 
 
 
Figure 6.4a          Figure 6.4b    
Figure 6.4 Effect of changing bolus consistency (water, bread, meal) for primary parameters known to affect bolus transport in patients with 






















IRP (mmHg) IBP (mmHg) PTZ break P
(mmHg)
PTZ length (cm) CFV (cm/s)
No GORD Water
No GORD Bread 
No GORD Meal










No GORD No GORD No GORD
 205 
Lower oesophageal sphincter (LOS) 
Comparing the study groups, there was no significant difference in LOS baseline 
pressure between healthy subjects (19.0 (11.8, 27.7) mmHg) and patients (18.4 (9.8, 
25.4) mmHg; p=0.649). Nor was there a difference compared to those with Functional 
heartburn (18.8 (18.4,31.1) mmHg; p=0.536). Although patients with GORD had a 
lower median LOS (10.4 (9.6, 20.8) mmHg) this did not achieve statistical 
significance (p=0.245). 
 
The total LOS length was similar in healthy subjects and all patients (3.2 (2.9,3.2) cm 
vs. 3.1 (2.8,3.6) cm; p=0.981) and this did not change during a sub-analysis of those 
with GORD (3.0 (2.4,3.3) cm; p=0.458) and Functional heartburn (3.2 (3.1,3.7) cm; 
p=0.325); however intra-abdominal LOS length was greater in healthy subjects than 
patients as a whole (2.3 (1.6,2.7) cm vs. 1.3 (-1.0,2.1) cm; p=0.023) and those with 
GORD (0.5 (-2.6,2.0) cm; p=0.014) but not in those with Functional heartburn (1.6 
(1.0,1.9) cm; p=0.221). Hiatus hernia was demonstrated HRM in 5 (28%) patients all 
of whom had GORD on ambulatory pH studies with an overall range of 1.4 - 6.4 cm. 
Three of those had hiatus hernia identified at endoscopy and 2 did not. On the other 
hand, three other patients who were described as having a small hiatus hernia at 
endoscopy showed no separation of the LOS components during manometry at rest 
nor during challenge swallows.  
 
6.3.3 Swallow effectiveness during the test meal 
During the standardised test meal, the median consumption time of 552 (range 
492,720) seconds was similar in healthy subjects and patients (p=0.132). A median 33 
(IQR 29,42) pharyngeal swallows were required to complete the meal in patients. This 
was similar to healthy subjects (Chapter 5) in whom the median consumption time for 
the standardised meal was 399 (range 307-550) and the median number of pharyngeal 
swallows required to complete the meal was 29 (IQR 27,32). An HRM trace 
representative of a test meal in a patient with typical symptoms of reflux is shown in 
Figure 6.5.  
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Figure 6.5 HRM trace of a patient with GORD following a refluxogenic test meal.  
30 mmHg isobaric contour was applied. A oesophageal function after every 
phyarngeal swallow is labelled. 
(PeP = Pan-oesophageal pressurisation. PTZ = Proximal transition zone.) 
 
 
Compared to healthy subjects, fewer effective swallows were observed in patients 
overall (51% vs. 28%; p<0.001) (Figure 6.6a). Further sub-analysis showed that both 
GORD (24%; p<0.001) and FH patients (33%; p=0.010) had fewer effective swallows 
than healthy subjects. In other words, there was an increased frequency of ineffective 
(simultaneous or wide breaks in peristalsis) and failed (< 3 cm contractility) swallows 
in both GORD and FH patients compared to normal volunteers. On the other hand, 
there was no significant difference in the frequency of effective swallows between the 
GORD and FH subgroups. (p=0.211) (Figure 6.6b).  
 
There was a correlation in the number of effective swallows and the time required to 
consume the test meal (PC 0.476, p=0.053) (Figure 6.7). This was unlike healthy 




   Figure 6.6a                                      Figure 6.6b 
 
Figure 6.6 Effectiveness of peristalsis box plot (a) The frequency of effective swallows during a standardised test meal was greater in healthy 
volunteers than patients overall (p<0.001). (b) There was no significant difference in the frequency of effective swallows between GORD and 




Figure 6.7 Frequency of effective swallows required to consume the test meal over time in patients overall (n=18) (PC = Pearson’s correlation) 
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6.3.4 Multiple water swallows (MWS) in health and in patients  
(Table 6.4)  
 
The overall number and duration of swallows required to freely drink 200ml of water 
was similar in healthy volunteers (n=10) and patients (n=18) (p=0.483 and 0.204 
respectively). Compared to the GORD group (n=11), patients with FH (n=7) required 
a similar number of swallows (p=0.361) over the same duration (p=0.469). There was 
a (statistically) similar subjective measure of oesophageal contractile suppression 
(p=0.076); however although the median MWS contractility suppression score was 
‘0’ in the patient group, 5 exhibited complete suppression of contractility (score of 
‘4’), suggesting resistance to flow at the level of the OGJ. Two of these comprised of 
patients with abnormal pH testing and may imply a peptic stricture (see discussion). 
 
An effective post-MWS oesophageal contraction was seen in 80% of healthy subjects 
and 39% of patients (p=0.055). Further sub-analysis showed that an effective post-
MWS oesophageal contraction was even less prevalent in patients with GORD (27%; 
p=0.030) although it was seen in just over half (57%) of those with FH (p=0.593); 
however the frequency of post-MWS oesophageal contractility between GORD and 
FH patients was statistically similar (p=0.332). There was no difference in the 
frequency of effective post-MWS LOS after-contraction between healthy volunteers 
and any of the subgroups (p>0.05 for all). All 7 FH patients and (6/11) 55% of the 
GORD sub-group had an effective post-MWS LOS contraction (p=0.101).  (Table 6.4 
and Figure 6.8) 
 
There was no difference in the median number of swallows required to open the LOS 
(at 15mmHg) between healthy subjects and patients (median of 2 swallows for both; 
p=0.166). Patients with FH required a greater number of pharyngeal deglutitions 
(median 7 swallows) to open the LOS than healthy volunteers (p=0.014); however the 
maximum number of swallows required was 21 in FH compared to 5 swallows in 
healthy subjects. There was no difference in the LOS shortening distance nor the LOS 
pressure pre- and post-MWS between healthy volunteers and patients overall nor in 
the sub-analysis between GORD and FH (p>0.05 for all). Also the calculated volume 
of water for every swallow was similar across all groups (between 13.5 and 15.4 ml 




Table 6.4 Measurements of oesophageal function during and after multiple water swallows (MWS) for healthy subjects and all patients. 
Measurements are presented also from the secondary analysis of patients with and without an objective evidence of GORD (i.e. GORD vs. 
Functional Heartburn; FH) 
Mann-Witney test was used to assess quantitative swallow parameters (number of swallows, duration, suppression of contractility) between groups 
(Healthy vs. Patients vs. GORD vs. FH). Fisher exact test was used to assess the difference in the frequency of effective/ineffective oesophageal 
and LOS aftercontraction between the groups. 
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Figure 6.8 Frequency of post-MWS oesophageal and lower oesophageal sphincter contraction in healthy volunteers and patients as well as sub-
group analysis of those with gastro-oesophageal reflux disease and Functional Heartburn (FH). 
 
 
Table 6.5 Secondary analysis results of MWS swallows for healthy subjects and patients as well as subgroup analysis for GORD and FH. 
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6.3.5 Dysmotility analysis   
(Patients are identified by their initials) 
 
Dysmotility - All patients (Table 6.6) 
Hypo-contractility and aperistalsis were the most common dysmotility events seen 
with any swallow modality. Oesophageal spasm was not identified in any patient 
during water swallows although it was seen in 1 patient during bread swallows and in 
2 additional patients with the test meal. Similarly, only 1 patient showed resistance to 
bolus passage at the LOS (raised IBP/IRP) during water swallows, while 2 new 
patients were found to have LOS obstruction during bread swallows and a further 2 
during the test meal. One patient (RB) had an unstable LOS which was seen only 
during bread swallows and the test meal (see functional heartburn section 6.3.6 and 
Figure 6.9). On the other hand, among those with a change in manometry findings 
across modalities, 2 showed normalisation of peristalsis with solids from hypo-
/aperistalsis with water swallows; one normalised initially with bread swallows and 
another during the test meal.  
 
Overall, of the 18 patients studied, 4 showed a change in manometric diagnosis when 
progressing from water to bread swallows and 12 from water swallows to the test 
meal. 
 
Dysmotility - GORD patients (Table 6.7) 
5/11 patients with GORD had hypotensive dysmotility or aperistalsis during solid 
swallows (bread or test meal). Oesophageal spasm was identified in one patient 
following bread swallows and 2 further patients during the test meal. In one of these 
(JB) the trace was suggestive of diffuse oesophageal spasm (prolonged spasm of the 
distal segment) although this patient also had a raised IRP with water and solids. 
(patient JB Figure 6.10) In this case it is unclear which was the chief pathology; 
spasm may be a consequence of the distal obstruction to bolus passage or it may have 
been the primary problem which manifest only after adding work to the oesophagus. 
Three episodes of dysphagia associated with dysmotility were reproduced in this 
patient (see symptoms section 6.3.6 and Table 6.18).  
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Two other patients had hypotensive peristalsis during the test meal; the first (AA) had 
a very wide hiatus hernia of 7 cm (Figure 6.11), and the second (CG) was associated 
with an episode of retch/vomit when bolus transport was interrupted after an 
aperistalsis event (see symptoms section 6.3.6 and Table 6.18). In a final patient (MO) 
resistance to flow at the LOS was only revealed with the test meal.  
 
In all, 8 patients had a change in manometry findings from water to solid swallows 
(bread or test meal), of which two showed normalisation of peristalsis with solids 
from hypo-/aperistalsis during water swallows (e.g. patient JL Figure 6.12). 
 
Dysmotility - Functional heartburn patients (Table 6.8) 
Of the 7 patients with functional heartburn, LOS obstruction was identified in 1 
patient with bread swallows (patient CC Figure 6.13) and 2 further patients with the 
test meal (JW and IS). With JW (Figure 6.14), only aperistalsis was noted during 
water and bread swallows and no abnormality at the LOS was seen. (Water swallows 
IBP 7.1 mmHg and IRP 8.1 mmHg; Bread swallows IBP 10 mmHg and IRP 8.7 
mmHg) With the test meal and during free drinking however, a non relaxing LOS 
became apparent (IBP 33.2 mmHg and IRP 26.6 mmHg) and was associated with 
pan-oesophageal pressurisation using the 30 mmHg isobaric contour. This was 
suggestive of achalasia. Manometry traces for IS are also shown in Figure 6.15. One 
patient’s unstable LOS (patient RB Figure 6.9) only became apparent when 
swallowing solids. An unstable LOS was defined as a delayed LOS relaxation 
response to deglutition which may follow a brief period when the LOS does not relax; 
thus the 4 second IRP often remains normal, a relatively novel phenomenon. This 
patient was also found to have prolonged spasm activity following free drinking of 




Table 6.6 Distribution of dysmotility and change in HRM-based diagnosis in all patients (N=18). 4 and 12 patients had a different diagnosis from 









Table 6.8 Distribution of dysmotility and change in HRM-based diagnosis in patients with Functional Heartburn. (N=7) 
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6.3.6 Symptom analysis  
(Patients are identified by their initials) 
 
I. Water (5ml and MWS) 
No symptoms were reproduced during 5 ml water swallows in any patient. 4/18 
patients reported symptoms during or immediately after MWS: 1 x retch/vomit (CC), 
2 x rumination (IS and DO) and 1 x belch during a prolonged transient relaxation of 
the LOS immediately after MWS (TT).  
 
II. Bread (1cc) 
All patients (Tables 6.9 and 6.10) 
6/18 (33%) patients reported symptoms during the bread swallows (mean 2.2 
symptom events; range 2-3). 5/18 (28%) patients overall, or 5/6 (83%) of those who 
were symptomatic, had at least one symptom event associated with oesophageal 
dysfunction (mean SAD 1.5 (range 0-2)). Overall, 3 events of raised IBP and 3 
hypotensive manometric events preceded symptoms by ≤ 10 seconds. 1 patient who 
retched mid-procedure had no symptom association. Symptoms that were associated 
with dysmotility included: dysphagia (4 patients), retch/regurgitate (1 patient) and 
cough (1 patient).  4 of these patients had a D-SI of 100% (i.e. all symptoms were 
associated with dysfunction).  
 
GORD patients (Tables 6.11 and 6.12) 
Of the 11 patients with GORD, 3 (27%) reported symptoms during bread swallows; 2 
with dysphagia (JB and DO) and 1 with cough (TT). All had an SAD of 2 with a D-SI 
of 100% with either hypo-peristalsis (n=2 events) or raised IBP (n=1 event) occurring 
prior to symptoms.  
 
Functional heartburn patients (Tables 6.13 and 6.14) 
Of the 7 patients with FH, 3 reported symptoms during bread swallows; 2 dysphagia 
(RB and CC) and 1 vomit/retching (KS). In RB and CC dysmotility events associated 
with symptoms were hypo-peristalsis (n=1) and raised IBP (n=2). One patient (RB) 
had a D-SI of 100% following 2 episodes of dysphagia and the other (CC) had a D-SI 
of 33% because 1 out of his 3 dysphagia events were associated with dysmotility. 
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Table 6.9 Total frequency of symptoms and Symptom-Associated Dysmotility (SAD) 
for all patients during bread swallows. (N=6) 
 
 
Table 6.10 Reproduced symptoms, SAD (Symptom-associated dysmotility) and D-SI 
(Dysmotility-Symptom Index) for all patients during bread swallows. (N=6) 
 
 
Table 6.11 Total frequency of symptoms and Symptom-Associated Dysmotility 
(SAD) for all GORD patients during bread swallows. (N=3) 
 
 
Table 6.12 Reproduced symptoms, SAD (Symptom-Associated Dysmotility) and D-
SI (Dysmotility-Symptom Index) for all GORD patients during bread swallows (N=3)  
 
 
Table 6.13 Total frequency of symptoms and Symptom-Associated Dysmotility 
(SAD) for all Functional heartburn patients during bread swallows. (N=3) 
 
 
Table 6.14 Reproduced symptoms, SAD (Symptom-Associated Dysmotility) and D-




All patients (Tables 6.15 and 6.16) 
12/18 (67%) patients reported symptoms during the test meal (mean 2.3 symptom 
events, range 0-10). 9/18 (50%) patients overall, or 9/12 (75%) of those who exhibited 
symptoms, had at least one symptom event which followed oesophageal dysfunction 
(mean SAD 1.8 (range 0-7)). Symptoms that were associated with dysmotility 
included: dysphagia/food sticking (3 patients), retch/regurgitation (2 patients), chest 
pain (1 patients), belch (1 patients) and cough (2 patients).  Manometric dysmotility 
events that preceded symptoms by ≤10 seconds were: hypo-/aperistalsis (ineffective 
or failed peristalsis; n=6), oesophageal spasm (n=3), hypertensive peristalsis (n=1), 
outflow obstruction (n=1) and TLOSR with belching (n=1). Three patients with cough 
had no symptom association. 7/9 (78%) patients had a D-SI of 100% (i.e. all 
symptoms associated with dysfunction).  
 
GORD patients (Tables 6.17 and 6.18) 
Of the 11 patients with GORD, 7 (63%) patients reported symptoms during the test 
meal (mean 1.1 symptom events, range 0-3) with a mean SAD of 1.1 (range 0-3). 
Abnormal pressure events associated with symptoms were: hypo-/aperistalsis, 
hypertensive peristalsis and segmental spasm. Four patients had a D-SI of 100% 
(dysphagia, cough, chest pain and vomiting), one had a D-SI of 67% (retch/vomiting) 
and two had no association of symptoms with dysmotility (both cough).  
 
Functional heartburn patients (Tables 6.19 and 6.20) 
Of the 7 patients with FH, 5 (71%) patients reported symptoms during the test meal 
(mean 3.4 symptom events, range 1-10) with a median SAD of 3 (range 0-7). 
Dysmotility associated with symptoms were: pan-oesophageal pressurization, 
increased intra-bolus pressure, hypo-/aperistalsis and TLOSR. Three had a D-SI of 
100% (dysphagia described as food sticking/difficulty swallowing, cough and painful 
belch), one had a D-SI of 70% (dysphagia followed by regurgitation) and one had no 
association with abnormal pressure events (cough).  
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Table 6.15 Total frequency of symptoms and Symptom-Associated Dysmotility 
(SAD) for all patients during the test meal (N=12) 
 
 
Table 6.16 Reproduced symptoms, SAD (Symptom-Associated Dysmotility) and D-
SI (Dysmotility-Symptom Index) for all patients during the test meal (N=12) 
(IBP = Intra-bolus pressure; PeP = Pan-oesophageal pressurisation; TLOSR = 
Transient Lower Oesophageal Sphincter Relaxation) 
 
 
Table 6.17 Total frequency of symptoms and Symptom-Associated Dysmotility 
(SAD) for all GORD patients during the test meal (N=7) 
 
 
Table 6.18 Reproduced symptoms, SAD (Symptom-Associated Dysmotility) and D-
SI (Dysmotility-Symptom Index) for all GORD patients during the test meal (N=7) 
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Table 6.19 Total frequency of symptoms and Symptom-Associated Dysmotility 
(SAD) for all Functional Heartburn patients during the test meal (N=5) 
 
 
Table 6.20 Reproduced symptoms, SAD (Symptom-Associated Dysmotility) and D-
SI (Dysmotility-Symptom Index) for all Functional Heartburn patients during the test 
meal (N=5) 
(IBP = Intra-bolus pressure; PeP = Pan-oesophageal pressurisation; TLOSR = 




Figure 6.9 Patient RB. 35 year old female with globus and dysphagia to dry foods for which she often needed to drink water. She also complained 
of heartburn and acid-like regurgitation which reached the pharynx and was associated with chest pain. Symptoms occurred during the day and 
night. Twice daily lansoprazole reduced the heartburn but not the dysphagia or regurgitation. Gastroscopy was normal and 24 hour pH monitoring 
showed no evidence of GORD or reflux-symptom association.  
Left panel: Normal 5ml water swallow. Middle and right panels: Although 1cc bread swallows and test meal showed a normal overall pressure 
gradient, on closer scrutiny there was an initial rise in IBP (up to 20 mmHg during bread swallows and 26 mmHg during the meal) followed by a 
sudden drop during which time the bolus would pass. This implies poor compliance of the LOS rather than a fixed obstruction. There was 100% 
association (D-SI) with dysphagia during bread swallows. Bottom panel: During the post-meal observation period and after drinking water, there 
was a prolonged high pressure event in the distal segment of the oesophagus during the clearance phase. This was suggestive of diffuse 
oesophageal spasm although no symptoms were reproduced.  
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Figure 6.10 Patient JB. 49 year old female with a daily sensation of food sticking in the proximal oesophagus as well as nocturnal regurgitation 
and heartburn. Acid-reducing medication did not improve her symptoms. Endoscopy was normal. 24 hour pH study was pathological for all reflux 
parameters: Total reflux (7.0%), Upright reflux (8.7%) and Supine reflux (5.9%). DeMeester score was 35.8 (normal <14.72). Symptom Index for 
regurgitation was 100% (positive >50%).  
Left panel: 5 ml water swallow was normal showing an effective well-coordinated peristalsis. Visually there was a recurrent and pronounced 
inspiratory diaphragmatic pinch at the LOS. Although the IBP was raised (23.6 mmHg) the mean IRP was normal (15.5 mmHg) which implied 
that the bolus passed through the LOS normally. No symptoms were reproduced and the patient was well throughout.  
Middle panel: 1 cc bread swallow also showed a raised IBP (32.1 mmHg) with normal mean IRP (15.1 mmHg), but now intermittent focal 
segmental spasms began to appear. Two episodes of dysphagia coincided with dysmotility (D-SI 100%). 
Right panel: Standardised meal showed clear evidence of obstruction with a raised IBP (55.3 mmHg) and an IRP (21 mmHg). All 3 episodes of 
dysphagia coincided with dysmotility (D-SI 100%). The symptomatic resistance to flow at the OGJ combined with positive ambulatory pH studies 




Figure 6.11 Patient AA. 75 year old lady who presented with a 4 year history of daytime and nocturnal heartburn, regurgitation and central 
burning chest pain. Intermittent Nexium, Gaviscon and Domperidone helped briefly. Endoscopy was normal. 24 hour pH study was pathological 
for all reflux parameters: Total reflux (38.0%), Upright reflux (38.0%), Supine reflux (38.2%). DeMeester score was 145 (normal <14.72). 
Symptom index for heartburn was 100%.  
Left panel: 5ml water swallows were normal although a wide (6.4 cm) hiatus hernia was visible.  
Middle panel: 1 cc bread swallows showed normal peristalsis, again with a very wide (8.3 cm) hiatus hernia.  
Right panel: Test meal showed that only 1 (6%) of the 17 swallows was effective, with the majority (59%) showing hypotensive contractility and 
the rest showing failed dysmotility.  
During the post meal observation there were 4 episodes of spontaneous LOS relaxations and 3 episodes of gradual drift of the LOS to a pressure of 





Figure 6.12 Patient JL. 55 year old male presented with the sensation of food sticking in the mid-oesophagus (requiring large amounts of water to 
pass) as well as a central burning chest pain and regurgitation. Omeprazole relieved the burning chest pain and dysphagia but not the regurgitation. 
Endoscopy showed grade A oesophagitis and the possibly a small hiatus hernia. 24 hour pH study showed evidence of oesophageal acid exposure 
for all parameters: Total Reflux (11.1%), Upright Reflux (11.8%) and Supine Reflux (10.4%) reflux. DeMeester score was 46.3 (normal <14.72). 
Symptom index for heartburn was 80% (positive >50%).  
Left panel: 5 ml water swallows showed absent or hypotensive peristaltic activity. 
Middle panel: 1cc bread swallows showed hypotensive peristalsis and a 1.7 cm hiatus hernia became apparent.  
Right panel: Test meal showed that peristalsis activity normalised during 1/3 of swallows and a 2-3 cm hiatus hernia became evident.  
Post-meal observation (see Figure 6.16) showed 11 LOS relaxation (LOSR) events, 9 of which were associated with a common cavity (i.e. reflux). 
Half of the LOSR events coincided with belch and 2 with rumination events. Also 3 episodes of LOS drift (to a pressure of 0) occurred; mean 
length of time of 28 seconds during the 10 minute observation period. 
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Figure 6.13 Patient CC. 63 year old lady with a daily sensation of food sticking in the mid-oesophagus often followed by cough and then food 
regurgitation. She also complained of heartburn when lying flat. Barium swallow only showed a hiatus hernia. Endoscopy was normal. Once daily 
Nexium helped with heartburn but not the dysphagia, cough or regurgitation. 24 hour pH study showed no reflux.  
Left panel: Aperistalsis (no contractility within the 30 mmHg isobaric contour) was seen with any 5ml water swallow. Middle and right panels: 
Bread and standardised meal showed resistance to flow at the OGJ with a raised IRP (18 mmHg) and IBP (24 mmHg). Cough/regurgitation was 
associated with dysmotility and resistance to flow (D-SI 100%). Bottom panel: free drinking elicited clearly the LOS obstruction which was 




Figure 6.14 Patient JW. 66 year old lady presented with a 7 year history of dysphagia and chest pain up to 2-3 times per week. Symptoms were 
especially worse when supine. Drinking water did not help.  Symptoms improved with Lansoprazole 30 mg and post-meal Gaviscon. Endoscopy 
was non-diagnostic. 24 hour pH study was normal.  
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Figure 6.14 (continued). Left and middle panels: water and bread swallows were aperistaltic (no contractility seen within the 30 mmHg 
isocontour). LOS basal tone (18.2 mmHg), IRP (8.1 mmHg) and IBP (7.1 mmHg) were normal. No symptoms were reproduced.  
Right panel: Standardised meal showed a non-relaxing LOS with a raised IRP (26.6 mmHg) and IBP (33.2 mmHg) as well as pan-oesophageal 
pressurisation with an isobaric contour of greater than 30 mmHg. Dysphagia was reproduced from the mid-point of the meal with every swallow.  
Bottom panel: 200ml multiple water swallow confirmed a non-relaxing LOS with resistance to flow and pan-oesophageal pressurisation. 
Achalasia (non-relaxing LOS and aperistalsis) was only confirmed with solid swallows and free drinking.  
The Chicago classification,118,125 which is based on water swallows alone, would define this as Type I (Classical achalasia); however it is more 
likely that this patient had pan-oesophageal pressurisation (pathognomic for Type II achalasia) which manifest only during free drinking and test 
meal. As described in the Chapter 1, Type II achalasia has a better prognosis than Type I (especially to myotomy) if treated early, and is theorised 






Figure 6.15 Patient IS. 72 year old lady presented with over 10 year history of heartburn refractory to low dose once daily Lansoprazole. 
Symptoms were worst after meals, although they could also recur at night. Endoscopy and 24 hour pH study was normal. 
Left and middle panels: 5ml water and bread swallows were normal.  
Right panel: Standardised meal showed evidence of resistance to flow with a raised IRP of 20 mmHg and IBP of 26.2 mmHg. There was also the 
sensation of food sticking in the oesophagus towards the end of the meal and the beginning of the observation period; however this occurred out-
with the 10 second interval limit required for a D-SI calculation.  
Bottom panel: Free drinking showed evidence of resistance to flow at the OGJ. This LOS outflow obstruction only manifest during the test meal 
and free drinking. 
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6.3.7 Post-meal observation (Table 6.21 and 6.22) 
16 patients completed the 10 minute post-prandial observation period. Compared to 
the 10 healthy controls, patients had similar numbers of LOS sphincter relaxations, 
common cavity events and associated symptoms (belching or chest pain) overall. 
Secondary analysis of patients with GORD showed a higher number of swallow-
associated LOS relaxations (SLOSRs) with and without common cavity events (2.5 
(1.3,4.0)) compared to healthy subjects (1.0 (0.0,1.0); p=0.019) and FH patients (1.0 
(0.3,1.0); 0.019 respectively). (Table 6.21) A gradual LOS drift with loss of pressure 
over >10 seconds but no common cavity was seen in 3/10 healthy volunteers (median 
15 seconds) and 3/16 patients (all GORD; median 28 seconds). Data for every healthy 
volunteer and patient is presented in Table 6.21. A representative trace of the post-





Figure 6.16 HRM snapshot of the post-meal observation in patient JL showing 2 x 
SLOSR, 1 x TLOSR and 2 x belch events one of which was associated with a 
common cavity event. An attempt at swallowing the refluxate after the first SLOSR 
was unsuccessful. This patient had evidence of severe GORD on pH studies.  
(See Figure 6.12 for details of patient JL) 
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Table 6.21  Post-meal observation for healthy subjects (n=10), all patients (n=16) as well as sub-analysis of patients with pH evidence of GORD 
(n=10) and with Functional Heartburn (FH; n=6). Parameters are presented as median (IQR). 




Table 6.22a Healthy subjects 
 
 




Table 6.22c Gastro-oesophageal reflux disease (GORD) 
 
 
Table 6.22d Functional heartburn (FH) 
 
Table 6.22 TLOSR, SLOSR, CC and LOS drift during post-meal observation. Distribution of transient (TLOSR), swallow-associated (SLOSR) 
and combined (LOSR) lower oesophageal relaxations with/without common cavity (CC) and belch and  the frequency and time the LOS drifts to a 
pressure of zero. Results are shown for every (a) healthy volunteer and (b) patient as well as a sub-analysis of patients with (c) GORD and (d) FH. 
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6.3.8 Final diagnosis and clinical outcome 
Management decisions were made by the referring physician/surgeon based on 
physiological challenge swallows (5ml water, 1cc bread, MWS, test meal, post-prandial 
observation) and ambulatory pH monitoring presented in the final report.  
GORD patients 
Of the 11 patients with GORD on pH-studies, 5 underwent anti-reflux surgery (assessed 
9-48 months after surgery) and all reported excellent functional outcome. 3 of these 
patients (RH, JL, TT) had a pathological oesophageal acid exposure with a raised Total 
reflux (TR 25%, 11% and 9.3% respectively) and reflux-symptom association (all SI for 
HB > 70%). On manometry all 3 had evidence of hypomotility, RH also exhibited 
episodes of focal spasm with the meal and both RH and TT had a D-SI of 100% for 
cough. Furthermore both RH and JL had >3 episodes of prolonged LOS drift to 0 mmHg 
(mean 13 and 28 seconds respectively) and JL had 11 LOSR and 9 CC events (Figure 
6.15). The other two patients who had surgery (SL, MR) had borderline measurements 
for oesophageal acid exposure and symptom association (TR 4.5% and SI for HB 50% 
for patient SL; TR 5.4% with negative SI for patient MR) although both had HRM 
findings that were suggestive of GORD: hypotensive dysmotility and increased frequency 
of post-prandial LOSR events (6 and 7 events respectively). 
 
3 patients (CG, DO, AA) had similar HRM findings as above (hypo-/aperistalsis with 
frequent post-meal LOSRs). All had clear pathology on pH-studies (TR 15%, 16% and 
38% respectively with SI >50% for all) which corroborated the manometry findings.  All 
three were offered anti-reflux surgery; however 2 declined (CG, DO) and 1 was not fit for 
an operation (AA; Figure 6.11). CG and AA have ongoing symptoms which are 
refractory to maximal therapy, while DO has responded well to twice daily Nexium. The 
remaining 3 GORD patients (JB, MO and JJ) were not offered anti-reflux surgery; JB had 
symptomatic oesophageal spasm (100% D-SI for dysphagia; Figure 6.10) and MO had 
OGJ outflow obstruction detected only during the meal (100% D-SI for chest pain). Both 
JB and MO have persistent symptoms. JJ had severe hypotensive dysmotility during all 
modalities and this was likely related to connective tissue disease. His ambulatory pH 
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study was only mildly elevated (TR 5.8%) with negative symptom association; however 
JJ described good symptom control with optimised Ranitidine and Domperidone. 
 
Functional Heartburn patients 
Of the 7 FH patients, none underwent anti-reflux surgery. DP and SM had normal 
manometry findings with no symptoms and a normal post-meal LOSR frequency. Such 
results suggest a true positive FH diagnosis. Symptoms resolved with dietary intervention 
and stress reduction respectively and no medication was required. 
 
Two patients had manometric changes supporting a diagnosis of GORD despite negative 
ambulatory catheter-based pH monitoring: i) KS had hypotensive dysmotility with 70% 
D-SI for dysphagia in which 7 dysphagia episodes coincided with hypo-/aperistalsis and 
5 LOSR events occurred during the observation period. ii) RB (Figure 6.9) had an 
unstable LOS noted during bread swallows and test meal with 100% D-SI for dysphagia 
and 4 LOSR events during the post-prandial observation period. Symptoms resolved in 
both with optimized acid-suppressant therapy, and in KS symptoms recurred on stopping 
medication. Therefore this was suggestive of a false-negative initial 24 hour pH result 
and it was recommended to the referrer that these patients might benefit from prolonged 
wireless pH monitoring if symptoms become refractory to acid-reducing medications, 
especially if anti-reflux surgery was being considered (Chapter 4). 
 
CC, IS and JW had symptomatic oesophageal dysfunction during the test meal. None had 
evidence of GORD on pH testing and symptoms failed to resolve with optimised acid-
suppressant therapy. CC (Figure 6.13) and IS (Figure 6.15) had OGJ outflow obstruction 
only during free drinking and the test meal (100% D-SI for dysphagia) but not with water 
or bread. Both were referred for dilation. CC described resolution of symptoms after OGJ 
dilation; although the procedure had to be repeated twice within the 2 year follow-up 
period. IS, who is elderly and frail was still awaiting the procedure and remained 
symptomatic at 2 years. JW (Figure 6.14) had achalasia after free drinking and meal 
studies (100% D-SI for dysphagia); however likely in view of her age and frailty, the 
referring physician was reluctant to offer surgery. She was informed that she may receive 














Figure 6.18 Functional Heartburn 2 year outcome algorithm 
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6.4 Summary of results 
• High Resolution Manometry facilitates the assessment of oesophageal function and 
the detection of symptomatic dysfunction during normal eating and drinking. 
• A methodology for the detection and analysis of oesophageal dysmotility during and 
after a standardised test meal and free drinking was introduced. 
• A novel metric which measures the association of symptoms with dysmotility was 
presented. 
• Reproducing normal swallowing behaviour in the ‘physiological’ upright-seated 
position had important effects on oesophageal physiology which induced dysmotility 
and typical symptoms. 
• Meal consumption was associated with more ineffective swallows in patients 
compared to healthy subjects (28% vs. 51%; p<0.001) 
• An effective post-MWS oesophageal contraction was seen in 80% of healthy subjects 
and 39% of patients (p=0.055). 
• Patients reported symptoms during solid swallows (single swallows and the test 
meal), free drinking and the postprandial observation period that were not present 
with single water swallows. No symptoms occurred with single water swallows 
although 9/12 (75%) patients with symptom associated dysmotility had a positive 
dysmotility symptom index during the test meal or postprandial observation. 
• Associating symptoms with dysmotility increased the sensitivity for detecting 
oesophageal motor disorders, improved diagnostic yield and influenced outcome. 
Compared to single water swallows alone, 12/18 (67%) patients had a change in 
manometry diagnosis during the test meal. 
• 2 year follow-up studies suggest that normal eating and drinking during HRM testing 
may help guide management. 
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6.5 Discussion 
This study proposes a paradigm shift in the assessment of oesophageal function by 
expanding the utility of existing High Resolution Manometry technology. Most 
importantly it provides evidence of how the classification of oesophageal dysmotility 
based on the identification of symptomatic oesophageal dysfunction while drinking and 
eating freely were superior to the current standard of detecting (any) dysmotility during 
single supine water swallows in reaching a clinically relevant diagnosis and influencing 
outcome. 
 
In the literature and in clinical practice, there is a poor understanding of how oesophageal 
dysmotility causes symptoms and many patients that undergo conventional manometry 
receive no clear diagnosis because results produced are not necessarily geared towards 
identifying symptoms.15,16 As seen in Chapter 5, even in health, many swallows can be 
considered to be abnormal, and without correlating these with symptoms there is an 
increased likelihood of providing a false positive diagnosis in a well individual.  
Combining conventional manometry with imaging or impedance can improve diagnosis 
and stratify patients in terms of oesophageal (dys)function;46,293 however the mechanisms 
of dysfunction and disease still lack clarity. HRM with closely spaced (21-36) sensors 
extending from the pharynx to the stomach clarifies the relationship between contractile 
force (motility) and the forces that drive bolus transport and reflux (function).243,291,292,294 
Still, even with HRM, studies that focus on single supine water swallows only provide an 
indirect assessment of the causes of symptoms that might occur during or after normal 
eating behaviour, with no real emphasis on reproducing relevant symptoms. Although it 
is the current standard, this may be inaccurate with far-reaching consequences not only 
on diagnosis but also on treatment decisions. The new emphasis on symptoms presented 
here is analogous to the shift in ambulatory reflux studies away from GORD diagnosis 
based only on oesophageal acid exposure to the modern definition of GORD which also 
includes the association of reflux events with symptoms.1 
 
Studies in this chapter showed how HRM can facilitate the analysis of relatively complex 
pressure data during drinking and eating. New techniques were standardised and novel 
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metrics were formulated which included symptom association in the final assessment. 
These techniques were then used to clarify the association between oesophageal 
dysmotility, dysfunction and symptoms which could influence therapy and outcome at 
two years. Furthermore, a postprandial observation period following a refluxogenic meal 
also provided insight into the mechanisms by which reflux events and their associated 
symptoms occur. 
 
The results confirm that by increasing the workload on the oesophagus and by 
reproducing normal eating and drinking behaviour, symptoms can be reproduced and the 
dysmotility that is related to these symptoms can be identified. Spontaneous reports of 
oesophageal symptoms were rare during water swallows, even in the presence of 
oesophageal dysmotility, but common during the test meal. In contrast, healthy 
volunteers (Chapter 5) were able to complete the meal and post-prandial observation 
period without complaint. 
 
Failed swallows and hypotensive dysmotility with water swallows were more common in 
patients compared to healthy controls. As reported previously,245 in several patients with 
endoscopy negative GORD, oesophageal motility ‘normalised’ with solid swallows 
resulting in improved peristalsis coordination and increased contractile pressures (Table 
6.7 and patient JL Figure 6.12). 
 
A variety of ‘dysmotility events’ were observed during the test meal. Although such 
events also occurred in healthy subjects (Figure 6.6a), the functional significance of the 
higher rate of abnormal swallows in the disease group is supported by the finding that 
patients took almost 30% longer than controls to complete the meal (median 399 vs. 
552s). This implies that patients with oesophageal disease try to compensate for 
underlying dysmotility and dysfunction by eating more slowly and producing an 
increased number of swallows even if these ‘events’ do not produce overt symptoms. In 
general, 12/18 (67%) patients had a change in diagnosis based on extending the HRM 
studies beyond water swallows. 
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Detailed analysis revealed that various abnormal pressure events were associated with 
symptoms during the test meal (Table 6.9 - 6.20). Some were clearly pathological and 
included: aperistalsis, outlet obstruction (increased intra-bolus pressure above the OGJ 
with or without pan-oesophageal pressurization) and high-pressure oesophageal spasm. 
Other events were simply more common in patients including: failed swallows, 
hypotensive peristalsis and low-pressure spasm. What differentiated the groups was that 
ineffective swallows in healthy subjects were commonly followed by an effective, 
primary or sometimes secondary peristalsis event, whereas patients tended to produce 
several abnormal swallows in sequence. Such behaviour would be expected to increase 
bolus retention and oesophageal wall stretch (distension) which could therefore illicit 
symptoms.295,296 (Figure 6.5) 
 
Free drinking provided further evidence of resistance to bolus flow in those with a non-
relaxing LOS. This was especially true for patients with achalasia as the accumulation of 
water followed by typical symptoms (regurgitation/cough) could be seen (by the patient 
and doctor) and measured (e.g. patient JW Figure 6.14). MWS could also identify 
patients with outflow obstruction not always noticed with other testing modalities; of the 
5 patients with increased suppression of contractility on MWS, 2 (JB and MR) comprised 
of patients with GORD on pH testing. This raises the suspicion of a fibrotic stricture 
related to chronic reflux. At two years follow-up, JB (Figure 6.10) continues to complain 
of symptoms of dysphagia and reflux not responding to acid reducing medication while 
MR had anti-reflux surgery with complete resolution of his symptoms. 
 
An effective post-MWS oesophageal contraction was seen in 80% of healthy subjects, 
and 39% of patients (p=0.055). Further sub-analysis showed that compared to health an 
effective post-MWS oesophageal contraction was seen in just over half (57%) of those 
with FH (p=0.593) but was less prevalent in patients with GORD (27%; p=0.030). Daum 
et al245 showed that patients with severe GORD were less likely to have effective 
swallows to solids compared to healthy subjects. Therefore a similar response to 
increased workload on the oesophagus may also be occurring here, albeit with the post-
MWS clearance of accumulated water rather than single bolus solid swallows. 
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After the test meal, transient (TLOSR) and swallow associated lower oesophageal 
sphincter relaxations (SLOSRs) were observed in both healthy subjects and patients 
(Figure 5.15 and 6.15). Many of these were accompanied by common cavity events (i.e. 
reflux); however, without pH and impedance, it is not clear whether such reflux events 
were acid/non-acid, liquid or gas. Consistent with previous reports,297 the overall 
frequency of these LOS relaxations was similar in patients and controls (Table 6.21 and 
Chapter 5 Table 5.10); however, on closer scrutiny an increased frequency of reflux 
events (especially SLOSRs) was noted in many individuals with GORD and, crucially, 
‘reflux symptoms’ related to these events were only reported in patients. This may be 
associated with the volume and composition of the refluxate in these patients, or an 
increased sensitivity to normal reflux.2,151 Additionally, HRM detected behavioural 
abnormalities such as rumination in some patients that would require biofeedback rather 
than medical management.298 
 
It is clear that many ‘dysmotility’ and ‘reflux events in patients did not produce 
symptoms and, conversely, symptoms were not always preceded with dysmotility. This 
inconsistent association between physiological events and symptoms is typical in 
functional gastrointestinal diseases and has been extensively studied in GORD.76 In this 
study, techniques used in ambulatory pH monitoring were adapted to provide a 
quantitative assessment of symptom association with dysmotility during and after the 
meal. This was a novel approach not yet considered in the literature. Symptoms 
associated with dysmotility (SAD) were defined as abnormal pressure events or reflux 
that preceded reports of symptoms within a 10 second interval. This short time window 
maximized the likelihood of causal association. The oesophageal dysmotility Symptom 
Index (D-SI) was then defined as the percentage of SAD divided by the total number of 
symptoms reported by the patient. 
 
Applying Symptom Association Probability (SAP) to determine the probability that 
dysmotility events were followed by symptoms was considered;76 however there were 
limitations to this approach. First, SAP gives a measure of ‘statistical confidence’ but no 
indication of ‘effect size’ and is unreliable if the number of ‘events’ is small. In contrast 
D-SI is sensitive to symptoms that are related to intermittent oesophageal dysfunction. 
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Moreover, considered together with the frequency and severity of events, D-SI provides 
an indication of patient responsiveness to oesophageal dysfunction (i.e. visceral 
sensitivity and/or vigilance).151 In other words, one D-SI could be compared to another 
and the closer the D-SI approaches 100% the more likely the association of reflux with 
symptoms is real. Looking ahead a method that combines the practical advantages of SI 
with a better assessment of statistical confidence is required, and in fact this is being 
developed for ambulatory pH studies at St Thomas’ Hospital.299 
 
In the absence of a ‘gold standard’ test, outcome data provides insight into the clinical 
impact of diagnostic tests. Although the patient group studied was small and 
heterogeneous, these findings provide initial evidence that methodology which includes a 
test meal, free drinking and post-prandial observation can provide useful and effective 
information. Patients with frequent symptomatic reflux events after the meal had 
excellent functional outcome after anti-reflux surgery even if ambulatory pH studies were 
borderline. Similarly, two FH patients who had similar HRM findings to the GORD 
group had a good response to optimized acid-suppression. Thus HRM appeared to be 
complementary to reflux studies in those with clear pH pathology, and was also able to 
detect GORD in those with no definitive results on ambulatory pH studies. Additionally, 
this approach identified oesophageal dysmotility and dysfunction that had not been 
detected with other forms of testing, including endoscopy and HRM with single water 
swallows. These findings included individuals with significant outflow obstruction due to 
structural or functional pathology. Thus, observations during and after a test meal did not 
only provide insight into the mechanisms of disease but also guided clinical management, 




In conclusion, this study showed that the inclusion of single solid swallows, a test meal, 
free drinking and a post-prandial observation period into routine HRM testing provided 
clinically relevant information that could explain the pathological basis of symptoms and 
establish a relevant diagnosis in patients presenting for investigation of ‘oesophageal 
symptoms’. A standardised methodology for HRM investigation and analysis of 
oesophageal dysmotility and symptoms during and after eating and drinking was 
presented. Classification of pathology was based on normative values achieved from 
healthy subjects. The long-term clinical outcome of this patient group indicated that these 
observations do not only increase diagnostic certainty and yield, but also guide effective 
clinical management. Larger studies are now in progress to confirm the clinical utility 
and cost-efficiency of this approach. 
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 Chapter 7 
Summary and Future direction 
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7.1 Prolonged wireless pH monitoring (BRAVO) 
 
Patients referred for ambulatory 24 hour catheter-based pH monitoring may not always 
receive a correct diagnosis. There are several possible explanations for this discrepancy: 
 
1) Intolerance to insertion of the nasal catheter 
2) In those who tolerate insertion, nasal and pharyngeal discomfort and social 
embarrassment reduce oral intake and impact on behaviour. 
3) With its wide day-to-day variability, brevity of the 24 hour studies may impact on 
diagnostic accuracy. 
 
Studies in this thesis demonstrate how prolonged measurement with wireless pH 
monitoring can address these concerns. Chapters 3 and 4 showed that 2/3 of patients who 
were either intolerant to the nasal catheter or had negative results yet ongoing typical 
symptoms were shown to have evidence of GORD with prolonged (≥48 hour) wireless 
pH monitoring. Improved comfort and tolerability facilitated normal dietary and physical 
behaviour which increased the number of naturally occurring reflux and symptom 
events.81,82,84 Additionally, increasing the duration of study beyond 24 hours appeared to 
improve the reliability of diagnosis, especially in patients with intermittent symptoms. 
These results are of more than academic interest. Follow-up results from Chapter 4 (and 
others106) suggest that this technology improves the ability to predict outcome following 
treatment with acid suppression therapy and/or anti-reflux surgery. This technology is not 
widely available, and many patients who fail catheter-based testing or experience undue 
discomfort do not receive an accurate or definitive diagnosis. This can lead to suboptimal 
treatment choices.  
 
In summary, prolonged measurement is better tolerated, improves diagnostic 
reproducibility and reduces measurement variation as it increases the number of ‘events’ 
available for analysis.85,106,261,262 It is most suitable for  those with wide day-to-day 
variability of oesophageal acid exposure87 and  in patients with intermittent symptoms 
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(e.g. less than 6/day) in whom it is difficult to establish a statistically significant and 
reliable symptom association.85,105,106  
 
In all, these studies suggest that wireless pH monitoring for 48 (and up to 96) hours is 
superior to 24 hour catheter-based pH monitoring. On the other hand, wireless pH 
monitoring is expensive and, in keeping with UK national guidelines, is most commonly 
reserved for cases where patients are either intolerant to the catheter or have negative 
results despite typical symptoms of GORD.  Until the evidence-base improves, Bravo 
will remain a second line investigation. Conversely, other emerging technologies and 
novel methods (High Resolution Manometry with challenge swallows; Chapter 5 and 6) 
might help discriminate between normal individuals and disease, and are not subject to 
limitations imposed by national guidelines. 
 
7.1.1 Limitations of Bravo studies 
Chapter 3 limitations  
Although patients were recruited from the same referral pool, those who were in the 
Bravo group may have represented a different cohort of patients as a result of their 
intolerance to the catheter. Although it would have been interesting to include a cohort of 
patients in whom both the catheter and Bravo capsule were analysed simultaneously, 
physical interference of the catheter with the capsule risked iatrogenic early capsule 
detachment. Furthermore, a dual-sensor or Impedance-pH assessment to exclude 
proximal reflux sensitivity was not performed. On the other hand, this study represents 
true clinical practice with strict adherence to NICE guidance whereby patients proceeded 
to Bravo when catheter-based studies were unsuccessful.102 Furthermore, had Bravo not 
been available, many patients would not have achieved a diagnosis of GORD; however 
the impact of these findings based on diagnostic outcome was not addressed and is a 
major weakness of this study.  
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Chapter 4 limitations 
This highly selected group of patients was referred by physicians and surgeons due to the 
clinical suspicion of a ‘false negative’ diagnosis on an initial catheter-based pH study. 
Thus these findings cannot be generalized to all patients with negative C-pH, many of 
whom have atypical reflux symptoms that are much less likely to be caused by gastro-
oesophageal reflux events.91 Furthermore the catheter-based studies performed at St 
Thomas’ Hospital did not routinely include impedance which is reported to increase test 
sensitivity ‘off PPI therapy’ by up to 20%.91 Although theoretically Impedance-pH could 
have reduced the pool of patients entering the study, the principle limitations of 24 hour 
catheter-based studies still applied and it was unlikely that this technology would have 
removed the requirement for prolonged wireless testing in some patients.  
 
More critically, this study did not have a control group. Inclusion of patients with a 
positive C-pH study would have provided information about the concordance and day-to-
day consistency of GORD diagnosis between methods. In other words, the results are 
biased in ‘favour’ of prolonged wireless pH monitoring in that the diagnosis could only 
either remain the same or change from negative to positive for GORD and not the other 
way.  
 
A true ‘gold standard’ does not exist. Therefore outcome data was critical. There were a 
high proportion of patients with a negative C-pH who then had a positive GORD 
diagnosis on Bravo and a good outcome following anti-reflux surgery. This provided 
support for the utility of this investigation. Despite these limitations, study procedures 
reflected ‘real life’ clinical practice in which most patients were re-referred for further 
testing only if reflux symptoms did not respond to initial therapy, patients had ongoing 




Bravo; areas of interest  
Results from Chapters 3 and 4 were presented using different formats, durations and cut-
off values as the most appropriate analysis method for this novel technology is yet to be 
established. As with any technological advance several areas of contention remain: 
 
 What is the optimal duration of Bravo? 
 48, 72, 96 hours, longer? 
 What is the most appropriate analysis method? 
 Worst day or Average? 
 What cut-off values should be used for the various parameters? 
 Total reflux = 4.2%250, 5.3%103 or 5.78%258 ? 
 Should different cut-off values be also established for Upright and Supine 
reflux? 
 What is the most appropriate pH threshold? 
 A fall in pH below 4, 4.5 or 5 threshold or a >1pH or 2pH unit drop? 
 What is the most appropriate reflux-symptom association method? 
 Symptom Index (SI; measures effect size, not confidence) 
 Symptom Association Probability (SAP; measure of confidence, not size) 
 What event → symptom time window provides the most sensitive and specific reflux-
symptom association measurement? 
 1 min, 2 min or other? 
 
As described in Chapters 3 and 4, the optimal duration of study and the most appropriate 
analysis method for oesophageal acid exposure and reflux-symptom association analysis 
have not yet been determined. Studies show that prolonged monitoring improves the 
diagnostic yield; however outcome is also dependent on the analysis methodology. In 
general, results based on ‘Average cumulative’ measurements are statistically robust and 
stable over time with high specificity for GORD diagnosis.85 With ‘Worst day’ analysis, a 
steady increase in yield is observed (Chapter 3 and 4). This is the result of high day-to-
day variation in oesophageal acid exposure such that prolonging monitoring increases the 
number of patients considered to have GORD over time if this decision is based on any 
given 24 hour period exceeding the diagnostic threshold. While ‘Worst day’ analysis 
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might be appropriate in patients with intermittent symptoms, specificity decreases and the 
risk of a false positive diagnosis increases.85,266 Nevertheless, ‘Worst day’ analysis is the 
most widely presented in the literature,85,103 and is commonly used at the St Thomas’ 
Hospital Oesophageal Unit and other major centres. As the aim of studies in this thesis 
was not to identify which analysis method was more statistically appropriate or clinically 
relevant, both ‘Worst day’ and ‘Average’ analyses were presented throughout. 
 
Notwithstanding the possible advantage of prolonged studies, there must be a limit to the 
‘Worst day’ approach. For example, it would be wrong to select 1 abnormal day out of 20 
days monitoring as it would be expected that even healthy subjects are likely to be 
labelled as having GORD by chance alone. One simple approach that can be applied in 
clinical practice is to decide at 48 hours whether to prolong the Bravo study; if the first 2 
days provide consistent results (i.e. both clearly positive or negative) then it is unlikely 
that the subsequent 2 days will alter the diagnosis and further prolongation is likely to be 
unnecessary. Conversely, if the results of the first 2 days are inconsistent, borderline or 
widely variable, prolonging the study duration would provide more data on which to base 
a definitive diagnosis. Alternatively, in patients with borderline or inconsistent results 
within the first two days of Bravo, High Resolution Manometry with challenge swallows 
and post-prandial observation (described in Chapter 6) might help bridge the gap of 
uncertainty; a future study worthy of consideration, although the challenge of catheter 
intolerance remains. 
 
Another question that needs to be addressed in future studies is in regards to parameters 
that measure reflux-symptom association. Only Symptom Index (SI) was available at St 
Thomas’ Hospital Oesophageal Lab during the initial Bravo studies (Chapter 3), 
subsequently SAP was included in Chapter 4. In the literature, both are intermittently 
used in isolation or in combination; however it remains unclear which provides the best 
and most clinically relevant summary. Neither SI nor SAP provides an ideal assessment 
of reflux-symptom association. SI does not take into account that the association between 
reflux and symptoms may occur by chance. In other words, if only one symptom event 
occurs and this happens to be associated with a reflux event by chance, this still produces 
an SI of 100%. Therefore if the number of reflux and symptom events are not included, 
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results need to be considered with caution.76 On the other hand SAP lacks the specificity 
required for prolonged studies as it is not stable over time (i.e. the chance of a positive 
SAP increases with study duration independent of disease severity). For the same reason, 
SAP cannot be used to compare the severity of disease between patients.76,151,300 Indeed 
in Chapter 3, agreements between diagnoses based on SI and SAP were far from perfect. 
Presently, in routine clinical practice at St Thomas’ Hospital, both parameters are 
presented to the referrer and the study is considered positive if either measurement is 
positive. Although studies in this thesis were not designed to address this question, the 
large dataset from prolonged monitoring greatly facilitate a statistically robust assessment 
of reflux-symptom association.151,300 
 
7.2 High Resolution Manometry with physiological 
‘challenge swallows’ 
 
The purpose of the oesophagus is to move food and fluid from the pharynx to the 
stomach and to minimise gastro-oesophageal reflux. Coordinated peristaltic activity is a 
multi-step process which usually requires: 
(i) a pharyngeal swallow that “pumps” food and fluid into the oesophagus 
(ii) gravity (weight of swallowed food and fluid) 
(iii) effective oesophageal motor function (deglutative inhibition followed by 
peristaltic contraction) 
(iv) sufficient relaxation and opening of the oesophago-gastric junction 
(v) a positive intra-bolus pressure gradient (i.e. a pressure drop from proximal to 
distal). 
 
In a healthy subject, all the above steps are usually satisfied. In disease, small volume 
water swallows can mask pathology as it can usually be cleared with an intact pharyngeal 
pump and passive gravitational drainage alone as long as the lower oesophageal sphincter 
(LOS) and oesophago-gastric junction (OGJ) relax (i.e. no achalasia) and open (i.e. no 
outflow obstruction). Indeed this passive clearing mechanism is observed in patients with 
hypo-/aperistalsis (e.g. severe GORD or connective tissue disorders such as scleroderma). 
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To better define pathology, an understanding of structure and function is required that 
extends beyond point measurements of contractility of conventional manometry, and 
defines parameters that are key to effective bolus transport. 
 
The Chicago Classification125,131,247 has been imperative in improving the understanding 
and categorising oesophageal and oesophago-gastric junction dysmotility, an important 
hurdle when considering therapeutic options.  For example it has described three 
achalasia subtypes based on their (high resolution) manometric signature and therapeutic 
response.136,301 Although less definitive, the Chicago Classification has also helped re-
define other phenotypes of dysmotility (e.g. hypotensive 294 and hypertensive302 
oesophageal dysmotility) that might respond to therapy.36,303 Nevertheless, standard 
methodology using HRM fails to establish a definitive diagnosis that can explain the 
aetiology of symptoms in many patients presenting with dysphagia or reflux.111,126 This is 
likely because tests based on small volume water swallows do not ‘challenge’ the 
oesophagus sufficiently nor do they represent normal behaviour, therefore symptoms are 
rarely triggered. Chapters 5 and 6 described novel methodologies which expand the 
utility of HRM by increasing consistency/volume of bolus (single bread swallows, eating 
and free drinking) while in the physiological upright, seated position. This and the 
addition of a 10 minute post-prandial observation period provided a better understanding 
of oesophageal (dys)function in health and disease. Furthermore, the emphasis shifted 
away from only assessing aberrant motility, and included interpretation of its association 
with symptoms. This is because in real life symptoms take place almost exclusively 
during and/or shortly after meals. Such observations could explain the cause of symptoms 
and may have the potential to direct specific medical, behavioural or surgical therapy, as 
well as identify patients who are inherently normal. (Chapter 6) 
 
Although intuitively obvious, these techniques have not entered routine clinical practice. 
This is likely because of the difficulty in interpreting the complex HRM findings and the 
absence of a standardised methodology with normative values.  Chapters 5 and 6 
developed and applied new techniques by which HRM could be used to facilitate the 
assessment of complex pressure activity while eating and drinking. Furthermore, 
reference values were formulated and used in the assessment of patients. These studies 
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showed that in both healthy subjects and patients, the oesophagus responded to solid 
swallows by improving coordination and increasing contractile vigour of peristaltic 
contraction.276 Using these techniques, challenge swallows identified pathology not 
detected with standard water swallows. Moreover, as these techniques reproduced normal 
behaviour, typical relevant symptoms were triggered and the frequency by which these 
coincided with dysmotility was measured using a parameter akin to the symptom-
association of reflux studies. In Chapter 6, when all study conditions were taken into 
account (single water and bread swallows, free drinking, test meal and post-prandial 
observations), 67% patients showed a change in diagnosis compared to water swallows 
alone. 
 
7.2.1 Limitation of HRM studies 
Chapter 5 limitations 
1) This study might be criticised because normative values for each study condition 
(change in position and bolus consistency) were based on five swallows in each position 
rather than the traditional 10 (water) swallows which constitute reference values in the 
literature.125,247 In addition, the numbers of patients used in the analysis (especially during 
the standardised meal, MWS and postprandial observation) were small and this needs to 
be taken into account when formulating normative data. Finally, it is not clear if the lack 
of correlation between the number of effective swallows and the time it took to complete 
the meal was due to a type I error as only 10 healthy subjects were included in the study. 
However, with the inclusion of bread swallows and a test meal, the overall number of 
swallows available for analysis was many times greater. Moreover as normal, 
physiological, eating behaviour was reproduced, this provided additional and more 
detailed information regarding the swallow mechanism that single water and bread 
swallows did not and, as will be shown in Chapter 6, produced a diagnostic yield that was 
superior. 
2) Investigators that performed the data analysis were not blind to the study conditions 
(i.e. position change, bolus consistency); however for inter-observer agreement analysis 
was performed by independent physicians in different countries without the benefit of 
any subject information (e.g. age, sex, name). Furthermore, for healthy volunteer (and 
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patient) analysis, the standardised meal, MWS and post-meal observation studies were all 
performed in the upright position and were technique specific which precluded the 
necessity for blinding in regards to position change or bolus consistency. Finally, all 
volunteer (and patient) analysis was carried out from the original HRM trace one year 
after being collected while blind to subject demographics and presenting complaint. 
3) Previous studies presenting normal values for HRM-based water swallows selected 
only single pharyngeal deglutitions that were followed by effective peristaltic 
contractions for analysis (i.e. multiple deglutitions and also failed contractions were not 
included);125,247 however for solid swallows it is not uncommon for more than one 
pharyngeal deglutition to be required before a bolus is successfully transported.304 
Therefore to analyse only successful swallows is not representative of normal physiology, 
and in this study a range of 1-3 deglutitions were sometimes required for the successful 
transport of solid bolus swallows. The frequency of pharyngeal swallows that preceded 
peristalsis was related to individual behaviour in response to increased bolus consistency 
as well as catheter-related pharyngeal irritation. Nonetheless, when key parameters which 
describe oesophageal function were compared, no differences were found between single 
and multiple pharyngeal swallows. 
 
Chapter 6 limitations 
Normative values were based on the results of only 10 healthy controls and patient data 
was acquired from 18 patients with both reflux and dysphagia symptoms; however, this 
relatively small number of participants was offset by the amount of data available for 
analysis (240 minutes eating and 280 minutes postprandial observation time).  Larger 
studies would provide more robust information about the prevalence of asymptomatic 
non-pathological dysmotility in healthy subjects and also the number of ineffective 
swallows in sequence that occur before symptoms are likely to be reported. Nonetheless 
the current findings suggest that the presence, not only of symptoms, but of symptomatic 
dysmotility during and after bread swallows/meal/drink thoroughly discriminates between 
patient and healthy subjects. 
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Although longer prandial and post-prandial observation periods and/or ambulatory 
studies would provide more information, such brief observations are informative because 
(i) dysmotility during meals is related to swallowing problems which reproduce relevant 
symptoms and (ii) sphincter relaxations and reflux events are most common immediately 
after meals.305 Such a brief study can be reproduced in routine clinical practice and 
provides important and discriminating information which can influence outcome. 
 
Another limitation was that the same clinician that recruited patients and performed the 
tests also performed the data analysis. To minimise bias due to lack of blinding, a clear, a 
priori definition of oesophageal dysmotility was applied based on studies presented in 
Chapter 5 that demonstrated high inter-observer reproducibility.275 Additionally, only 
spontaneous reports of symptoms were recorded and a very narrow time window (10 
seconds) was utilized to define the association between dysmotility and symptoms. 
 
HRM; areas of interest 
A recent study showed that although hypotensive dysmotility with water swallows is 
common in endoscopy negative reflux disease, only failure to respond to the ‘challenge’ 
of bread swallows was associated with poor bolus clearance and increased oesophageal 
acid exposure (pH-monitoring and endoscopy).245 This new observation shows how 
oesophageal function can be affected even in chronic reflux disease. (Figure 7.1).271,290 
 
Techniques described in Chapters 5 and 6 have also helped identify non-benign 
pathology missed during other investigation pathways. The case presented in Figure 7.2 
is an example of a patient who’s presenting symptoms, endoscopic findings and HRM 
with water swallows were unremarkable. If it was not for ‘challenge swallows’ the 




Figure 7.1 HRM of ENRD and ERD. Water and solid swallows of 2 patients with 
endoscopy negative reflux disease (ENRD; top panels) and erosive reflux disease (ERD; 
bottom panels). 
Left top and bottom panels: Water swallows show ineffective peristalsis with a wide (>3 
cm) separation between the proximal and mid-oesophageal contractions 
Top right panel: In contrast, solid swallows show an ‘effective peristaltic response’ only 
in the patient with ENRD.  Bottom right panel: Solid swallows produce a failed 
peristalsis in the patient with ERD. 
Note: a small hiatus hernia is seen in the patient with ERD (bottom) 




Figure 7.2 HRM of patient with a submucosal tumour at the OGJ. 41 year old gentleman 
who presented with minimal symptoms of food and fluid regurgitation and some mild 
dysphagia to solids. Endoscopy was normal. 
Top left panel: 5ml water swallows showed hypotensive dysmotility with only a 
marginally wide (3 cm) proximal transition zone, a feature not uncommonly found with 
small volume water swallows in the upright position. 
Top middle and right panels: Solid swallows showed a raised IRP of 24.3 mmHg with 
variable ineffective peristaltic response (segmental spasm (middle panel) and nutcracker 
oesophagus with a peak DCI 6100 mmHg (right panel)) as well as evidence of 
obstruction at the level of the lower oesophageal sphincter (LOS) throughout. Typical 
symptoms of dysphagia were reproduced only with solids. 
Bottom panel: Free drinking showed resistance to flow at the LOS as it did not relax. 
These studies were suggestive of an obstructive pathology. Endoscopic ultrasound 
revealed a sub-mucosal tumour at the level of the OGJ. This patient was alive and well 1 
year following chemotherapy, trans-hiatal oesophagectomy and gastrectomy. 
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7.3 The future 
Prolonged (up to 96 hour) wireless pH monitoring and High Resolution Manometry with 
‘challenge swallows’ provide a better assessment of patients with borderline or 
inconclusive results compared to the current standard. Studies presented in this thesis 
have standardised novel methodology and produced normative values thereby permitting 
these techniques to be performed routinely in any clinical practice. 
 
Studies at St Thomas’ Hospital are currently being undertaken with colleagues at the 
NIHR Biomedical Research Unit in Nottingham and Menne Biomed in Tuebingen 
Germany to address several of the areas of contention described in Section 7.1 with the 
aim of optimising the use of prolonged, wireless pH studies.261 This will include outcome 
measurements and will be the largest set of pH data ever subjected to systematic analysis 
of reflux-symptom association. Prospective studies are also underway at St Thomas’ 
Hospital and NIHR Biomedical Research Unit to investigate the impact of using the 
standardised meal and free drinking in a large group of patients with predominant 
symptoms of dysphagia.290 The anticipated favourable outcomes may pave the way 
towards abandoning the ‘non-physiological’ single bolus test altogether. 
 
It would be interesting to compare results of HRM with ‘challenge swallows’ with 
prolonged wireless pH monitoring in patients presenting with reflux symptoms. 
Furthermore, the methodology described in this thesis paves the way for ambulatory 
HRM, thereby assessing swallows and symptoms in a ‘real life’ setting outside of the 
hospital. Technological advances have already combined non-ambulatory HRM with 
Impedance. In the future both technologies could be combined to include ambulatory 
HRM with the addition of Impedance and a pH sensor yet without a nasal catheter. Such 
a technological advance might be achieved by temporarily securing a mid- or proximal 
oesophageal catheter to the oesophageal body in a manner similar to the Bravo capsule; 
however this too would require tolerability testing.  
 
The ongoing progress in our understanding of oesophageal physiology and the continuous 
development of new technology highlights the dynamic and complex structure and 
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Appendix 1 - Information for patients attending 
oesophageal tests -Manometry and pH study 
 
The aim of this information sheet is to help answer some of the questions you may 
have about having a manometry and 24 hour pH study. It explains the benefits and 
risks of the procedure as well as what you can expect when you come to hospital. If 
you have any questions or concerns, please do not hesitate to speak to a Clinical 
Physiologist for more information, the contact number is at the end of this leaflet. 
 
What is a manometry and 24 hour pH study and why do I need 
these tests? 
 
Manometry is a procedure to assess the function of your gullet (oesophagus), which may be 
causing the trouble you have been having recently. The test involves passing a small 
pressure catheter, consisting of 36 pressure sensors at 1 cm intervals, into your gullet via 
your nose to monitor your gullet function. The test measures the pressures and co-ordination 
of pressure activity within your gullet when you swallow. From this we can make an 
assessment of how the gullet is working and determine if your symptoms are due to certain 
disorders of the gullet. The test is also required before anti-reflux surgery to make sure the 
gullet is working well enough for you to have the operation. 
 
The 24-hour pH study is a procedure to detect the presence of acid in your gullet. The test 
measures the amount of acid that refluxes (flows back) from your stomach into your gullet 
and will help to find out if your symptoms are caused by acid reflux. 
 
How can I prepare for a manometry test? 
Please have nothing to eat or drink for four hours prior to these tests. Water is 
allowed. 
If you are having problems fasting for four hours because you are diabetic please 
contact us on the telephone number shown at the end of this leaflet. 
 
Please bring with you a list of all the medicines that you are currently taking, including 
anything bought over the counter, or any herbal or homeopathic medicines. If you are 
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asthmatic, it would be helpful if you could bring your inhaler(s) with you. If you are on any 
blood thinning medicine (e.g. Warfarin) please inform us. 
 
If you have been referred because of difficulty in swallowing or have the sensation of food 
sticking, please bring a sandwich with you which you can eat during the test. We advise 
female patients not to apply eye make-up for this particular test as it may cause a slight 
watering of the eye while inserting the tube. 
 
What are the risks? 
There is a minor risk of having a slight nose bleed or a sore throat with this procedure. 
 
How can I prepare for a 24 hour pH study? 
We ask that you temporarily stop taking any medicines for heartburn, acid regurgitation, 
nausea or tummy pain before the test, as they may affect the results. If your symptoms are 
so severe that you can’t stop the medication please contact us on the number at the end of 
the leaflet. 
 
Below is a list of the medication that you should stop taking, and for how long: 
• Stop taking the following tablets for seven days before the test: omeprazole, 
esomeprazole, lansoprazole, pantoprazole and rabeprazole. 
• Stop taking the following tablets for two days before the test: 
ranitidine, cimetidine, famotidine, nizatidine, metoclopramide, domperidone or 
cisapride. 
• Stop taking any antacids for 24 hours before the test. For example, Gaviscon®, 
Sucralfate, Milk of Magnesia. 
 
You can restart taking any of the above medicines on completion of the test. 
 
Please continue taking your other regular medicines unless you are told otherwise. 
 
Patients should wear a loose top. This is because you will be going home with the 
acidmeasuring tube inserted into your nose and taped over your ear, down the side of your 
neck, under your top and connected to the acid-monitoring recorder which is strapped 
around your waist. The purpose of doing this is to ensure that you can change into more 
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comfortable clothing later. If there is any feeling of embarrassment a scarf would help to 
disguise the inserted tube. 
 
What happens during a manometry test? 
You will be made comfortable on the couch, sitting upright. Local anaesthesia spray or gel is 
used to numb your nose. A catheter (tube) with pressure sensors along its length will then be 
passed through your nose and into your gullet. You should feel only a slight discomfort from 
this so you will not be put to sleep or sedated. 
 
Once the pressure catheter is inserted you are allowed to rest for few minutes. You will be 
aware of the catheter in the back of your throat throughout the test. Although you may find it 
uncomfortable it will not cause you any pain. 
 
The catheter is connected to a computer which displays and records the pressures in each 
sensor. During the test period we ask you to sit as quietly as possible and to talk as little as 
possible, and try to get used to not swallowing so frequently. This is because talking or 
frequent swallowing can interfere with the measurements. At some point we will ask you to 
take a deep breath in and out quickly to determine the position of your diaphragm. A short 
sharp breath is all that is required; we do not want you to hold your breath. 
 
An exact amount of water is given through a syringe 5mls at a time (1 teaspoonful). We 
would like you to swallow the water in one go so that we can monitor the muscle contractions 
in the gullet correctly. Up to twenty swallows may be needed so that we can get an accurate 
assessment of the muscle activity. Please swallow normally and try not to swallow between 
the samples of water. We appreciate that this may be difficult but frequent dry swallow 
(swallowing saliva) will prolong the test. 
 
Depending on your symptoms and our findings with the wet swallows we may also ask you 
to swallow several small pieces of bread or a large volume of water or milk shake. The 
procedure will take approximately one hour. 
 
What happens during 24-Hour pH test? 
This test will take place after the manometry in the Oesophageal Investigation Unit and will 
take up to 30 minutes. The testing will continue whilst you are at home over an 
approximately 24-hour period. 
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 A small tube (catheter) will be passed into your gullet via your nose to monitor the amount 
acid reflux in your gullet. If it necessary, more local anaesthetic spray or gel are used to 
freeze your nose before inserting the tube. Placement of the tube in your gullet should 
therefore not be painful, although the back of your throat may feel slightly uncomfortable. 
The acid-measuring tube will be connected to a portable recorder and you will be able to 
return home, continuing with your normal activities. 
 
After the tube is inserted you will be aware of the catheter in the back of your throat 
throughout the test but most patients find they become less aware of it with time. 
 
This procedure requires no sedation, so you will be able to travel to and from the hospital 
unassisted. You may however wish to bring a relative or friend for support or company just in 
case the local anaesthetic affects your driving ability. 
 
To encourage you to carry on with your normal activities in your usual environment during 
the test, it is important that you go home as soon as possible and do not stay in the hospital, 
unless there are exceptional circumstances. 
 
Information on diet-restriction will be given to you and you will be asked to fill in a form about 
the times over the next 24 hours when you lie down, get up, have symptoms, have breakfast, 
lunch, dinner and also to state the contents of your meal. 
 
When you come into the Oesophageal Laboratory further information will be available from 
us. You will need to return to the Unit on the following day at about the same time to have 
the tube removed. Your second appointment takes only 15 minutes. The recorder is stopped 
and the catheter is removed. Removing the catheter only takes two to three seconds and is 
not uncomfortable. The doctor will want to look at your diary sheet with you to ensure that we 
have all the relevant information. 
 
Giving my consent (permission) 
The staff caring for you will ask your permission to perform the procedure. It is important that 
you understand the benefits, risks and alternatives. If there is anything you don’t understand 
or you need more time to think about it, please tell the staff caring for you. 
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Remember, it is your decision. You can change your mind at any time. Let staff know 
immediately if you change your mind. Your wishes will be respected at all times. If you would 
like to read our consent policy, please tell a member of staff. 
 
What do I need to do after I have gone home? 
When you go home after your first appointment, if possible please follow your normal daily 
routine as we need to see what happens during a normal day. However, if you feel it is 
inappropriate to remain at work please be as active as you normally would be at home. 
 
The recorder must not get wet so please do not have a bath, shower, or go swimming. The 
equipment is expensive and we ask you to treat it with care. The catheter is particularly 
vulnerable and if it catches on a door handle, for example, it will be irreversibly damaged and 
the test would need to be repeated. It is therefore advisable to wear a loose top over the 
recorder and catheter to protect against this. 
 
Try to carry on with the next 24 hours as you would normally e.g. usual routines, normal 
meal times/portions, etc. But avoid acidic foods or drinks, as acidic foods and drinks interfere 
with the result of the test. We need to see what happens during a normal day. The catheter 
may move very slightly as you eat and it may feel strange but we would like you to persevere 
as it is important to know what happens after mealtimes. 
 
You are requested to record when you experience your symptoms such as heartburn, 
regurgitation or chest pain etc. You do this: 
 By pressing the marker button on the recorder every time you become aware of your 
symptoms (this inserts an electronic mark on to the recording), and 
 By writing on the diary sheet the nature of the symptom and the time that it occurs, as 
displayed on the recorder 
 You will also need to write down lying down and getting up times and everything you eat 
and drink, noting the start and finish times. 
 
The catheter will be securely taped to your cheek and behind your ear and is not likely to 
move. Very rarely the catheter can be vomited back up into your mouth and in this situation 
you will have to remove it. To do this undo the tapes, take a deep breath in and pull the 
catheter out from the nose, cut the catheter off and dispose of it. Then place the recorder 
and your diary sheet into a box and return as arranged. 
 285 
 It is rare, but if you cannot tolerate the presence of the catheter you can remove it yourself as 
described above. Obviously if this happens we are less likely to be able to effectively 
diagnose and treat your problem, so please persevere with the catheter for as long as you 
can. 
 
As stated above please do not take any medicines for heartburn, acid regurgitation, nausea 
or tummy pain during the test. 
 
The information on the recorder is downloaded onto a computer and the results printed. The 
result of both the pressure recording and 24-hour pH tests will need to be carefully analysed. 





If you need further information please call the Administrative Team on 020 7188 4194 who 
will guide you to the correct member of staff. 
 
Patient Advice and Liaison Service (PALS) – To make comments or raise concerns about 
the Trust’s services, please contact PALS. Ask a member of staff to direct you to the PALS 
office or: t: 020 7188 8801 at St Thomas’ t: 020 7188 8803 at Guy’s e: pals@gstt.nhs.uk 
 
Knowledge & Information Centre (KIC) – For more information about health conditions, 
support groups and local services, or to search the internet and send emails, please visit the 
KIC on the Ground Floor, North Wing, St Thomas’ Hospital. 
t: 020 7188 3416 
 
Language support services – If you need an interpreter or information about your care in a 
different language or format, please get in touch using the following contact details. 
t: 020 7188 8815 fax: 020 7188 5953 
 
NHS Direct – Offers health information and advice from specially trained nurses over the 
phone 24 hours a day. 
t: 0845 4647 w: www.nhsdirect.nhs.uk 
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Appendix 3 – Bravo 
instructions and diary 
 
Patient Instruction 
The purpose of pH monitoring is to monitor the 
frequency and duration of gastro-oesophageal 
reflux during a normal day. It is important that 
you eat, drink, work and exercise as you 
normally would. Not keeping to your normal 
routine may mean that the test results do not 
reflect an accurate picture of your oesophageal 
pH exposure. 
 
DO NOT take any acid suppressants (drugs 
such as Omeprazole, Esomeprazole, 
Lansoprazole, Pantoprazole, Ranitidine, 
Metoclopramide, Domperidone or Gaviscon 
etc) during your study unless instructed to 
by your doctor. 
 
Using the Patient Diary 
 








 Record events (i.e. meals and sleep) in the 
patient diary using the time on the 
Receiver’s display. 
 
Using the Symptom Buttons 
 During the pH study symptoms (Heartburn, 
Regurgitation, Chest Pain) can be recorded 
in this diary or automatically recorded by 
pressing the appropriate symptom button. 
Please only press the symptom button after 
5 minute interval if the symptom recurs.  
To confirm that the button has been pressed, a 
green indicator light remains lit for 3 
seconds and a beep is heard if this feature 




Receiver out of range 
If the Receiver is too far from the Bravo 
Capsule, a beep will be heard for 30 
seconds and the display will flash C1 or C2. 
Move the Receiver to your breastbone until 
the beep stops and the C1 or C2 is no 
longer visible. 
 
   
 At the completion of your pH study, 
return the Bravo pH Receiver and your 
diary to the Oesophageal Laboratory, 4th 
Floor Bermondsey Wing, Guy’s Hospital 
promptly. Any delay will cause 
inconvenience to other patients waiting 
for the Bravo test. 
 
Instructions: 
1. Carry on with the next 48 hours as you 
would NORMALLY. Eg usual routine, 
normal meal times/portions etc 
2. Chew your food well as this will help 
when swallowing 
3. Use the clock on the recorder to record 
the time of your activities and write all 
times down in 24 hour clock format. 
Restrictions: 
1. Avoid acidic food and drink. Eg. 
PICKLES, TOMATO BASED FOOD, 
YOGHURT, FRUIT, SOFT DRINKS, 
FRUIT JUICE, ALCOHOL etc. 
2. Always have milk with your tea or coffee 
to buffer the acidity. Otherwise drink 
milk, hot choc, horlicks or water only. 
3. Make sure the receiver DOES NOT GET 
WET or drops into the toilet, so place 
the receiver in the dry place during 
showering or bathing 
4. Use a maximum of two pillows when 
sleeping as we need you to lie as flat as 
possible 
 
If you have any problems or questions during the 






 BRAVO PATIENT DIARY 
Start Time __:__  End Time __:__ 
Patient _____________________________________ 
Receiver ____________________________________ 
Day 1 ___ / ___ 20__ 











         
         
         
         
         
         
         
Day 2 ___ / ___ 20__ 
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Day 3 ___ / ___ 20__ 
         
         
         
         
         
         
         
 
Day 4 ___ / ___ 20__ 
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Appendix 4 - Inclusion/Exclusion criteria for patients 
recruited for Wireless pH Monitoring studies 
 
Participants 
Patients aged 18-65 with a history of predominantly typical reflux symptoms (e.g. 
heartburn, acid regurgitation) referred for Bravo-pH studies are eligible.  
 
Inclusion Criteria 
- Provision of written, fully informed consent to undergo mechanistic procedures: 
endoscopy, 4 day wireless pH monitoring by the Bravo system  
- All subjects should be off acid suppression medication (e.g. PPI, H2RA)  for at 
least 5 days prior to endoscopy  
 
Exclusion Criteria 
- Significant gastrointestinal symptoms or disease other than reflux  
- Previous upper GI surgery or interventions such as oesophageal dilatations 
- Predominant symptoms of motility disorders, e.g. dysphagia 
- Presence of major oesophageal dysmotility on manometry, e.g. achalasia 
- Significant co-morbidity requiring ongoing treatment or investigation 
- Physical, neurological or psychiatric conditions preventing repeated visits to 
hospital or compliance with study procedures (e.g. physical impairment / reduced 
mobility) 
- Pregnant at the time of enrolment    
- No haematological abnormalities (no anticoagulants) 
No medications influencing gastrointestinal function within 3 days of the study. 
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Appendix 7 – Ambulatory pH monitoring satisfaction 
questionnaire 
 
Satisfaction Questionnaire for 24 hr pH catheter and Bravo  
1. What was your overall experience of the system?   
1 (very unhappy/intolerant)-2-3-4-5 (very satisfied) 
2. Did you experience any chest pain immediately after placement of the device?  
1 (very severe)-2-3-4-5 (none) 
3. Did you experience any swallowing difficulty after the device was placed?  
1 (very severe/unable to swallow)-2-3-4-5 (normal) 
4. Did eating feel different? 
1 (very unhappy/unable to eat)-2-3-4-5 (no difference) 
5. Did you experience restriction in your daily activities? and how severe? 
1 (very severe/unable to move)-2-3-4-5 (normal for me)  
6. Did you go to work the day following the procedure? 
yes  no unemployed 
7. Would you recommend this test to another person? 
yes  no 
8. Did you experience throat discomfort? 
1 (very severe)-2-3-4-5 (none) 
9. Did you experience nasal discomfort? 
1 (very severe)-2-3-4-5 (none) 
 
Additional questions for Bravo Satisfaction Questionnaire 
10. Do you think you were able to tell when the capsule fell off? 
yes  no 
11. Would you prefer the Bravo system or the standard 24 hour catheter? 
       Bravo system  Standard 24 hour catheter 
12. Why was the standard 24 hour catheter test unsuccessful? 
a. Failed insertion through the nose. 
b. Unable to tolerate the catheter after it was placed. 
c. Vomited pH catheter before the test was finished. 
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Appendix 8 - Inclusion/Exclusion criteria for healthy 
subjects and patients recruited for HRM 
 
Study Population 
Healthy volunteers will be recruited by local advertisement 
Patients with oesophageal symptoms (reflux/dysphagia) will be recruited from lab  
Inclusion criteria 
1. male or female 
2. at least 18 years of age 
3. have given informed consent for the HRM procedure 
Exclusion Criteria 
For normal controls: 
1. with symptoms or a history of oesophageal gastrointestinal disease 
2. with regular intake of medication. Occasional analgesics (e.g. aspirin) is allowed 
3. with any hematological abnormalities 
4. with any evidence of infectious disease 
5. who are pregnant or breast-feeding. 
6. with evidence or history of drug or alcohol abuse within the past two years 
7. with diabetes mellitus 
8. with mental impairment limiting the ability to comply with study requirements 
9. who are taking or planning to take other investigational drugs during the study 
10. with use of medications influencing upper GI motility within one week of the 
study (i.e. calcium channel blockers, prokinetic drugs, macrolide antibiotics). 
11. with use of PPIs and H2 blockers 
For patients: 
1. with no oesophageal symptoms (e.g. referred for studies prior to bariatric surgery) 
2. with mental impairment limiting the ability to comply with study requirements 
3. who are taking or planning to take other investigational drugs during the study 
4. with use of medications influencing upper GI motility within one week of the 
study (i.e. calcium channel blockers, prokinetic drugs, macrolide antibiotics). 
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Interruption or discontinuation of treatment 
Subjects who are unable to tolerate the HRM catheter or are unable to complete the test 
will be declared non-evaluable. The study is not a trial of treatment and will be analyzed 
on a per protocol basis. Thus, patients declared non-evaluable will be replaced to 
maintain numbers and sufficient power to detect the changes in oesophageal function. 
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Appendix 9 – Ethics approval + amendment for HRM 
healthy controls physiological study 
St Thomas' Hospital Research Ethics Committee 
South London REC Office 3 
Ethics Committee Office 
Governors' Hall Suite,  
Ground Floor South Wing  




Tel: 0207 188 2257 
Fax: 0207 188 2258 
06 March 2008 
Dr. Rami Sweis 
SpR Gastroenterology 
St Thomas' Hospital 
 
Dear Dr. Sweis 
 
Study title: The effect of position on oesophageal peristalsis and LOS 
pressures: a high resolution manometry study 
REC reference: 07/Q0702/3 
Amendment number: 2 
Amendment date: February 2008 
 
The above amendment was reviewed at the meeting of the Sub-Committee of the REC 




The members of the Committee present gave a favourable ethical opinion of the 




The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date  
Protocol  2 - Feb 2008    
Participant Consent Form  4 - Feb 2008    
Notice of Substantial Amendment (non-CTIMPs)    25 February 2008  





Membership of the Committee 





All investigators and research collaborators in the NHS should notify the R&D office for 
the relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 












Enclosures List of names and professions of members who were present at the 
meeting and those who submitted written comments 
 
Copy to: R & D Office, Guy’s & St Thomas’ NHS Foundation Trust 
 
St Thomas' Hospital Research Ethics Committee 
 




             Name                     Profession                                       Capacity 
             Dr Adrian Hopper        Co Chair/Consultant Physician         Expert 





Appendix 10 - Publications and talks arising from 
studies in this thesis 
 
Original articles 
• Rami Sweis, Angela Anggiansah, Terry Wong, Gareth Brady, Mark Fox 
Assessment of oesophageal dysfunction and symptoms during and after a 
standardized test meal in patients with reflux symptoms: a high-resolution 
manometry study. Gut  (revision advised) 
• Rami Sweis, Mark Fox, Angela Anggiansah, Terry Wong. Prolonged, wireless pH-
studies have a high diagnostic yield in patients with reflux symptoms and negative 
24-h catheter-based pH-studies. Neurogastroenterol Motil 2011;23(5):419-26 
• Rami Sweis, Angela Anggiansah, Terry Wong, Elad Kaufman, Sabina Obrecht, 
Mark Fox. Normative values and inter-observer agreement for liquid and solid 
bolus swallows in upright and supine positions as assessed by esophageal high-
resolution manometry. Neurogastroenterol Motil 2011;23(6):509-e198 
• Rami Sweis, Mark Fox, Angela Anggiansah R, et al. Patient acceptance and 
clinical impact of Bravo monitoring in patients with previous failed catheter-based 
studies. Aliment Pharmacol Ther 2009;29(6):669-76. 
 
Invited reviews 
• Mark Fox, Rami Sweis. Future Directions in Esophageal Motility and Function – 
New Technology and Methodology. Neurogastroent Motil 2012;24 Suppl 1:48-56. 
 
Invited book chapters 
• Rami Sweis. Oesophagus. In: Diet and Nutrition for Gastrointestinal Disease 
(Wiley Blackwell) 
• Rami Sweis, Mark Fox. Free drinking and Solid Swallows using HRM  In: Manual 
of High Resolution Esophageal manometry (Uni-Med Science) 2012 
• Rami Sweis, Abraham Botha. Pathophysiology and investigation of gastro-
oesophageal reflux disease. In: Griffin SM, Raimes SA, eds. Oesophagogastric 
Surgery. 4th ed: WB Saunders (Elsevier), 2009: 229-250. 
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Invited speaker (selected talks) 
• Upper GI Day; Benign Oesophageal Disease conference; St Thomas’ Hospital, 
London  
Therapeutic options in the treatment of dysphagia 
• First Symposium on Gastro-esophageal Diseases: Present and Future of GERD; 
Fundacion Mutua Madrileña, Madrid  
o Wireless pH monitoring 
• Advances in Clinical Oesophageal Investigation conference; Ascona, Switzerland  
o Wireless pH monitoring 
o Solid swallows and a test meal increase the clinical utility of High Resolution 
Manometry - Prize for best oral presentation 
• European Society of Esophagology 2010; Controversies in Esophageal Disease; Frankfurt 
o Advances in High Resolution Manometry 
• Royal London Hospital NGM meeting; Royal London Hospital, London  
o High Resolution Manometry; Physiological Challenge testing.  
• Jordan Gastroenterology Society Congress; Amman 
o Advanced technology in the assessment of GORD and Dysmotility; Bravo 
wireless pH monitoring and High Resolution Manometry - Keynote speaker 
• Gastro 2009 UEGW/WCOG; High Resolution Consensus Meeting - The Next 
Steps: Z-HRM, test meals and other advances 
o Inclusion of solid swallows and a test meal increase the clinical utility of High 
Resolution Manometry in patients with dysphagia 
o Solid swallows and a test meal increase the clinical utility of High Resolution 
Manometry in patients presenting with reflux symptoms 
• St. George’s Gastroenterology Day; St George’s Hospital, London  
o Advances in Investigation of Oesophageal Dysmotility and Reflux Disease  
• British Society of Gastroenterology; Glasgow - Keynote speaker 
o Investigation and treatment of the patient that fails to respond to PPIs.  
• European Society of Neurogastroenterology and Motility Meeting; Lucerne 
o High Resolution Manometry with large volume multiple repeated swallows aids 
detection of oesophageal pathology 
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Selected oral abstracts 
• Rami Sweis, Angela Anggiansah, Roy Anggiansah, Jayne Fong, Terry Wong, 
Mark R. Fox. Inclusion of solid swallows and a test meal increase the diagnostic 
yield of High Resolution Manometry (HRM) in patients with dysphagia. 
Gastroenterology 2011; 140 (Supplement 1)(5): S-77 
• Rami Sweis, Angela Anggiansah, Terry Wong, Mark R. Fox. Solid swallows and a 
test meal increase the clinical utility of High Resolution Manometry in patients 
presenting with reflux symptoms - Joint Regional BSG society meeting (2010) 
 1st place prize 
• Rami Sweis, Angela Anggiansah, Terry Wong, Mark R. Fox. The effect of 
‘physiologic challenge’ on coordination between proximal and distal oesophageal 
contractions in healthy volunteers. King’s College London Nutritional Society 
Symposium. (2010) 
• Rami Sweis, Angela Anggiansah, Mark R. Fox, Terry Wong, 96 hour bravo 
increases yield in patients with negative 24 hour oesophageal catheter pH tests 
results. Gut 2009;58:Suppl 1 A1-A156. 
 
Selected posters 
• Rami Sweis, Angela Anggiansah, Terry Wong, Mark R. Fox. Normal Values for 
Esophageal Motility and Function During Multiple Swallows of Low vs. High 
Consistency Liquid. Gastroenterology 2011; 140 (Supplement 1)(5): S-869-S-870  
• Rami Sweis, Angela Anggiansah, Roy Anggiansah, Jayne Fong, Terry Wong, 
Mark R. Fox. Inclusion of solid swallows and a test meal increase the diagnostic 
yield of High Resolution Manometry (HRM) in patients with reflux symptoms. 
Gastroenterology 2011; 140 (Supplement 1)(5): S-231  
• Rami Sweis, Angela Anggiansah, Terry Wong, Mark Fox. The effect of bolus 
consistency and position change on the coordination of peristaltic contractions in 
healthy volunteers. Gut 2011;60:Suppl 1 A186 – Distinction  
• Rami Sweis, Angela Anggiansah, Terry Wong, Mark Fox. High resolution 
manometry during a standardised test meal and free drinking. Gut 2011;60:Suppl 1 
A185 
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• Rami Sweis, Elad Kaufman, Sabina Obrecht, et al. Inter-observer agreement of 
water and solid swallows in high resolution manometry. Gut 2011;60:Suppl 1 
A184-A185 
• Rami Sweis, Angela Anggiansah, Terry Wong, Mark Fox. The effect of 
‘physiologic challenge’ on coordination between proximal and distal esophageal 
contractions in healthy volunteers. Gastroenterology 2010; 138 (Supplement 1)(5): 
S-600. (T1890) 
• Rami Sweis, Angela Anggiansah, Terry Wong, Mark Fox. Effects of bolus 
consistency and body position on oesophageal function assessed by High 
Resolution Manometry. Gastro 2009 UEGW/WCOG P1624. 
• Rami Sweis, Terry Wong, Angela Anggiansah, Mark Fox. Normal values for HRM 
assessment of liquid, solid and multiple repeated swallows in the upright and supine 
positions. Gut 2009;58(Suppl I):A1–A156 
• Rami Sweis, Terry Wong, Angela Anggiansah, Mark Fox. High resolution 
manometry with large volume Multiple Rapid Swallows aids the detection of 
esophageal pathology. Gastroenterology 2009; 136, Supplement 1(5):A-286. 
(S1892) - Distinction  
 
 302 
